## (19) <br> Patent Application Publication <br> KESSEL et al.

(43)

Pub. No.: US 2020/0231984 A1
Pub. Date:
Jul. 23, 2020

Inventors: Bettina KESSEL, Einbeck (DE); Milena OUZUNOVA, Göttingen (DE); Daniela SCHEUERMANN, Einbeck
(DE); Beat KELLER, Zurich (CH); Simon KRATTINGER, Bonstetten
(CH); Coraline PRAZ, Zurich (CH);
Ping YANG, Zurich (CH); Matthias ERB, Bern (CH)

Assignees: KWS SAAT SE \& co., KGaA, Einbeck (DE); University of Zurich, Zurich (CH); University of Bern, Zurich (CH)

Appl. No.: $\quad 16 / 640,857$
PCT Filed:
Aug. 22, 2018
(86) PCT No.:

PCT/EP2018/072688
§ 371 (c)(1),
(2) Date:

Feb. 21, 2020

Foreign Application Priority Data
Aug. 22, 2017 (EP)
P) .
17187309.4

## Publication Classification

(51) Int. Cl.

C12N 15/82
(2006.01)
(52) U.S. Cl.

CPC ..... C12N 15/8282 (2013.01); C12N 15/8216
(2013.01)

## (57)

## ABSTRACT

The present invention relates to methods for producing plants with increased fungal resistance, preferably seedling resistance against Northern Corn Leaf Blight. Further provided are methods for introducing, modifying, or modulating at least one wall-associated kinase (WAK) in(to) a plant cell, tissue, organ, or whole plant and thereby causing a reduced synthesis of benzoxazinoid and in turn increased fungal resistance. There are further provided methods to identify and/or modify downstream effector molecules in a WAK signalling cascade. Finally, plant cells, tissues, organs or whole plants having increased fungal resistance and methods using substances to activate signalling pathways in a targeted way are provided. The present invention thus relates to WAKs as master regulators and crucial signaling mediators in plant defense against fungal disease and the regulation and cross-talk mechanisms in the WAK signaling cascade and further gives examples for establishing novel anti-fungal strategies relevant for a series of crop plants.

Specification includes a Sequence Listing.
A)

B)


Figure 1
A)

B)


Figure 2


Figure 3


Figure 4


Figure 5


Figure 5 continued


Figure 6


Figure 7


Figure 8


B


C


D

ZmWAK-RLK1


BXDs synthesis

NCLB susceptibility

Figure 9


Figure 10


Figure 11


Figure 11 continued


Figure 11 continued


Figure 11 continued





Figure 12


Figure 13


Figure 13 continued

| 31 | GRMZM2G165387 | -6,70 | -3,46 | -7,67 | -3,20 | -5,95 | -2,59 | -5,12 | -2,61 | *Receptor-like protein kinase 5 precursor | LOC_Os02g40180.1 | Receptor like kinase |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 32 | GRMZM2G436455 | -6,82 | -8,20 | -4,40 | -9,40 | $-2,71$ | -9,96 | -2,76 | $-10,80$ | *Resistance-related receptor-like kinase putative expressed | LOC_Os01g02810.1 | Receptor like kinase |
| 33 | GRMZM2G089836 | 3,28 | 3,40 |  |  | 2,98 | 5,03 |  |  | Beta-fructofuranosidase 1; IVR2 - Invertase 2 | LOC OS02g01590. | Cell wall |
| 34 | GRMZM2G123107 | 3,17 | 4,69 |  |  |  |  |  |  | Glycosyl hydrolases tamily 17 putative expressed | LOC.OS01g71410.1 | Cell wall |
| 35 | GRMZM2G125032 | 2,89 | 5,88 |  |  |  |  |  |  | Beta-1,3-glucanase | LOC_0s01g71670.1 | Cell wall |
| 36 | GRMZM2G162359 | 4,34 | 2,46 |  |  |  |  |  |  | *Glycosyt hydrolase putative expressed | LOC, Os06g25010.1 | Cell wall |
| 37 | GRMZM2G135966 | -2,72 | -11,17 | -3,90 | -8,50 | -5,99 | -10,22 |  |  | *Glycosyl hydrolase family 47 domain contain protein expressed | LOC, OS04g51690.1 | Cell wall |
| 38 | AC214360.3 - FG001 |  |  | 3,58 | 3,10 |  |  |  |  | KS4 - Kaurene Synthase 4 | LOC, Os02g36220.1 | Secondary metabolism |
| 39 | GRMZM2G067225 | 2,06 | 3,84 |  |  |  |  |  |  | Putative cytochrome P450 superfamily protein | LOC, Os03g12500.1 | Secondary metabolism |
| 40 | GRMZM2G070304 | 8,75 | 5,70 |  |  |  |  |  |  | Glycerol-3-phosphate acyltransferase putative expressed | LOC. OS11g45400.1 | Secondary metabolism |
| 41 | GRMZM2G087875 | 2,96 | 3,84 |  |  |  |  |  |  | Putative cytochrome P450 superfamily protein | LOC. Os03g55240.1 | Secondary metabolism |
| 42 | GRMZM2G106950 | 3,11 | 3,13 |  |  |  |  |  |  | Indole-3-glycerol phosphate synthase chloroplast precursor | LOC. Os09g08130.2 | Secondary metabolism |
| 43 | GRMZM2G117878 | 3,35 | 4,60 |  |  |  |  |  |  | *Cytokinin- N -glucosyltransferase putative expressed | LOC, Os07g13800.1 | Secondary metabolism |
| 44 | GRMZM2G140817 | 3,13 | 2,92 |  |  |  |  |  |  | Armino acid permease | LOC OS04g35540.1 | Secondary metabolism |
| 45 | GRMZM2G145242 | 2,36 | 2,79 |  |  |  |  |  |  | Putative cytochrome P450 superfamily protein | LOC OSOSg41440,1 | Secondary metabolism |
| 46 | GRMZM2G146206 |  |  |  |  | -2,46 | $-2,81$ | -2,37 | -5,28 | TPI5 - triose phosphate isomerase 5 | LOC_ Os01g62420.4 | Secondary metabolism |
| 47 | GRMZM2G132550 | 4,15 | 4,52 |  |  |  |  |  |  | bHLH124 - bHLH-transcription factor 124 | LOC Os01g09990,1 | Transcription factors |
| 48 | GRMZM2G395749 | 3,30 | 2,79 |  |  |  |  |  |  | Putative MYB DNA-binding domain superfamily protein | LOC. Os01g09760.1 | Transcription factors |
| 49 | GRMZM2G421256 | 2,11 | 2,03 |  |  |  |  |  |  | MYB20 - MYB-related-transcription factor 20 | LOC. Os 04849450.1 | Transcription factors |
| 50 | GRMZM2G425430 |  |  | 5,64 | 4,38 | 6,06 | 3,86 | 4,81 | 4,84 | *WRKY81 | LOC. Os03g 33012.1 | Transcription factors |
| 51 | AC193786.3-FG005 |  |  | -3,92 | -3,17 |  |  |  |  | bHLH54 - bHLH-transcription factor 54 | LOC Os01g72370.1 | Transcription factors |
| 52 | GRMZM2G305901 | -6,40 | -11,29 |  |  |  |  |  |  | Zinc finger C3HC4 type domain containing protein expressed | LOC_OS01g06590.1 | Transcription factors |
| 53 | GRMZM2G326783 | 2,24 | 2,74 | 3,30 | 2,22 | 2.49 | 2,52 | 2,33 | 3,45 | THXTrihelix-transcription factor 29 | LOC. Os02g 33610.1 | Transcription factors |
| 54 | GRMZM2G016150 | -4,86 | -3,06 |  |  |  |  |  |  | OHP1 - Opaque2 Heterodimerizing Protein1 | LOC_Os03g58250.1 |  |
| 55 | AC196502.3 FFG003 | 8.65 | 4.81 |  |  |  |  |  |  | *Proline-rich family protein putative expressed | LOC_Os07g44830.1 |  |
| 56 | AC206788.3. FG015 | 2,19 | 2,23 |  |  |  |  |  |  | *Anthocyanidin 53-0-glucosyltransferase putative expressed | LOC. OsOSg 45100.1 |  |
| 57 | GRMMZM2G002173 | 3,25 | 5,27 | 2,88 | 3,96 | 2,88 | 2,82 | 5,22 | 3,31 | Phosphopantothenate cysteine ligase | LOC.Os02g36550.1 |  |
| 58 | GRMZM2G004349 | 3,10 | 2,15 |  |  |  |  |  |  | Seed maturation protein | LOC. Os05g 45050.2 |  |
| 59 | GRMZM2G006219 | 3,38 | 2,54 |  |  | 3,82 | 2,88 |  |  | *Major sperm protein (MSP) domain containing protein | LOC. Os02g42940.1 |  |
| 60 | GRMZM2G006878 | 4,86 | 3,69 | 5,70 | 4,37 | 5,86 | 2,78 |  |  | Expressed proteìn | LOC_Os03g63870.1 |  |
| 61 | GRMZM2G009045 | 5.11 | 3,95 | 3,04 | 5,89 |  |  |  |  | Phosphate transporter 3;2 | LOC.Os09828160.1 |  |
| 62 | GRMZM2G010048 | 5,55 | 2,92 |  |  |  |  |  |  | Thaumatin family domain containing protein expressed | LOC, Os03g46060.1 |  |
| 63 | GRMZM2G010596 | 2,97 | 2,20 |  |  |  |  |  |  | 3-methyl-2-oxobutanoate hydroxymethyltransferase | LOC. Os01g12560.1 |  |
| 64 | GRMZM2G011253 | 3,33 | 2,10 |  |  |  |  |  |  | 605 ribosomal protein 131 | LOC Os08g395001 |  |
| 65 | GRMZM2G011523 | 3,41 | 4,92 |  |  |  |  |  |  | BET11 - Bowman-Birk type bran trypsin inhibitor precursor putative expressed | LOC, O501g04040.1 |  |
| 66 | GRMZM2G011559 | 2,13 | 2,39 |  |  |  |  |  |  | Alpha-soluble NSF attachment protein | LOC OsO8g18110.1 |  |
| 67 | GRM2M2G020471 |  |  |  |  | 2,40 | 8,94 | 2,19 | 9,24 | Uncharacterized protein | n.a |  |
| 68 | GRMZM2G022972 | 2,45 | 5,15 |  |  |  |  |  |  | Calmodulin binding protein putative expressed | LOC.Os01g04280.1 |  |

Figure 13 continued


Figure 13 continued

| 10C Os03g29960.1 |  |
| :---: | :---: |
| 10 C Os03g29960.1 |  |
| LOC. 0507 g 37156.1 |  |
| LOC_0s12g42884.1 |  |
| LOC_Os02g56570.1 |  |
| LOC O504g33110.1 |  |
| LOC Os11g39990.1 |  |
| LOC Os07g 17310.1 |  |
| 100.0502 g 42310.1 |  |
| LOC_Os12g04510.1 |  |
| LOC_Os01g54870.1 |  |
| LOC O501g42320.1 |  |
| LOC_OsO7233410.1 |  |
| LOC. Os11g48020.1 |  |
| 100.0512 g 36110.1 |  |
| LOC Os08g 13690.1 |  |
| LOC_Os01g19450.2 |  |
| LOC. Os01g43380.1 |  |
| 10 C |  |
| LOC=Os11g37700.1 |  |
| 100.0501 g 25610.1 |  |
| LOC Os10g 36610.1 |  |
| LOC_Os04g52250.1 |  |
| 10 Cos 04 g 4.4980 .1 |  |
| 100.0507 g 42960.1 |  |
| 10 CO 12 g 33300.1 |  |
| $10 \mathrm{CosO2g} 44870.1$ |  |
| 100.0501 g 13260.1 |  |
| $10 \mathrm{C}=0 \mathrm{~s} 10 \mathrm{~g} 36170.1$ |  |
| n/a |  |
| LOC_0s02g36390.4 |  |
| LOC. Os01g04370.1 |  |
| LOC Os04g37760.1 |  |
| $\mathrm{m} / \mathrm{a}$ |  |
| m/a |  |
| LOC. Os01g58100.1 |  |
| LOC. Os12g25700.1 |  |
| $10 C .0 s 12 \mathrm{~g} 24320.1$ |  |

Figure 13 continued

| 145 | GRMZM5G898668 | 4,69 | 2,94 |  |  |  |  |  |  | * Exostosin family domain containing protein expressed | LOC Os01g70200.1 |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 146 | AC196158.3 FG002 | -2,26 | -2,92 |  |  |  |  |  |  | Uncharacterized protein | n/a |  |
| 147 | AC204539.4.F6003 | -8,91 | -3,39 | -6,59 | -4,65 | -5,88 | -3,79 | -9,39 | -3,31 | *Profilin domain containing protein expressed | LOC_Os06g05880.1 |  |
| 148 | AC205886.3 FG001 | -4,13 | $-2,51$ |  |  |  |  |  |  | * 405 ribosomal protein 54 putative expressed | LOC Os01g25610.1 |  |
| 149 | AC217050.4..FG007 | -2,08 | -6,76 |  |  |  |  |  |  | TPS7- terpene synthase 7 | LOC_ O507g 11790.1 |  |
| 150 | GRMZM26005170 | $-2,36$ | -2,03 | -2,19 | $-2,78$ |  |  |  |  | *MSP domain containing protein putative expressed | LOC_Os01g 71050.1 |  |
| 151 | GRMZM26005459 | -3,70 | -3,86 |  |  | -2,96 | -2,98 |  |  | *RNA recognition motif containing protein putative expressed | LOC, Os01g71200.1 |  |
| 152 | GRMZM2G013920 | $-4,28$ | -6,84 |  |  |  |  |  |  | Uncharacterized protein | n/a |  |
| 153 | GRMZM2G021256 | $-5,10$ | -3,72 | $-4,60$ | -4,94 | -3,49 | -3,46 | -3,29 | -3,82 | Oxygen evolving enhancer protein 3 | LOC_Os02g36850.1 |  |
| 154 | GRMZM26024738 | -2,68 | -2,01 |  |  |  |  |  |  | Uroporphyrinogen decarboxylase | LOC Os01g43390.1 |  |
| 155 | GRMZM2G028302 | -6,18 | -5,27 | -4,98 | -4,30 | -3,24 | -3,88 | -3,80 | -3,58 | Uncharacterized protein | LOC_Os10g39150.1 |  |
| 156 | GRMZM2G028733 | -3,88 | -4,32 | -3,23 | -4,58 | -3,71 | -4,37 | -3,20 | -3,92 | * Ubiquitin carboxyl-terminal hydrolase 6 putative expressed | LOC_Os01g 36930.1 |  |
| 157 | GRMZM2G031204 | -9,16 | -9,58 | -7,82 | -5,31 | -7,55 | $-7,36$ | -7,70 | -8,79 | Peptidyl-prolyl cis-trans isomerase | LOC_Os01g68710.1 |  |
| 158 | GRMZM2G036605 | -3,59 | -10,03 | -3,79 | -10,11 | $-4,70$ | -12,24 | -4,79 | -11,26 | *Tetratricopeptide repeat domain containing protein expressed | LOC. Os02g01030.1 |  |
| 159 | GRMZM2G036880 |  |  | -2,96 | -3,13 |  |  |  |  | Chlorophyll a-b binding protein 6A | LOC_Os06g21590.1 |  |
| 160 | GRMZM2G037334 | -2,11 | -8,58 | -3,18 | -4,75 | -2,01 | -6,02 |  |  | *Remorin C-terminal domain containing protein putative expressed | LOC. OSO2g44102.1 |  |
| 161 | GRMZM2G044851 | -2,19 | -2,45 |  |  |  |  |  |  | *Peptide transporter PTR2 putative expressed | LOC. O502g46460. |  |
| 162 | GRMZM2G045699 | -4,29 | -11,07 |  |  |  |  |  |  | Uncharacterized protein | n/a |  |
| 163 | GRMZM2G050875 | -7,06 | -11,33 |  |  |  |  |  |  | Uncharacterized protein | n/a |  |
| 164 | GRMZM2G056743 | -2,39 | -3,14 |  |  |  |  |  |  | Uncharacterized protein | n/a |  |
| 165 | GRMMZM2G057491 | -8,08 | -9,59 |  |  |  |  |  |  | * Glutamyl-tRNA synthetase cytoplasmic putative expressed | LOC_Os10g22380.1 |  |
| 166 | GRMZM2G060886 |  |  | -2,70 | -4,81 |  |  |  |  | *CPuORF25-conserved peptide uORF-containing transcript expressed | LOC, Os01g50030.1 |  |
| 167 | GRMZM2G061126 | -9,07 | -8,10 | -7,92 | -10,85 | -7,66 | -7.59 | -5,51 | -7,33 | Uncharacterized protein | m/a |  |
| 168 | GRMZM2G064374 | -8,56 | -6,22 |  |  |  |  |  |  | Uncharacterized protein | m/a |  |
| 169 | GRMZM26067929 | -10,74 | -4,45 | -11,02 | -5,47 |  |  | -10,56 | -5,50 | Uncharacterized protein | n/a |  |
| 170 | GRMZM2G068707 | $-2,70$ | -5,44 |  |  |  |  |  |  | Uncharacterized protein | n/a |  |
| 171 | GRMZM26072117 | 2,05 | $-2,53$ |  |  |  |  | $-2,08$ | $-2,62$ | AT-hook protein 1 | LOC_Os10g42230,1 |  |
| 172 | GRM2M26074083 | -2,01 | $-2,43$ |  |  |  |  |  |  | *C8S domain containing membrane protein putative expressed | LOC. O504g05010.1 |  |
| 173 | GRMZM2G074307 | -10,26 | -5,96 | -10,71 | -9,50 | -10,68 | -9,20 | -10,38 | -8,33 | Uncharacterized protein | n/a |  |
| 174 | GRMZM2G081192 |  |  |  |  |  |  | -3,71 | $-2,68$ | Aquaporin PIP2-3 | LOC_O502g41860.2 |  |
| 175 | GRMZM2G082608 |  |  | -2,32 | -2,62 |  |  |  |  | Uncharacterized protein | LOC Os01g69840.1 |  |
| 176 | GRMZM2G091743 | -2,85 | -5,47 | -5,31 | -3,62 |  |  |  |  | Uncharacterized protein | n/a |  |
| 177 | GRMZM26098460 | -2,07 | $-3,24$ | $-2,29$ | -2,38 | $-2,86$ | $-2,72$ | -2,19 | -3,30 | Drought-induced protein 1 | LOC Os02g30320.1 |  |
| 178 | GRMZM2G100568 | $-4,53$ | -4,02 |  |  |  |  |  |  | *Expressed protein | LOC Os02g14500.1 |  |
| 179 | GRMZM2G106429 |  |  |  |  |  |  | -2,11 | -2,13 | *Dnak family protein putative expressed | LOC_OS11g47760.1 |  |
| 180 | GRMZM2G106795 |  |  | -2,34 | -2,45 | -2,74 | -2,46 | -2,19 | $-3,34$ | ADP-ribosylation factor | LOC_Os02g47110.1 |  |
| 181 | GRMZM26107082 |  |  |  |  |  |  | $-2,27$ | -2,05 | *ATP-grasp domain containing protein expressed | LOC.Os11g47330.1 |  |
| 182 | GRMZM2G108527 | -3,88 | -5,27 |  |  |  |  |  |  | Uncharacterized protein | n/a |  |

Figure 13 continued

| n/a |  |
| :---: | :---: |
| LOC_0502g32980.1 |  |
| Loc OS02g 14500.1 |  |
| LOC. Os06g 13350.1 |  |
| Loc_Os01g43890.1 |  |
| LOC Os01g 38660.1 |  |
| LOC, Os02g40040.1 |  |
| n/a |  |
| LOC OS02g41590.1 |  |
| m/a |  |
| LOC_Os02g48110.1 |  |
| LOC. 0503 g 37290.1 |  |
| LOC, Os03g64290.1 |  |
| n/a |  |
| LOC Os05g 39000.1 |  |
| LOC. Os01g 42650.1 |  |
| LOC Os03g23980.1 |  |
| LOC. Os03g23980.1 |  |
| n/a |  |
| LOC Os01g69870.1 |  |
| LOC O504g01690.1 |  |
| LOC. Os04g55610.1 |  |
| n/a |  |
| n/a |  |
| LOC O503g58590.1 |  |
| n/a |  |
| n/a |  |
| n/a |  |
| LOC_Os01g25610.1 |  |
| n/a |  |
| n/a |  |
| n/a |  |
| LOC_Os01g02790.1 |  |

## INCREASED FUNGAL RESISTANCE IN CROP PLANTS

## TECHNICAL FIELD

[0001] The present invention relates to methods for producing plants with increased fungal resistance, preferably seedling resistance against Northern Corn Leaf Blight. Further provided are methods for introducing, modifying, or modulating at least one wall-associated kinase (WAK) in(to) a plant cell, tissue, organ, or whole plant and thereby causing a reduced synthesis of benzoxazinoid and in turn increased fungal resistance. There are further provided methods to identify and/or modify downstream effector molecules in a WAK signalling cascade. Finally, plant cells, tissues, organs or whole plants having increased fungal resistance and methods using substances to activate signalling pathways in a targeted way are provided. The present invention thus relates to WAKs as master regulators and crucial signaling mediators in plant defense against fungal disease and the regulation and cross-talk mechanisms in the WAK signaling cascade and further gives examples for establishing novel anti-fungal strategies relevant for a series of crop plants.

## BACKGROUND OF THE INVENTION

[0002] Infections and infestations of crop plants by pathogens encompassing viruses, bacteria, fungi, nematodes and insects and the resulting damages cause significant yield losses of cultivated plants. In maize (Zea mays) as one of the major crop plants worldwide there are a large number of fungal pathogens which cause leaf diseases. The fungus which can cause by far the most damage under tropical and also under temperate climatic conditions, such as those in large parts of Europe and North America as well as in Africa and India, is known as Helminthosporium turcicum or synonymously as Exserohilum turcicum (teleomorph: Setosphaeria turcica). H. turcicum/E. turcicum is the cause of the leaf spot disease known as "Northern Corn Leaf Blight" (NCLB), which can occur in epidemic proportions during wet years, attacking vulnerable maize varieties and causing a great deal of damage and considerable losses of yield of $30 \%$ and more over wide areas (Perkins, J. M., and W. L. Pedersen. "Disease development and yield losses associated with northern leaf blight on corn." Plant disease 71.10 (1987): 940-943; Raymundo, A. D., A. L. Hooker, and J. M. Perkins. "Effect of gene HtN on the development of northern corn leaf blight epidemics." Plant disease (1981); Ullstrup, A J, and Miles, S R 1957. The effects of some leaf blights of corn on grain yield. Phytopathology 47:331-336). Since the 1970 s, then, natural resistance in genetic material has been sought.
[0003] The race for defining and establishing new resistance strategies against pathogens for major crop plants is more and more accelerated due to the increasing resistance breaking characteristics of pathogens, i.e., the evolutionary strategy of pathogens to adapt to and survive pressure of plant protective agents and/or to subvert the endogenous plant defense mechanisms.
[0004] Currently, quantitative and qualitative resistances are known. While the oligo- or polygenically inherited quantitative resistance appears incomplete and non-specific as regards race in the phenotype and is influenced by additional and partially dominant genes, qualitative resistance is typically race-specific and can be inherited through
individual: For instances, mostly dominant resistance genes with regard to NCLB are $\mathrm{Ht} 1, \mathrm{Ht} 2, \mathrm{Ht} 3, \mathrm{Htm}, \mathrm{Htn} 1$, or Htp (Lipps, P. E., R. C. Pratt, and J. J. Hakiza. "Interaction of Ht and partial resistance to Exserohilum turcicum in maize." Plant disease 81.3 (1997): 277-282; Wang, H., et al. "Expression of Ht2-related genes in response to the HTToxin of Exserohilum turcicum in Maize." Annals of applied biology 156.1 (2010): 111-120). Backcrosses in many frequently used inbred maize lines such as W22, A619, B37 or B73 have successfully brought about introgression of the HT genes, where they exhibit a partial dominance and expression as a function of the respective genetic background (Welz, H G (1998). "Genetics and epidemiology of the pathosystem Zea mays/Setosphaeria turcica." Habilitationsschrift Institut für Pflanzenzüchtung, Saatgutforschung and Populationsgenetik, Universität Hohenheim). WO 2011/ 163590 A1 annotated the presumed Htn1 gene in the resistance source PH26N and PH99N as a tandem protein kinase-like gene and disclosed its genetic sequence, but did not determine its functionality, for example in a transgenic maize plant. WO $2015 / 032494$ A2 discloses the identification of another allelic variant of HTN1 gene derived from the donor Peptilla as well as a resistant maize plant into the genome of which a chromosome fragment from the donor Pepitilla has been integrated, which chromosome fragment comprises the resistance locus HTN1.
[0005] The hemibiotrophic fungal pathogen Exserohilum turcicum (anamorph form of the fungus) causing NCLB is found in humid climates wherever corn is grown. E. turcicum survives in corn debris and builds up over time in high-residue and continuous corn cropping systems. High humidity and moderate temperatures favor the persistence of the E. turcicum fungus causing tremendous yield losses, e.g., due to decreased photosynthesis resulting in limited ear fill, or harvest losses if secondary stalk rot infection and stalk lodging accompany loss of leaf area.
[0006] As a natural defense mechanism against various kinds of pathogens, Plants have evolved multiple layers of defense against infection by pathogenic microbes (Jones, Jonathan DG, and Jeffery L. Dangl. "The plant immune system." Nature 444.7117 (2006): 323). The primary defense is based on the extracellular perception of pathogenassociated or host damage-associated molecular patterns or signatures (PAMPs/DAMPs) by plasma membrane-anchored pattern recognition receptors (PRRs). These receptor proteins monitor the extracellular space for the presence of microbial- or host-derived elicitors, i.e., PAMPs or DAMPs, respectively. These signatures can be highly conserved and characteristic for entire pathogen classes as in the case of the bacterial flagellin that is perceived by the leucine-rich repeat receptor kinase (LRR-RK) FLS2, which results in basal and broad-spectrum resistance against most bacteria (Macho, Alberto P., and Cyril Zipfel. "Plant PRRs and the activation of innate immune signaling." Molecular cell 54.2 (2014): 263-272). Other receptor kinases only confer resistance to certain races of a particular pathogen (Hu, Keming, et al. "Improvement of multiple agronomic traits by a disease resistance gene via cell wall reinforcement." Nature plants 3 (2017): 17009). Receptor kinases have different types of extracellular domains, including leucine-rich repeats (LRRs), lysine motifs (LysMs), lectin motifs or epidermal growth factor (EGF) like extracellular domains (Dardick, Chris, Benjamin Schwessinger, and Pamela Ronald. "Non-arginine-aspartate (non-RD) kinases are associated with
innate immune receptors that recognize conserved microbial signatures." Current opinion in plant biology 15.4 (2012): 358-366).
[0007] In grasses, there is emerging evidence that WAKs might be important players in fungal and bacterial disease resistance. The WAK genes qHSR1, Htn1 and OsWAK (Xa4) confer disease resistance (Hurni, Severine, et al. "The maize disease resistance gene Htn1 against northern corn leaf blight encodes a wall-associated receptor-like kinase." Proceedings of the National Academy of Sciences 112.28 (2015): 8780-8785., Hu et al. 2017), yet little is known about the underlying mechanisms and signaling cascades responsible for the observed phenotypes.
[0008] OsWAK underlying resistance involves strengthening of the cell intensity by enhancing cellulose biosynthesis ( Hu et al. 2017). Interestingly, there is also one case described where the wheat WAK encoded by the Snn1 gene acts as a susceptibility factor. It has been shown that Snn1 perceives the SnTox1 toxin encoded by the fungal pathogen Stagonospora nodorum, which triggers cell death and allows the necrotrophic $S$. nodorum pathogen to proliferate on wheat (Shi, Gongjun, et al. "Marker development, saturation mapping, and high-resolution mapping of the Septoria nodorum blotch susceptibility gene Snn3-B1 in wheat." Molecular genetics and genomics 291.1 (2016): 107-119). In dicots, the Arabidopsis AtWAK1 was found to physically associate with and recognized cell wall-derived oligogalactouronides (OGs), which result from polysaccharide degradation (Kohorn, Bruce D., et al. "Pectin activation of MAP kinase and gene expression is WAK2 dependent." The Plant Journal 60.6 (2009): 974-982). In contrast to the Arabidopsis WAK gene family that consists of only five members, WAK genes in monocots belong to a large family. For instance, in rice $>100$ members were found (Kanneganti, Vydehi, and Aditya K. Gupta. "Wall associated kinases from plants an overview." Physiology and Molecular Biology of Plants 14.1-2 (2008): 109-118). The emergence of WAKs in monocots might be associated to several functional aspects, e.g. biotic diseases (Li, Hui, et al. "A novel wall-associated receptorlike protein kinase gene, OsWAK1, plays important roles in rice blast disease resistance." Plant molecular biology 69.3 (2009): 337-346; Hurni et al. 2015; Zuo, Weiliang, et al. "A maize wall-associated kinase confers quantitative resistance to head smut." Nature genetics 47.2 (2015): 151-157; Shi, Gongjun, et al. "The hijacking of a receptor kinase-driven pathway by a wheat fungal pathogen leads to disease." Science advances 2.10 (2016): e1600822; Hu et al. 2017), tolerance of phosphorus deficiency (Hufnagel, Barbara, et al. "Duplicate and conquer: Multiple homologs of PHOS-PHORUS-STARVATION TOLERANCE1 enhance phosphorus acquisition and sorghum performance on low-phosphorus soils." Plant physiology 166.2 (2014): 659-677), root growth (Kaur, Ravneet, Kashmir Singh, and Jaswinder Singh. "A root-specific wall-associated kinase gene, HvWAK1, regulates root growth and is highly divergent in barley and other cereals." Functional \& integrative genomics 13.2 (2013): 167-177) as well as gametophyte development (Wang, Na, et al. "The rice wall-associated receptorlike kinase gene OsDEES1 plays a role in female gametophyte development." Plant physiology 160.2 (2012): 696-707; Hu et al. 2017). Therefore, there is emerging evidence that wall-associated kinases (WAKs) could play a pivotal role in plant immunity specifically in cereal crops.
[0009] Still, presently little is known about the specific molecular mechanisms underlying plant immunity based on WAKs, said immune mechanisms being highly specific for each pathogen and thus PAMP/DAMP to be recognized and furthermore depending on the downstream signaling cascade and the subsequently initiated effector mechanisms. So far, rather the phenotypic outcome of a plant comprising or not comprising a receptor-like kinase on pathogen resistance has been matched with the genotype of a plant. The molecular mechanisms which are responsible for the action of the WAKs, the precise signaling pathways and also the crosstalk between different pathways remain elusive.
[0010] Chemical fungicides have long been utilised for controlling fungal diseases. A different approach relies on the examination and elucidation of the complex biosynthetic pathways involved in pathogen resistance causing a natural pathogen defence of plants by studying the resistance ability of an existing plant cultivar to inhibit or at least limit any infestation of a pathogen to provide new strategies to combat plant pathogens and to provide new plants carrying resistance traits of interest.
[0011] Benzoxazinoids (BXDs) were identified in the 1960s as secondary plant metabolites functioning as natural pesticides. BXDs are a class of secondary metabolites found in maize and other cereal species and certain dicots and contain a 2-hydroxy-2H-1,4-benzoxazin-3(4H)-one skeleton (Niemeyer, Hermann M. "Hydroxamic acids derived from 2-hydroxy-2 H-1, 4-benzoxazin-3 (4 H)-one: key defense chemicals of cereals." Journal of Agricultural and Food Chemistry 57.5 (2009): 1677-1696). BXDs are synthesized in seedlings and stored as glucosides. The main aglucone moieties are 2,4 -dihydroxy- 2 H -1,4-benzoxazin- 3 $(4 \mathrm{H}$ )-one (DIBOA) and 2,4-dihydroxy-7-methoxy-2H-1,4-benzoxazin- $3(4 \mathrm{H}$ )-one (DIMBOA). BXDs are synthesised in two subfamilies of the Poaceae and sporadically found in single species of the dicots. BXDs are predominantly stored as inactive glucosides, while upon biotic stress they are hydrolyzed to the respective toxic hydroxamic acids (e.g., DIMBOA). The first step in BXD biosynthesis converts indole-3-glycerol phosphate into indole. In maize (Zea mays), this reaction is catalyzed by either Benzoxazineless1 (BX1), or Indole glycerol phosphate lyase (IGL or Igl herein). The bx1 gene is under developmental control and is mainly responsible for BX production, whereas the Ig 1 gene is inducible by stress signals, such as wounding, herbivory, or jasmonates. The enzymatic properties of IGL are similar to BX1, but the transcriptional regulation of their corresponding genes is different. Like other Bx genes, bx 1 is constitutively expressed during the early developmental stages of the plant, which correlates with endogenous BX levels. The introduction of four oxygen atoms into the indole moiety that yields DIBOA is catalyzed by four cytochrome P 450 monooxygenases termed BX 2 to BX 5 . A further Bx enzyme, BX6, is responsible for the hydroxylation in position C-7 of the benzoxazinoids in maize (Frey, Monika, et al. "A 2-oxoglutarate-dependent dioxygenase is integrated in DIMBOA-biosynthesis." Phytochemistry 62.3 (2003): 371376). Bx7, as further example, is an O-methyltransferase (OMT) catalyzing the formation of DIMBOA-glc from TRIBOA-glc.
[0012] Little is known about the role of these compounds in fungal disease resistance. Few field studies decades ago proposed a correlation between benzoxazinoid hydroxamic acids concentration and the disease resistance to maize stalk
rot, maize northern corn leaf blight and wheat stem rust (Long, B. J., G. M. Dunn, and D. G. Routley. "Relationship of hydroxamate concentration in maize and field reaction to Helminthosporium turcicum." Crop Science 18.4 (1978): 573-575) without providing any molecular basis for this phenomenon. Other studies even found no effect of BXDs in fungal disease resistance, including maize stalk rot, Southern corn leaf blight, maize anthracnose, corn smut and head blight at all (Niemeyer, 2009).
[0013] Therefore, it was an outstanding aim of the present invention to provide new tools and methods to allow for a tight resistance management for major crop plants concerning the control of fungal plant pathogens.
[0014] Further, it was an object of the present invention to provide new strategies and methods to combat fungal leaf diseases based on exploiting plant-endogenous defense mechanisms as mediated by secondary metabolites and further to provide plants having a specific genotype as source of increased resistance or tolerance against fungal pathogens causing severe plant diseases. Basically, it was an object of the present invention to elucidate the molecular basis of the maize Htn1 northern corn leaf blight (NCLB) resistance that is cause by the WAK gene ZmWAK-RLK1 to establish molecular targets and cross-talk mechanisms between relevant biosynthesis pathways to provide new urgently needed resistance strategies for a variety of important crop plants by characterizing the molecular players involved in disease resistance in a plant.

## SUMMARY OF THE INVENTION

[0015] The above object was achieved by identifying the molecular basis of the maize Htn1 northern corn leaf blight (NCLB) resistance that is caused by the WAK gene ZmWAK-RLK1. It was demonstrated that ZmWAK-RLK1 modulates, i.e. it functions upstream of the benzoxazinoids (BXD) biosynthesis pathway, resulting in reduced BXD concentrations. Furthermore, the interaction of WAK with downstream effectors, i.e., BX enzymes and Igl, in the regulation of BXD biosynthesis and fungal disease were demonstrated. Furthermore, the present invention builds on relevant information of the cross-talk and cross-regulation of the plant WAK signaling pathway with the jasmonic acid (JA) and further relevant plant biosynthesis pathways to elucidate the regulatory networks important to modulate and to induce plant defense against major pathogens.
[0016] Interestingly, maize plants with compromised BXD biosynthesis showed increased resistance against NCLB. Thus, these new insight into WAK-mediated quantitative disease resistance and for the first time provided a functional link between WAKs and the secondary metabolites BXDs which was used to define new fungal defense strategies going beyond the use of fungicides for disease control which are applicable for several associated fungal pathogens inducing comparable plant immune reactions by pathogen-associated PAMPs/DAMPs in several important crop plants.
[0017] The present invention thus transforms the information on molecular mechanisms, the effect of specific mutations in kinase domains on the signaling function of a WAK, and further on the cross-talk and interplay of signaling cascades to provide plants having a defined genetic background and thus to provide plants with increased resistance against fungal pathogens. Furthermore, the present invention provides methods to modulate (increase/decrease) or
neutralize the action of plant secondary metabolites and the relevant genes responsible for the synthesis pathways of said secondary metabolites to enhance fungal pathogen resistance in a targeted way.
[0018] In one aspect, there is thus provided a method for producing a plant having increased fungal resistance as compared to a corresponding control plant, wherein the fungal resistance is regulated by at least one wall-associated kinase, the method comprising: (i) (a) providing at least one plant cell, tissue, organ, or whole plant having a specific genotype with respect to the presence of at least one gene encoding a wall-associated kinase in the genome of said plant cell, tissue, organ, or whole plant; or (i) (b) introducing at least one gene encoding at least one wall-associated kinase into the genome of at least one cell of at least one of a plant cell, tissue, organ, or whole plant; and (ii) (a) modifying at least one gene encoding at least one wallassociated kinase in the at least one plant cell, tissue, organ, or whole plant; and/or (ii) (b) modulating the expression level of at least one wall-associated kinase and/or the transcription level, the expression level, or the function of at least one molecule within the signalling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid or within the synthesis pathway of at least one benzoxazinoid in the at least one plant cell, tissue, organ, or whole plant; (iii) producing a population of plants from the at least one plant cell, tissue, organ, or whole plant, and (iv) selecting/identifying a plant having increased fungal resistance, from the population based on the determination of a reduced synthesis of at least one benzoxazinoid preferably in response to a fungal pathogen infection, wherein the selected plant have an increased fungal resistance based on the reduced synthesis of a benzoxazinoid, and/or wherein the synthesis of the at least one benzoxazinoid is regulated by the at least one wall-associated kinase.
[0019] In one embodiment of the various aspects of the present invention, the at least one wall-associated kinase is a WAK-RLK1 gene, preferably selected from Htn1, Ht2, or Ht 3 , or an allelic variant thereof, a mutant or a functional fragment thereof, or a gene encoding the same, preferably wherein the at least one wall-associated kinase a) is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 7 , or a functional fragment thereof, $b$ ) is encoded by a nucleic acid molecule comprising the nucleotide sequence having at least $60 \%, 65 \%, 70 \%$, $75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%, 87 \%, 88 \%$, $89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to nucleotide sequence of SEQ ID NO: 1 or 7, preferably over the entire length of the sequence, c) is encoded a nucleic acid molecule hybridizing with a complementary sequence to a) or b) under stringent conditions, d) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence of SEQ ID NO: 2 or 8 , or a functional fragment thereof, e) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence having at least $60 \%, 65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%, 83 \%$, $84 \%, 85 \%, 86 \%, 87 \%, 88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%$, $94 \%, 95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to amino acid sequence of SEQ ID NO: 2 or 8, preferably over the entire length of the sequence, f) comprising the amino acid sequence of SEQ ID NO: 2 or 8 , or g) comprising an amino acid sequence having at least $60 \%, 65 \%, 70 \%, 75 \%$, $80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%, 87 \%, 88 \%, 89 \%$,
$90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to amino acid sequence of SEQ ID NO: 2 or 8 , preferably over the entire length of the sequence, provided that the any sequence of a) to $g$ ), optionally after expression, still encodes at least one functional Htn1, Ht2, or Ht3, or an allelic variant, a mutant, or a functional fragment thereof. Preferably, the at least one wall-associated kinase of the invention causes after expression a reduced synthesis of at least one benzoxazinoid. More preferably, in Zea mays the gene or nucleic acid molecule encoding the at least one wall-associated kinase is located at or mapped on a locus in bin 5 or bin 6 on the long arm of chromosome 8 .
[0020] In a further embodiment of the various aspects of the present invention, the benzoxazinoid whose biosynthesis is regulated by the at least one wall-associated kinase, is selected from at least one of DIM $_{2} \mathrm{BOA}$, DIMBOA, HMBOA, $\mathrm{HM}_{2} \mathrm{BOA}, \mathrm{HDMBOA}, \mathrm{HDM}_{2} \mathrm{BOA}, \mathrm{HBOA}$, DHBOA, DIBOA or TRIBOA, the aforementioned benzoxazinoid being in the glucoside or aglucone form, or a benzoxazolinone, or any combination of the aforementioned benzoxazinoids, preferably wherein the benzoxazinoid whose biosynthesis is regulated by the at least one wallassociated kinase is selected from at least one of DIM $_{2} \mathrm{BOA}$, DIMBOA, HMBOA or HDMBOA, the aforementioned benzoxazinoid being in the glucoside or aglucone form, or any combination of the aforementioned benzoxazinoids.
[0021] In another embodiment, there is provided a method, wherein the reduced synthesis of at least one benzoxazinoid is achieved by providing at least one wallassociated kinase, an allelic variant, a mutant or a functional fragment thereof, or a gene encoding the same, wherein the at least one wall-associated kinase comprises a sequence which can directly or indirectly influence the benzoxazinoid (synthesis) pathway and at least one further plant metabolic pathway, preferably a disease resistance associated pathway, wherein the plant metabolic pathway is selected from the group consisting of the jasmonic acid pathway, the ethylene pathway, the lignin synthesis pathway, a defense pathway, a receptor-like kinase pathway, and/or a cell wall associated pathway.
[0022] In yet a further embodiment of the various aspects of the present invention, the fungus resistance against which resistance is increased, or the disease caused by said fungus is selected from a fungus of the order of Pleosporales, comprising E. turcicum/H. turcicum causing northern corn leaf blight (NCLB), particularly affecting maize and wheat plants, southern corn leaf blight (Bipolaris maydis), the order of Pucciniales causing rust disease, comprising common rust (Puccinia sorghi), or Diploida leaf streak/blight (Diploida macrospora/Stenocarpella macrospora), or Colletotrichum graminicola, or Fusarium spp., preferably Fusarium verticilioides causing Fusarium stalk rot, or Gibberella spp., e.g., Gibberella zeae causing Giberella stalk rot, rust, stalk rot, maize head smut (Sphacelotheca reiliana), and Diploida leaf streak/blight.
[0023] In one of the embodiments of the various aspects of the present invention, the at least one gene encoding at least one wall-associated kinase is stably integrated/introduced into the genome of the at least one plant cell, tissue, organ, or whole plant, or the at least one gene encoding at least one wall-associated kinase is transiently introduced into a plant cell, tissue, organ, or whole plant.
[0024] In a further embodiment of the various aspects of the present invention, the at least one molecule within the
signalling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid or within the synthesis pathway of at least one benzoxazinoid is selected from the group consisting of the genes bx1 (SEQ ID NO: 10), bx2 (SEQ ID NO: 12), ig1 (SEQ ID NO: 14), bx6 (SEQ ID NO: 16), bx11 (SEQ ID NO: 18), bx 14 (SEQ ID NO: 20), opr2 (SEQ ID NO: 22), lox3 (SEQ ID NO: 24) or aoc1 (SEQ ID NO: 26), or a homologous genes thereof, or the proteins BX1 (SEQ ID NO: 11), BX2 (SEQ ID NO: 13), IGL (SEQ ID NO: 15), BX6 (SEQ ID NO: 17), BX11 (SEQ ID NO: 19), BX14 (SEQ ID NO: 21), OPR2 (SEQ ID NO: 23), LOX3 (SEQ ID NO: 25) or AOC1 gene (SEQ ID NO: 27), or a homolog thereof.
[0025] In another embodiment of the various aspects of the present invention, the at least one gene encoding at least one wall-associated kinase is stably integrated into the genome of the at least one plant cell, tissue, organ, or whole plant, and the introduction of the at least one gene encoding at least one wall-associated kinase comprises the introgression of the at least one gene during plant breeding.
[0026] In a further embodiment of the of the various aspects of the present invention, the modification of the at least one gene encoding at least one wall-associated kinase within step (ii) (a) or (ii) (b) of the method of the above disclosed aspect is performed by at least one of a sitespecific nuclease (SSN) or a catalytically active fragment thereof, or a nucleic acid sequence encoding the same, oligonucleotide directed mutagenesis, chemical mutagenesis, or TILLING.
[0027] In a further embodiment of the of the various aspects of the present invention, the at least one site-specific nuclease (SSN), or the nucleic acid sequence encoding the same, is selected from at least one of a CRISPR nuclease, including Cas or Cpfl nucleases, a TALEN, a ZFN, a meganuclease, a base editor complex, a restriction endonuclease, including FokI or a variant thereof, or two sitespecific nicking endonucleases, or a variant or a catalytically active fragment thereof.
[0028] According to one embodiment of the various aspects of the present invention, the at least one plant cell, tissue, organ, or whole plant provided in step (i) is selected from the group consisting of Hordeum vulgare, Hordeum bulbusom, Sorghum bicolor, Saccharum officinarium, Zea spp., including Zea mays, Setaria italica, Oryza minuta, Oryza sativa, Oryza australiensis, Oryza alta, Triticum aestivum, Triticum durum, Secale cereale, Triticale, Malus domestica, Brachypodium distachyon, Hordeum marinum, Aegilops tauschii, Daucus glochidiatus, Beta spp., including Beta vulgaris, Daucus pusillus, Daucus muricatus, Daucus carota, Eucalyptus grandis, Nicotiana sylvestris, Nicotiana tomentosiformis, Nicotiana tabacum, Nicotiana benthamiana, Solanum lycopersicum, Solanum tuberosum, Coffea canephora, Vitis vinifera, Erythrante guttata, Genlisea aurea, Cucumis sativus, Marus notabilis, Arabidopsis arenosa, Arabidopsis lyrata, Arabidopsis thaliana, Crucihimalaya himalaica, Crucihimalaya wallichii, Cardamine nexuosa, Lepidium virginicum, Capsella bursa pastoris, Olmarabidopsis pumila, Arabis hirsute, Brassica napus, Brassica oleracea, Brassica rapa, Raphanus sativus, Brassica juncacea, Brassica nigra, Eruca vesicaria subsp. sativa, Citrus sinensis, Jatropha curcas, Populus trichocarpa, Medicago truncatula, Cicer yamashitae, Cicer bijugum, Cicer arietinum, Cicer reticulatum, Cicer judaicum, Cajanus cajanifolius, Cajanus scarabaeoides, Phaseo-
lus vulgaris, Glycine max, Gossypium sp., Astragalus sinicus, Lotus japonicas, Torenia fournieri, Allium cepa, Allium fistulosum, Allium sativum, Helianthus annuus, Helianthus tuberosus and Allium tuberosum, or any variety or subspecies belonging to one of the aforementioned plants, preferably wherein the plant cell, tissue, organ, or whole plant in step (i) is selected from Zea mays or Triticum spp., or any variety or subspecies belonging to one of the aforementioned plants
[0029] In a further aspect, there is provided a plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, obtainable by a method according to any one of the embodiments of the methods of the present invention.
[0030] In a further aspect of the present invention, there is provided a method for identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material as compared to a corresponding control plant cell, tissue, organ, whole plant, or plant material the method comprising: (i) determining the genotype of at least one plant cell, tissue, organ, whole plant, or plant material with respect to the presence of at least one gene encoding a wall-associated kinase in the genome of said plant cell, tissue, organ, whole plant or plant material; (ii) optionally: determining the benzoxazinoid signature of the at least one plant cell, tissue, organ, whole plant, or plant material of step (i); (iii) exposing the at least one plant cell, tissue, organ, whole plant, or plant material of step (i) or (ii) to a stimulus, optionally wherein the stimulus is correlated with the benzoxazinoid signature in the at least one plant cell, tissue, organ, whole plant, or plant material, preferably wherein the stimulus is associated with a fungal pathogen infection; (iv) performing an analysis of at least one analyte obtained from the at least one plant cell, tissue, organ, whole plant, or plant material of step (i) or (ii) after exposition to the stimulus; (v) determining at least one gene being regulated upon exposition to a stimulus according to step (iii) in at least one cell of the at least one plant cell, tissue, organ, whole plant, or plant material as derivable from the analysis of at least one analyte as defined in step (iv), (vi) subjecting the at least one gene as determined in step (v) to a functional characterization; and (vii) providing at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material.
[0031] Further provided is a plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, obtainable by introducing at least one gene as provided by the method for identifying at least one gene involved in increased pathogen resistance into at least one cell of at least one of a plant cell, tissue, organ, or whole plant.
[0032] In another embodiment of the present invention, there is provided a plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, obtainable by the methods of the present invention, wherein the introduction of at least one gene as provided by the method for identifying at least one gene involved in increased pathogen resistance is a stable introduction, preferably a stable introduction mediated by conventional plant breeding, or a stable introduction mediated by means of molecular biology, comprising genome editing, or a combination thereof.
[0033] In yet a further aspect of the present invention there is provided a method of increasing pathogen resistance, preferably fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material as compared to a corresponding control plant cell, tissue, organ, whole plant, or plant material, the method comprising: (i) providing at least one plant cell, tissue, organ, whole plant or plant material; (ii) (a) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance neutralizing the effect of at least one benzoxazinoid, and/or (ii) (b) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance activating the signalling pathway downstream of at least one wall-associated kinase; and/or (ii) (c) modifying at least one promoter or at least one regulatory sequence of at least one gene of the at least one plant cell, tissue, organ, whole plant or plant material of step (i), wherein said at least promoter or at least one regulatory sequence is involved in the regulation of transcription of at least on gene involved in the signalling pathway of, or downstream of at least one wall-associated kinase; (iii) reducing the amount of at least one benzoxazinoid and thereby increasing pathogen resistance, preferably fungal resistance, in at least one plant cell, tissue, organ, whole plant, or plant material.
[0034] Further provided is a use of a substance as defined for the aspect of a method of increasing pathogen resistance for increasing pathogen resistance, preferably fungal resistance, in at least one plant cell, tissue, organ, whole plant, or plant material.

## Definitions

[0035] The term "active fragment" or "functional fragment" as used herein referring to amino acid sequences denotes the core sequence derived from a given template amino acid sequence, or a nucleic acid sequence encoding the same, comprising all or part of the active site of the template sequence with the proviso that the resulting catalytically active fragment still possesses the activity characterizing the template sequence, for which the active site of the native enzyme or a variant thereof is responsible. Said modifications are suitable to generate less bulky amino acid sequences still having the same activity as a template sequence making the catalytically active fragment a more versatile or more stable tool being sterically less demanding. For amino acid sequences not representing enzymes, the term "functional fragment" can also imply that part or domain of the amino acid sequence involved in interaction with another molecule, and/or involved in any structural function within the cell.
[0036] An "allele" or "allelic variant" as used herein refers to a variant form of a given gene. As most multicellular organisms have two sets of chromosomes; that is, they are diploid (or, if more chromosome sets are present, they are polyploidy), these chromosomes are referred to as homologous chromosomes. If both alleles at a gene (or locus) on the homologous chromosomes are the same, they and the organism are homozygous with respect to that gene (or locus). If the alleles are different, they and the organism are heterozygous with respect to that gene. Alleles can result in the same, or a different observable phenotype. The term "allele" thus refers to one or two or more nucleotide sequences at a specific locus in the genome. A first allele is on a chromosome, a second on a second chromosome at the same position. If the two alleles are different, they are heterozy-
gous, and if they are the same, they are homozygous. Various alleles of a gene (gene alleles) differ in at least one SNP (single nucleotide polymorphism).
[0037] "Complementary" or "complementarity" as used herein describes the relationship between two DNA, two RNA, or, regarding hybrid sequences according to the present invention, between an RNA and a DNA nucleic acid region. Defined by the nucleobases of the DNA or RNA, two nucleic acid regions can hybridize to each other in accordance with the lock-and-key model. To this end the principles of Watson-Crick base pairing have the basis adenine and thymine/uracil as well as guanine and cytosine, respectively, as complementary bases apply. Furthermore, also non-Watson-Crick pairing, like reverse-Watson-Crick, Hoogsteen, reverse-Hoogsteen and Wobble pairing are comprised by the term "complementary" as used herein as long as the respective base pairs can build hydrogen bonding to each other, i.e., two different nucleic acid strands can hybridize to each other based on said complementarity.
[0038] The term "construct", especially "genetic construct", or "recombinant construct", or "expression construct" as used herein refers to a construct comprising, inter alia, plasmids or plasmid vectors, cosmids, artificial yeast chromosomes or bacterial artificial chromosomes (YACs and BACs), phagemides, bacterial phage based vectors, an expression cassette, isolated single-stranded or doublestranded nucleic acid sequences, comprising DNA and RNA sequences, or amino acid sequences, viral vectors, including modified viruses, and a combination or a mixture thereof, for introduction or transformation, transfection or transduction into a target cell or plant, plant cell, tissue, organ or material according to the present disclosure.
[0039] The term "delivery construct" or "delivery vector" as used herein refers to any biological or chemical means used as a cargo for transporting a nucleic acid, including a hybrid nucleic acid comprising RNA and DNA, and/or an amino acid sequence of interest into a target cell, preferably a eukaryotic cell. The term delivery construct or vector as used herein thus refers to a means of transport to deliver a genetic or a recombinant construct according to the present disclosure into a target cell, tissue, organ or an organism. A vector can thus comprise nucleic acid sequences, optionally comprising sequences like regulatory sequences or localization sequences for delivery, either directly or indirectly, into a target cell of interest or into a plant target structure in the desired cellular compartment of a plant. A vector can also be used to introduce an amino acid sequence or a ribonucleomolecular complex into a target cell or target structure. Usually, a vector as used herein can be a plasmid vector. Furthermore, according to certain preferred embodiments according to the present invention, a direct introduction of a construct or sequence or complex of interest is conducted. The term direct introduction implies that the desired target cell or target structure containing a DNA target sequence to be modified according to the present disclosure is directly transformed or transduced or transfected into the specific target cell of interest, where the material delivered with the delivery vector will exert its effect. The term indirect introduction implies that the introduction is achieved into a structure, for example, cells of leaves or cells of organs or tissues, which do not themselves represent the actual target cell or structure of interest to be transformed, but those structures serve as basis for the systemic spread and transfer of the vector, preferably comprising a genetic construct
according to the present disclosure to the actual target structure, for example, a meristematic cell or tissue, or a stem cell or tissue. In case the term vector is used in the context of transfecting amino acid sequences and/or nucleic sequences, including hybrid nucleic acid sequences, into a target cell the term vector implies suitable agents for peptide or protein transfection, like for example ionic lipid mixtures, cell penetrating peptides (CPPs), or particle bombardment. In the context of the introduction of nucleic acid material, the term vector cannot only imply plasmid vectors but also suitable carrier materials which can serve as basis for the introduction of nucleic acid and/or amino acid sequence delivery into a target cell of interest, for example by means of particle bombardment. Said carrier material comprises, inter alia, gold or tungsten particles. Finally, the term vector also implies the use of viral vectors for the introduction of at least one genetic construct according to the present disclosure like, for example, modified viruses and bacterial vectors, like for example Agrobacterium spp., like for example Agrobacterium tumefaciens. Finally, the term vector also implies suitable chemical transport agents for introducing linear nucleic acid sequences (single- or doublestranded), or amino sequences, or a combination thereof into a target cell combined with a physical introduction method, including polymeric or lipid-based delivery constructs.
[0040] Suitable "delivery constructs" or "vectors" thus comprise biological means for delivering nucleotide and/or amino acid sequences into a target cell, including viral vectors, Agrobacterium spp., or chemical delivery constructs, including nanoparticles, e.g., mesoporous silica nanoparticles (MSNPs), cationic polymers, including PEI (polyethylenimine) polymer based approaches or polymers like DEAE-dextran, or non-covalent surface attachment of PEI to generate cationic surfaces, lipid or polymeric vesicles, or combinations thereof. Lipid or polymeric vesicles may be selected, for example, from lipids, liposomes, lipid encapsulation systems, nanoparticles, small nucleic acid-lipid particle formulations, polymers, and polymersomes.
[0041] The term "derivative" or "descendant" or "progeny" as used herein in the context of a prokaryotic or a eukaryotic cell, preferably a plant or plant cell or plant material according to the present disclosure relates to the descendants of such a cell or material which result from natural reproductive propagation including sexual and asexual propagation. It is well known to the person having skill in the art that said propagation can lead to the introduction of mutations into the genome of an organism resulting from natural phenomena which results in a descendant or progeny, which is genomically different to the parental organism or cell, however, still belongs to the same genus/ species and possesses mostly the same characteristics as the parental recombinant host cell. Such derivatives or descendants or progeny resulting from natural phenomena during reproduction or regeneration are thus comprised by the term of the present disclosure. These terms, therefore, do not refer to any arbitrary derivative, descendant or progeny, but rather to a derivative, or descendant or progeny phylogenetically associated with, i.e., based on, a parent cell thereof, whereas this relationship between the derivative, descendant or progeny and the "parent" is clearly inferable by a person skilled in the art. "Progeny" comprises any subsequent generation of a plant, plant cell, plant tissue, or plant organ.
[0042] Furthermore, the term "derivative" can imply, in the context of a substance or molecule rather than referring to a cell or organism, directly or by means of modification indirectly obtained from another. This might imply a nucleic acid sequence derived from a cell or a plant metabolite obtained from a cell or material.
[0043] Furthermore, the terms "derived", or "derived from" as used herein in the context of a biological sequence (nucleic acid or amino acid) or a molecule or a complex imply that the respective sequence is based on a reference sequence, for example from the sequence listing, or a database accession number, or the respective scaffold structure, i.e., originating from said sequence, whereas the reference sequence can comprise more sequences, e.g., the whole genome or a full polyprotein encoding sequence, of a virus, whereas the sequence "derived from" the native sequence may only comprise one isolated fragment thereof, or a coherent fragment thereof. In this context, a cDNA molecule or a RNA can be said to be "derived from" a DNA sequence serving as molecular template. The skilled person can thus easily define a sequence "derived from" a reference sequence, which will, by sequence alignment on DNA or amino acid level, have a high identity to the respective reference sequence and which will have coherent stretches of DNA/amino acids in common with the respective reference sequence ( $>75 \%$ query identity for a given length of the molecule aligned provided that the derived sequence is the query and the reference sequence represents the subject during a sequence alignment). The skilled person can thus clone the respective sequences based on the disclosure provided herein by means of polymerase chain reactions and the like into a suitable vector system of interest, or use a sequence as vector scaffold. The term "derived from" is thus no arbitrary sequence, but a sequence corresponding to a reference sequence it is derived from, whereas certain differences, e.g., certain mutations naturally occurring during replication of a recombinant construct within a host cell, cannot be excluded and are thus comprised by the term "derived from". Furthermore, several sequence stretches from a parent sequence can be concentrated in a sequence derived from the parent. The different stretches will have high or even $100 \%$ homology to the parent sequence.
[0044] The term an "endogenous" in the context of nucleic acid and/or amino acid sequences refers to the nucleic acid and/or amino acid as found in a plant genome in its natural form and natural genetic context. As it is known to the skilled person, several variants, e.g., allelic variants, of a gene nucleic acid sequence may exist in a given species of plants.
[0045] A "fungus" or "fungal pathogen" as used herein means any plant pathogenic fungus including oomycetes in any developmental stage, including spores, or any part of such a fungus, which can interact with a plant or plant part or cell to induce a response in said plant or plant part or cell.
[0046] As used herein, "fusion" can refer to a protein and/or nucleic acid comprising one or more non-native sequences (e.g., moieties). A fusion can be at the N-terminal or C-terminal end of the modified protein, or both, or within the molecule as separate domain. For nucleic acid molecules, the fusion molecule can be attached at the $5^{\prime}$ or $3^{\prime}$ end, or at any suitable position in between. A fusion can be a transcriptional and/or translational fusion. A fusion can comprise one or more of the same non-native sequences. A fusion can comprise one 10 or more of different non-native
sequences. A fusion can be a chimera. A fusion can comprise a nucleic acid affinity tag. A fusion can comprise a barcode. A fusion can comprise a peptide affinity tag. A fusion can provide for subcellular localization of the site-specific effector or base editor (e.g., a nuclear localization signal (NLS) for targeting to the nucleus, a mitochondrial localization signal for targeting to the mitochondria, a chloroplast localization signal for targeting to a chloroplast, an endoplasmic reticulum (ER) retention signal, and the like). A fusion can provide a non-native sequence (e.g., affinity tag) that can be used to track or purify. A fusion can be a small molecule such as biotin or a dye such as alexa fluor dyes, Cyanine3 dye, Cyanine 5 dye. The fusion can provide for increased or decreased stability. In some embodiments, a fusion can comprise a detectable label, including a moiety that can provide a detectable signal. Suitable detectable labels and/or moieties that can provide a detectable signal can include, but are not limited to, an enzyme, a radioisotope, a member of a specific binding pair; a fluorophore; a fluorescent reporter or fluorescent protein; a quantum dot; and the like. A fusion can comprise a member of a FRET pair, or a fluorophore/ quantum dot donor/acceptor pair. A fusion can comprise an enzyme. Suitable enzymes can include, but are not limited to, horse radish peroxidase, luciferase, beta- 25 galactosidase, and the like. A fusion can comprise a fluorescent protein. Suitable fluorescent proteins can include, but are not limited to, a green fluorescent protein (GFP), (e.g., a GFP from Aequoria victoria, fluorescent proteins from Anguilla japonica, or a mutant or derivative thereof), a red fluorescent protein, a yellow fluorescent protein, a yellow-green fluorescent protein (e.g., mNeonGreen derived from a tetrameric fluorescent protein from the cephalochordate Branchiostoma lanceolatum) any of a variety of fluorescent and colored proteins. A fusion can comprise a nanoparticle. Suitable nanoparticles can include fluorescent or luminescent nanoparticles, and magnetic nanoparticles, or nanodiamonds, optionally linked to a nanoparticle. Any optical or magnetic property or characteristic of the nanoparticle(s) can be detected. A fusion can comprise a helicase, a nuclease (e.g., Fok1), an endonuclease, an exonuclease (e.g., a $5^{\prime}$ exonuclease and/or 3' exonuclease), a ligase, a nickase, a nuclease-helicase (e.g., Cas3), a DNA methyltransferase (e.g., Dam), or DNA demethylase, a histone methyltransferase, a histone demethylase, an acetylase (including for example and not limitation, a histone acetylase), a deacetylase (including for example and not limitation, a histone deacetylase), a phosphatase, a kinase, a transcription (co-) activator, a transcription (co-) factor, an RNA polymerase subunit, a transcription repressor, a DNA binding protein, a DNA structuring protein, a long non-coding RNA, a DNA repair protein (e.g., a protein involved in repair of either single- and/or double-stranded breaks, e.g., proteins involved in base excision repair, nucleotide excision repair, mismatch repair, NHEJ, HR, microhomology-mediated end joining (MMEJ), and/or alternative non-homologous endjoining (ANHEJ), such as for example and not limitation, HR regulators and HR complex assembly signals), a marker protein, a reporter protein, a fluorescent protein, a ligand binding protein (e.g., mCherry or a heavy metal binding protein), a signal peptide (e.g., Tat-signal sequence), a targeting protein or peptide, a subcellular localization sequence (e.g., nuclear localization sequence, a chloroplast localization sequence), and/or an antibody epitope, or any combination thereof.
[0047] The term "genetically modified" or "genetic manipulation" or "genetic(ally) manipulated" is used in a broad sense herein and means any modification of a nucleic acid sequence or an amino acid sequence, a target cell, tissue, organ or organism, which is accomplished by human intervention, either directly or indirectly, to influence the endogenous genetic material or the transciptome or the proteome of a target cell, tissue, organ or organism to modify it in a purposive way so that it differs from its state as found without human intervention. The human intervention can either take place in vitro or in vivo/in planta, or also both. Further modifications can be included, for example, one or more point mutation(s), e.g. for targeted protein engineering or for codon optimization, deletion(s), and one or more insertion(s) or deletion(s) of at least one nucleic acid or amino acid molecule (including also homologous recombination), modification of a nucleic acid or an amino acid sequence, or a combination thereof. The terms shall also comprise a nucleic acid molecule or an amino acid molecule or a host cell or an organism, including a plant or a plant material thereof which is/are similar to a comparable sequence, organism or material as occurring in nature, but which have been constructed by at least one step of purposive manipulation. A "targeted genetic manipulation" or "targeted (base) modification" as used herein is thus the result of a "genetic manipulation", which is effected in a targeted way, i.e. at a specific position in a target cell and under the specific suitable circumstances to achieve a desired effect in at least one cell, preferably a plant cell, to be manipulated, wherein the term implies that the sequence to be targeted and the corresponding modification are based on preceding sequence considerations so that the resulting modification can be planned in advance, e.g., based on available sequence information of a target site in the genome of a cell and/or based on the information of the target specificity (recognition or binding properties of a nucleic acid or an amino acid sequence, complementary base pairing and the like) of a molecular tool of interest.
[0048] The term "genome" refers to the entire complement of genetic material (genes and non-coding sequences) that is present in each cell of an organism, or virus or organelle, and/or a complete set of chromosomes inherited as a (haploid) unit from one parent. The genome thus also defines the "genotype" being the part of the genetic makeup of a given cell, and therefore of an organism or individual, which determines a specific characteristic (phenotype) of that cel1/ organism/individual.
[0049] The terms "genome editing", "genome engineering", or "gene editing/engineering" are used interchangeably herein and refer to strategies and techniques for the targeted, specific modification of any genetic information or genome of a living organism. As such, the terms comprise gene editing, but also the editing of regions other than gene encoding regions of a genome. It further comprises the editing or engineering of the nuclear (if present) as well as other genetic information of a cell. Furthermore, the terms "genome editing" and "genome engineering" also comprise an epigenetic editing or engineering, i.e., the targeted modification of, e.g., methylation, histone modification or of non-coding RNAs possibly causing heritable changes in gene expression.
[0050] "Germplasm", as used herein, is a term used to describe the genetic resources, or more precisely the DNA of an organism and collections of that material. In breeding
technology, the term germplasm is used to indicate the collection of genetic material from which a new plant or plant variety can be created.
[0051] The terms "guide RNA", "gRNA" or "single guide RNA" or "sgRNA" are used interchangeably herein and either refer to a synthetic fusion of a CRISPR RNA (crRNA) and a trans-activating crRNA (tracrRNA), or the term refers to a single RNA molecule consisting only of a crRNA and/or a tracrRNA, or the term refers to a gRNA individually comprising a crRNA or a tracrRNA moiety. The tracr and the crRNA moiety thus do not necessarily have to be present on one covalently attached RNA molecule, yet they can also be comprised by two individual RNA molecules, which can associate or can be associated by non-covalent or covalent interaction to provide a gRNA according to the present disclosure. The terms "gDNA" or "sgDNA" or "guide DNA" are used interchangeably herein and either refer to a nucleic acid molecule interacting with an Argonaute nuclease. Both, the gRNAs and gDNAs as disclosed herein are termed "guiding nucleic acids" or "guide nucleic acids" due to their capacity to interacting with a site-specific nuclease and to assist in targeting said site-specific nuclease to a genomic target site.
[0052] The term "hybridization" as used herein refers to the pairing of complementary nucleic acids, i.e., DNA and/or RNA, using any process by which a strand of nucleic acid joins with a complementary strand through base pairing to form a hybridized complex. Hybridization and the strength of hybridization (i.e., the strength of the association between the nucleic acids) is impacted by such factors as the degree and length of complementarity between the nucleic acids, stringency of the conditions involved, the Tm of the formed hybrid, and the G:C ratio within the nucleic acids. The term hybridized complex refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bounds between complementary G and C bases and between complementary A and T/U bases. A hybridized complex or a corresponding hybrid construct can be formed between two DNA nucleic acid molecules, between two RNA nucleic acid molecules or between a DNA and an RNA nucleic acid molecule. For all constellations, the nucleic acid molecules can be naturally occurring nucleic acid molecules generated in vitro or in vivo and/or artificial or synthetic nucleic acid molecules. Hybridization as detailed above, e.g., Watson-Crick base pairs, which can form between DNA, RNA and DNA/RNA sequences, are dictated by a specific hydrogen bonding pattern, which thus represents a non-covalent attachment form according to the present invention. In the context of hybridization, the term "stringent hybridization conditions" should be understood to mean those conditions under which a hybridization takes place primarily only between homologous nucleic acid molecules. The term "hybridization conditions" in this respect refers not only to the actual conditions prevailing during actual agglomeration of the nucleic acids, but also to the conditions prevailing during the subsequent washing steps. Examples of stringent hybridization conditions are conditions under which primarily only those nucleic acid molecules that have at least at least $80 \%$, preferably at least $85 \%$, at least $90 \%$ or at least $95 \%$ sequence identity undergo hybridization. Stringent hybridization conditions are, for example: $4 \times \mathrm{SSC}$ at $65^{\circ} \mathrm{C}$. and subsequent multiple washes in $0.1 \times \mathrm{SSC}$ at $65^{\circ} \mathrm{C}$. for approximately 1 hour. The term "stringent hybridization conditions" as used herein may also
mean: hybridization at $68^{\circ} \mathrm{C}$. in 0.25 M sodium phosphate, $\mathrm{pH} 7.2,7 \%$ SDS, 1 mM EDTA and $1 \%$ BSA for 16 hours and subsequently washing twice with $2 \times \mathrm{SSC}$ and $0.1 \%$ SDS at $68^{\circ} \mathrm{C}$. Preferably, hybridization takes place under stringent conditions.
[0053] The term "introgression" as used herein refers to the transfer of at least one allele of a gene of interest on a genetic locus from one genetic background to another. For example, introgression can proceed through sexual crossing of two parents of the same species. Alternatively, the transfer of a gene allele can take place by recombination between two donor genomes, e.g., in a fused protoplast, wherein at least the donor protoplast carries the gene allele of interest in its genome. In any case, any progeny or derivatives comprising the gene allele of interest can then be subjected to repeated back-crossing steps with a plant line carrying a genetic background of interest to select for the gene allele of interest in the resulting derivatives or progeny. The result may be the fixation of the gene allele of interest such introgressed in a selected genetic background. The whole process of introgression can, for example, take place by a mixture of breeding strategies and techniques of molecular biology to achieve at a genotype/phenotype of interest for a given germplasm, plant, plant cell or plant material.
[0054] The term "locus" generally refers to a genetically defined region of a chromosome carrying a gene or, possibly, two or more genes so closely linked that genetically they behave as a single locus responsible for a phenotype.
[0055] As used herein, the terms "mutation" and "modification" are used interchangeably to refer to a deletion, insertion, addition, substitution, edit, strand break, and/or introduction of an adduct in the context of nucleic acid manipulation in vivo or in vitro. A deletion is defined as a change in a nucleic acid sequence in which one or more nucleotides is absent. An insertion or addition is that change in a nucleic acid sequence which has resulted in the addition of one or more nucleotides. A "substitution" or "edit" results from the replacement of one or more nucleotides by a molecule which is a different molecule from the replaced one or more nucleotides. For example, a nucleic acid may be replaced by a different nucleic acid as exemplified by replacement of a thymine by a cytosine, adenine, guanine, or uridine. Pyrimidine to pyrimidine (e.g., C to Tor T to C nucleotide substitutions) or purine to purine (e.g., G to A or A to $G$ nucleotide substitutions) are termed transitions, whereas pyrimidine to purine or purine to pyrimidine (e.g., $G$ to $T$ or $G$ to $C$ or $A$ to $T$ or $A$ to $C$ ) are termed transversions. Alternatively, a nucleic acid may be replaced by a modified nucleic acid as exemplified by replacement of a thymine by thymine glycol. Mutations may result in a mismatch. The term mismatch refers to a non-covalent interaction between two nucleic acids, each nucleic acid residing on a different nucleotide sequence or nucleic acid molecule, which does not follow the base-pairing rules. For example, for the partially complementary sequences 5'-AGT-3' and 5'-AAT-3', a G-A mismatch (a transition) is present.
[0056] "Near isogenic lines" or "NILs" as used herein are useful for identifying genes responsible for a phenotypic trait by mapping them to genetic chromosomes by analyzing NILs. To create a near isogenic line, an organism with the phenotype of interest, often a plant, is crossed with a standard line of the same plant. The F1 generation is selfed to produce the F2 generation. F2 individuals with the target
trait are selected for crossing with the standard line (the recurrent parent). This process is repeated for several generations. The genetic make-ups of sister lines can be compared. Alleles derived from the donor parent that can be found in all sister lines are said to be associated with the trait.
[0057] The terms "nucleotide" and "nucleic acid" with reference to a sequence or a molecule are used interchangeably herein and refer to a single- or double-stranded DNA or RNA of natural or synthetic origin. The term nucleotide sequence is thus used for any DNA or RNA sequence independent of its length, so that the term comprises any nucleotide sequence comprising at least one nucleotide, but also any kind of larger oligonucleotide or polynucleotide. The term(s) thus refer to natural and/or synthetic deoxyribonucleic acids (DNA) and/or ribonucleic acid (RNA) sequences, which can optionally comprise synthetic nucleic acid analoga. A nucleic acid according to the present disclosure can optionally be codon optimized "Codon optimization" implies that the codon usage of a DNA or RNA is adapted to that of a cell or organism of interest to improve the transcription rate of said recombinant nucleic acid in the cell or organism of interest. The skilled person is well aware of the fact that a target nucleic acid can be modified at one position due to the codon degeneracy, whereas this modification will still lead to the same amino acid sequence at that position after translation, which is achieved by codon optimization to take into consideration the species-specific codon usage of a target cell or organism. Nucleic acid sequences according to the present application can carry specific codon optimization for the following non limiting list of organisms: Hordeum vulgare, Sorghum bicolor, Secale cereale, Saccharum officinarium, Zea mays, Setaria italic, Oryza sativa, Oryza minuta, Oryza australiensis, Oryza alta, Triticum aestivum, Triticum durum, Triticale, Hordeum bulbosum, Brachypodium distachyon, Hordeum marinum, Aegilops tauschii, Ma'us domestica, Beta vulgaris, Helianthus annuus, Daucus glochidiatus, Daucus pusillus, Daucus muricatus, Daucus carota, Eucalyptus grandis, Erythranthe guttata, Genlisea aurea, Nicotiana sylvestris, Nicotiana tabacum, Nicotiana tomentosiformis, Nicotiana benthamiana, Solanum/ycopersicum, Solanum tuberosum, Coffea canephora, Vitis vinifera, Cucumis sativus, Marus notabilis, Arabidopsis thaliana, Arabidopsis lyrata, Arabidopsis arenosa, Crucihimalaya himalaica, Crucihimalaya wallichii, Cardamine flexuosa, Lepidium virginicum, Capsella bursa-pastoris, Olmarabidopsis pumila, Arabis hirsuta, Brassica napus, Brassica oleracea, Brassica rapa, Brassica juncacea, Brassica nigra, Raphanus sativus, Eruca vesicaria sativa, Citrus sinensis, Jatropha curcas, Glycine max, Gossypium ssp., or Populus trichocarpa
[0058] The term "particle bombardment" as used herein, also named "biolistic transfection" or "microparticle-mediated gene transfer", refers to a physical delivery method for transferring a coated microparticle or nanoparticle comprising a nucleic acid or a genetic construct of interest into a target cell or tissue. The micro or nanoparticle functions as projectile and is fired on the target structure of interest under high pressure using a suitable device, often called gene-gun. The transformation via particle bombardment uses a microprojectile of metal covered with the gene of interest, which is then shot onto the target cells using an equipment known as "gene gun" (Sanford, John C., et al. "Delivery of substances into cells and tissues using a particle bombardment
process." Particulate Science and Technology 5.1 (1987): 27-37) at high velocity fast enough ( $\sim 1500 \mathrm{~km} / \mathrm{h}$ ) to penetrate the cell wall of a target tissue, but not harsh enough to cause cell death. For protoplasts, which have their cell wall entirely removed, the conditions are different logically. The precipitated nucleic acid or the genetic construct on the at least one microprojectile is released into the cell after bombardment, and integrated into the genome. The acceleration of microprojectiles is accomplished by a high voltage electrical discharge or compressed gas (helium). Concerning the metal particles used it is mandatory that they are non-toxic, non-reactive, and that they have a lower diameter than the target cell. The most commonly used are gold or tungsten. There is plenty of information publicly available from the manufacturers and providers of gene-guns and associated system concerning their general use.
[0059] A "pathogen" as used herein refers to an organism which can infect a plant, or which can cause a disease in a plant. Pathogens which can infect a plant, or which can cause a disease in a plant, include fungi, oomycetes, bacteria, viruses, viroids, virus-like organisms, phytoplasmas, protozoa, nematodes and parasitic plants. Plant parasites can cause damage by feeding on a plant and can be selected from ectoparasites like insects, comprising aphids and other sapsucking insect, mites, and vertebrates.
[0060] The term "plant" as used herein is to be construed broadly and refers to a whole plant organism, a plant organ, differentiated and undifferentiated plant tissues, plant cells, seeds, and derivatives and progeny thereof. "Plant cells" include without limitation, for example, cells from seeds, from mature and immature embryos, meristematic tissues, seedlings, callus tissues in different differentiation states, leaves, flowers, roots, shoots, gametophytes, grains, kernels, sporophytes, pollen and microspores, protoplasts, macroalgae and microalgae. The different plant cells can either be haploid, diploid or multiploid. The term "plant organ" refers to plant tissue or a group of tissues that constitute a morphologically and functionally distinct part of a plant. Typically, the term "grain" is used to describe the mature kernel produced by a plant grower for purposes other than growing or reproducing the species, and "seed" means the mature kernel used for growing or reproducing the species. For the purposes of the present invention, "grain", "seed", and "kernel", will be used interchangeably.
[0061] A "plant material" as used herein refers to any material which can be obtained from a plant during any developmental stage. The plant material can be obtained either in planta or from an in vitro culture of the plant or a plant tissue or organ thereof. The term thus comprises plant cells, tissues and organs as well as developed plant structures as well as sub-cellular components like nucleic acids, polypeptides and all chemical plant substances or metabolites which can be found within a plant cell or compartment and/or which can be produced by the plant, or which can be obtained from an extract of any plant cell, tissue or a plant in any developmental stage. The term also comprises a derivative of the plant material, e.g., a protoplast, derived from at least one plant cell comprised by the plant material. The term therefore also comprises meristematic cells or a meristematic tissue of a plant.
[0062] A "control" or "control plant cell" or "control tissue" or "control organ" or "control plant" provides reference point for measuring changes in phenotype of a subject plant or plant part in which (genetic) modification,
modulation and/or alteration, such as indicated in the various aspects of the present invention, has been affected to a gene, a protein or a substance or molecule of interest. A control plant or control plant part (e.g. control plant cell, control tissue, or control organ) may comprise, for example: (a) a wild-type plant or cell, i.e., of the same genotype as the starting material for the (genetic) modification, modulation and/or alteration which resulted in the subject plant or plant part; (b) a plant or plant part of the same genotype as the starting material but which has been transformed with a null construct (i.e., with a construct which has no known effect on the trait of interest, such as a construct comprising a marker gene); or (c) a plant or plant part which is a non-transformed segregant among progeny of a subject plant or plant part. In particular, a control plant or control plant cell may comprise a plant or plant part of the same genotype, but lacking the modification of the at least one gene encoding at least one wall-associated kinase or the modulation of the expression level of at least one wall-associated kinase and/or the transcription level, the expression level, or the function of at least one molecule within the signaling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid or within the synthesis pathway of at least one benzoxazinoid.
[0063] A "plasmid" refers to a circular autonomously replicating extrachromosomal element in the form of a double-stranded nucleic acid sequence. In the field of genetic engineering these plasmids are routinely subjected to targeted modifications by inserting, for example, genes encoding a resistance against an antibiotic or an herbicide, a gene encoding a target nucleic acid sequence, a localization sequence, a regulatory sequence, a tag sequence, a marker gene, including an antibiotic marker or a fluorescent marker, and the like. The structural components of the original plasmid, like the origin of replication, are maintained. According to certain embodiments of the present invention, the localization sequence can comprise a nuclear localization sequence, a plastid localization sequence, preferably a mitochondrion localization sequence or a chloroplast localization sequence, or a localization sequence for targeting a kinase of interest to the plasma membrane of a cell of interest. Said localization sequences are available to the skilled person in the field of plant biotechnology. A variety of plasmid vectors for use in different target cells of interest is commercially available and the modification thereof is known to the skilled person in the respective field.
[0064] The terms "protein", "amino acid" or "polypeptide" are used interchangeably herein and refer to an amino acid sequence having a catalytic enzymatic function or a structural or a functional effect. The term "amino acid" or "amino acid sequence" or "amino acid molecule" comprises any natural or chemically synthesized protein, peptide, polypeptide and enzyme or a modified protein, peptide, polypeptide and enzyme, wherein the term "modified" comprises any chemical or enzymatic modification of the protein, peptide, polypeptide and enzyme, including truncations of a wild-type sequence to a shorter, yet still active portion. In accordance with the present invention there may be employed conventional molecular biology, microbiology, and recombinant DNA techniques within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch \& Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989) Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (herein
"Sambrook et al., 1989"); DNA Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis (M. J. Gait ed. 1984); Nucleic Acid Hybridization (B. D. Hames \& S J. Higgins eds. (1985); Transcription and Translation (B. D. Hames \& S. J. Higgins, eds. (1984); among others.
[0065] The term "regulatory sequence" or "regulatory region" as used herein refers to a nucleic acid or an amino acid sequence, which can direct and/or influence the transcription and/or translation and/or modification of a nucleic acid sequence of interest. A regulatory sequence may be a promoter sequence, an enhancer, a silencer, a transcription factor and the like.
[0066] The terms "resistance" or "tolerance" or "resistant" or "tolerant" as used herein refers to the capacity of a plant to resist to the phenotype as caused by infestation with a pathogen, in particular a fungal pathogen, disclosed herein to a certain degree, i.e., the prevention, reduction or delay of an infection caused by a (fungal) pathogen. "Resistance"/ "Tolerance", therefore, does not exclusively refer to a "black or white" phenotype implying a phenotype where no symptoms occur at all after infestation for a resistant plant. The terms "resistance" or "tolerance" or "resistant" or "tolerant" rather imply a gradual improvement of infestation symptoms as observed for a plant having no resistance to a given pathogen. A classification score scheme for phenotyping experiments in field trials at various locations with natural and artificial H. turcicum inoculation (from the Deutsche Maiskomitee (DMK, German maize committee); AG variety 27.02.02; (DMK J. Rath; R P Freiburg H. J. Imgraben) shows a resistance level from 9 (low) to 1 (high) for maize as exemplary plant, wherein each score represents the following phenotype: 1: Plants exhibit no symptoms of disease, $0 \%$; 2: Beginning of infestation, first small spots (less than 2 cm ) visible. Less than $5 \%$ of leaf surface affected. 3: Some spots have developed on a leaf stage. Between 5-10\% of leaf surface affected. 4: 10-20\% of leaf surface affected. Clearly visible spots on several leaf stages. 5: 20-40\% of leaf surface affected. Spots start to coalesce. 6: 40-60\% of leaf surface affected. Systematic infestation visible on leaves. 7: 60-80\% of leaf surface affected. Approximately half of leaves destroyed or dried out because of fungal infestation. 8: $80-90 \%$ of leaf surface affected. More than half of leaves destroyed or dried out because of fungal infestation. 9: $90-100 \%$ of leaf surface affected. The plants are almost completely dried out.
[0067] The term "TILLING" as used herein is an abbreviation for "Targeting Induced Local Lesions in Genomes" and describes a well-known reverse genetics technique designed to detect unknown SNPs (single nucleotide polymorphisms) in genes of interest using an enzymatic digestion and is widely employed in plant genomics. The technique allows for the high-throughput identification of an allelic series of mutants with a range of modified functions for a particular gene. TILLING combines mutagenesis (e.g., chemical or via UV-light) with a sensitive DNA screeningtechnique that identifies single base mutations.
[0068] The terms "transgene" or "transgenic" as used herein refer to at least one nucleic acid sequence that is taken from the genome of one organism, or produced synthetically, and which is then introduced into a host cell or organism or tissue of interest and which is subsequently integrated into the host's genome by means of "stable" transformation or transfection approaches. In contrast, the
term "transient" transformation or transfection or introduction refers to a way of introducing molecular tools including at least one nucleic acid (comprising at least one of DNA, RNA, single-stranded or double-stranded or a mixture thereof) and/or at least one amino acid sequence, optionally comprising suitable chemical or biological agents, to achieve a transfer into at least one compartment of interest of a cell, including, but not restricted to, the cytoplasm, an organelle, including the nucleus, a mitochondrion, a vacuole, a chloroplast, or into a membrane, resulting in transcription and/or translation and/or association and/or activity of the at least one molecule introduced without achieving a stable integration or incorporation and thus inheritance of the respective at least one molecule introduced into the genome of a cell.
[0069] The term "transient introduction" as used herein thus refers to the transient introduction of at least one nucleic acid and/or amino acid sequence according to the present disclosure, preferably incorporated into a delivery vector or into a recombinant construct, with or without the help of a delivery vector, into a target structure, for example, a plant cell, wherein the at least one nucleic acid sequence is introduced under suitable reaction conditions so that no integration of the at least one nucleic acid sequence into the endogenous nucleic acid material of a target structure, the genome as a whole, occurs, so that the at least one nucleic acid sequence will not be integrated into the endogenous DNA of the target cell. As a consequence, in the case of transient introduction, the introduced genetic construct will not be inherited to a progeny of the target structure, for example a prokaryotic or a plant cell. The at least one nucleic acid and/or amino acid sequence or the products resulting from transcription, translation, processing, posttranslational modifications or complex building thereof are only present temporarily, i.e., in a transient way, in constitutive or inducible form, and thus can only be active in the target cell for exerting their effect for a limited time. Therefore, the at least one sequence or effector introduced via transient introduction will not be heritable to the progeny of a cell. The effect mediated by at least one sequence or effector introduced in a transient way can, however, potentially be inherited to the progeny of the target cell.
[0070] A "variant" in the context of a nucleic acid or amino acid sequence protein means a nucleic acid or amino acid sequence derived from the native nucleic acid or amino acid sequence, or another starting sequence, by deletion (so-called truncation) or addition of one or more sequences to the $5^{\prime} / \mathrm{N}$-terminal and/or $3^{1} / \mathrm{C}$-terminal end of the native nucleic acid or amino acid sequence; deletion or addition of one or more nucleic acid or amino acid sequence at one or more sites in the native nucleic acid or amino acid sequence; or substitution of one or more nucleic acid or amino acid sequence at one or more sites in the native protein. Variant proteins encompassed by the present invention are biologically active, that is they continue to possess all or some of the activity of the native proteins of the invention as described herein. Such variants may result from, for example, genetic polymorphism or from human manipulation.
[0071] As used herein, a "homolog" means a protein in a group of proteins that perform the same biological function, e.g. proteins that belong to the same Pfam protein family. Homologs are expressed by homologous genes. With reference to homologous genes, homologs include orthologs,
e.g., genes expressed in different species that evolved from a common ancestral genes by speciation and encode proteins retain the same function, but do not include paralogs, e.g., genes that are related by duplication but have evolved to encode proteins with different functions. Homologous genes include naturally occurring alleles and artificially-created variants. Degeneracy of the genetic code provides the possibility to substitute at least one base of the protein encoding sequence of a gene with a different base without causing the amino acid sequence of the polypeptide produced from the gene to be changed. When optimally aligned, homolog proteins have typically at least about $60 \%$ identity, in some instances at least about $70 \%$, for example about $80 \%$ or $85 \%$ and even at least about $90 \%, 92 \%, 94 \%, 96 \%, 97 \%, 98 \%$, $99 \%$ or $99.5 \%$ identity, preferably over the full length of the protein; homologous genes have typically at least about $60 \%$ identity, in some instances at least about $70 \%$, for example about $80 \%$ or $85 \%$ and even at least about $90 \%, 92 \%, 94 \%$, $96 \%, 97 \%, 98 \%, 99 \%$ or $99.5 \%$ identity, preferably over the full length of the gene, in particular the coding regions of the gene. Homologs are identified by comparison of amino acid sequence, e.g. manually or by use of a computer-based tool using known homology-based search algorithms such as those commonly known and referred to as BLAST, FASTA, and Smith-Waterman. A local sequence alignment program, e.g. BLAST, can be used to search a database of sequences to find similar sequences, and the summary Expectation value ( E -value) used to measure the sequence base similarity. Because a protein hit with the best E-value for a particular organism may not necessarily be an ortholog, e.g., have the same function, or be the only ortholog, a reciprocal query is used to filter hit sequences with significant $E$-values for ortholog identification. The reciprocal query entails search of the significant hits against a database of amino acid sequences from the base organism that are similar to the sequence of the query protein. A hit can be identified as an ortholog, when the reciprocal query's best hit is the query protein itself or a protein encoded by a duplicated gene after speciation. A further aspect of the homologs encoded by DNA useful in the transgenic plants of the invention are those proteins that differ from a disclosed protein as the result of deletion or insertion of one or more amino acids in a native sequence.
[0072] Other functional homolog proteins differ in one or more amino acids from those disclosed herein as the result of one or more of the well-known conservative amino acid substitutions, e.g., valine is a conservative substitute for alanine and threonine is a conservative substitute for serine. Conservative substitutions for an amino acid within the native sequence can be selected from other members of a class to which the naturally occurring amino acid belongs. Representative amino acids within these various classes include, but are not limited to: (1) acidic (negatively charged) amino acids such as aspartic acid and glutamic acid; (2) basic (positively charged) amino acids such as arginine, histidine, and lysine; (3) neutral polar amino acids such as glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; and (4) neutral nonpolar (hydrophobic) amino acids such as alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine. Conserved substitutes for an amino acid within a native amino acid sequence can be selected from other members of the group to which the naturally occurring amino acid belongs. For example, a group of amino acids having aliphatic side
chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains is cysteine and methionine. Naturally conservative amino acids substitution groups are: valine-leucine, valineisoleucine, phenylalanine-tyrosine, lysine-arginine, alaninevaline, aspartic acid-glutamic acid, and asparagine-glutamine. A further aspect of the invention includes proteins that differ in one or more amino acids from those of a described protein sequence as the result of deletion or insertion of one or more amino acids in a native sequence.
[0073] Whenever the present disclosure relates to the percentage of the homology or identity of nucleic acid or amino acid sequences these values define those as obtained by using the EMBOSS Water Pairwise Sequence Alignments (nucleotide) programme (www.ebi.ac.uk/Tools/psa/ emboss_water/nucleotide.html) nucleic acids or the EMBOSS Water Pairwise Sequence Alignments (protein) programme (www.ebi.ac.uk/Tools/psa/emboss_water/) for amino acid sequences, preferably over the entire length of the sequence, i.e., any percentage value provided means the $\%$ homology or \% identity as measured over the whole length of a subject or starting sequence in comparison to an identical or variant further sequence. Those tools provided by the European Molecular Biology Laboratory (EMBL) European Bioinformatics Institute (EBI) for local sequence alignments use a modified Smith-Waterman algorithm (see www.ebi.ac.uk/Tools/psa/ and Smith, T. F. \& Waterman, M. S. "Identification of common molecular subsequences" Journal of Molecular Biology, 1981147 (1):195-197). When conducting an alignment, the default parameters defined by the EMBL-EBI are used. Those parameters are (i) for amino acid sequences: Matrix=BLOSUM62, gap open penalty $=10$ and gap extend penalty $=0.5$ or (ii) for nucleic acid sequences: Matrix=DNAfull, gap open penalty=10 and gap extend penalty $=0.5$.

## BRIEF DESCRIPTION OF THE DRAWINGS

[0074] FIG. 1 (FIGS. 1 A and B) shows (FIG. 1 A) the structure of benzoxazinone (BXD) in the aglucone form. Derivatives from the BXD basic structure of FIG. 1 A are: HBOA $\left(R^{1}=H, \quad R^{2}=H, \quad R^{3}=H\right), \quad$ DHBOA $\quad\left(R^{1}=H\right.$, $\mathrm{R}^{2}=\mathrm{OH}, \mathrm{R}^{3}=\mathrm{H}$ ), $\mathrm{HMBOA}\left(\mathrm{R}^{1}=\mathrm{H}, \mathrm{R}^{2}=\mathrm{OMe}, \mathrm{R}^{3}=\mathrm{H}\right)$, $\mathrm{HM}_{2} \mathrm{BOA} \quad\left(\mathrm{R}^{1}=\mathrm{H}, \quad \mathrm{R}^{2}=\mathrm{OMe}, \quad \mathrm{R}^{3}=\mathrm{OMe}\right), \quad$ DIBOA $\left(\mathrm{R}^{1}=\mathrm{OH}, \mathrm{R}^{2}=\mathrm{H}, \mathrm{R}^{3}=\mathrm{H}\right)$, TRIBOA $\left(\mathrm{R}^{1}=\mathrm{OH}, \mathrm{R}^{2}=\mathrm{OH}\right.$, $\left.\mathrm{R}^{3}=\mathrm{H}\right), \quad$ DIMBOA $\quad\left(\mathrm{R}^{1}=\mathrm{OH}, \quad \mathrm{R}^{2}=\mathrm{OMe}, \quad \mathrm{R}^{3}=\mathrm{H}\right)$, $\mathrm{DIM}_{2} \mathrm{BOA}\left(\mathrm{R}^{1}=\mathrm{OH}, \mathrm{R}^{2}=\mathrm{OMe}, \mathrm{R}^{3}=\mathrm{OMe}\right)$, HDMBOA $\left(\mathrm{R}^{1}=\mathrm{OMe}, \mathrm{R}^{2}=\mathrm{OMe}, \mathrm{R}^{3}=\mathrm{H}\right)$, or HDM2BOA $\left(\mathrm{R}^{1}=\mathrm{OMe}\right.$, $\mathrm{R}^{2}=\mathrm{OMe}, \mathrm{R}^{3}=\mathrm{OMe}$ ). FIG. 1 B shows the basic structure of a benzoxazolinone, a natural degradation product of BXDs and also comprised by the term BXD as used herein. Specific benzoxazolinones are $B O A\left(R^{2}=H, R^{3}=H\right)$, MBOA ( $\mathrm{R}^{2}=\mathrm{OMe}, \mathrm{R}^{3}=\mathrm{H}$ ), or $\mathrm{M}_{2} \mathrm{BOA}\left(\mathrm{R}^{2}=\mathrm{OMe}\right.$, $\mathrm{R}^{3}=\mathrm{OMe}$ ).
[0075] FIG. 2 (FIGS. 2 A and B) shows the rate of successful penetration events for fungal penetrations as described in Example 9. (FIG. 2 A) Hyphae detected inside of host tissues. In the upper and lower panels the focus is on the epidermis and hyphae, respectively. The arrows in the
lower image of Fig. A indicate the hyphae inside the host tissues. (FIG. 2 B) RLK1b, RLK1d and RLK1f are ZmWAK-RLK1 mutants with compromised NCLB resistance that were produced in RP3Htn1, while RLK1b-wt, RLK1d-wt and RLK1f-wt are the corresponding sister lines, respectively. Statistics was conducted using Student's $t$ test, based on three independent experiments. The asterisks represent a significant difference of $* * p<0.01$ or $* p<0.05$. Error bars indicate $\pm$ standard error.
[0076] FIG. 3 (FIG. 3 A to C) shows the disease phenotype of Htn1-NILs and the corresponding parents as detailed in Example 10 below. (FIG. 3 A) The disease symptom of the second leaves at 16 dpi (from left to right for the lines w22, w22Htn1, B37 and B37Htn1). (FIG. 3 B) Rate of infected of tested plants B37, w22, w22Htn1, and B37Htn1. (FIG. 3 C) Area under the disease progress curve (AUDPC) for the isogenic lines detailed below the $x$-axis. *AUDPC in this panel was calculated as described in Hurni et al. 2015, based on calculating sum of rate of infected plants (\%).
[0077] FIG. 4 shows the result of a transcriptome analysis in Htn1-NILs, which revealed a set of DEGs. FIG. 4 shows the number of DEGs in the two Htn1 NILs compared to the corresponding susceptible lines as further described in Example 10 below.
[0078] FIG. 5 (FIG. 5 A to F) shows the content of BXDs in w22 and w22Htn1. (FIG. 5 A) shows the proposed bio-synthesis pathway of secondary metabolites BXDs. The genes encoding the proteins catalyzing each step of enzymatic reactions are presented besides and below the arrows. The contents of BXDs compounds DIMBOA-Glc (FIG. 5 B), DIMBOA (FIG. 5 C), HMBOA-Glc (FIG. 5 D), DIM ${ }_{2}$ BOA-Glc (FIG. 5 E ) and HDMBOA-Glc (FIG. 5 F) were determined at before inoculation, at 3 dpi and 10 dpi . The statistics were conducted using Tukey's HSD ( $\mathrm{P}=0.05$ ) in eight biological replicates. The ns stands for no significance. Error bars are $\pm$ SE. See also Example 10 below.
[0079] FIG. 6 (FIG. 6 A to D ) shows that the presence of ZmWAK -RLK1 results in decreased DIM ${ }_{2} \mathrm{BOA}$-Glc content possibly by down-regulating Igl expression in the maize RP3 genetic background (see also Example 11). (A) Content of DIM ${ }_{2}$ BOA-Glc ( $\mathrm{n}=8$ ). Expression analysis of $\mathrm{Bx} 1(\mathrm{~B}), \mathrm{Igl}$ (C) and ZmWAK -RLK 1 (D) in Htn1 mutants and sister lines before infection at 21 days after sowing ( $\mathrm{n}=5$ ). Statistics was conducted using Student's $t$ test. The asterisks represent a significant difference of $* * \mathrm{p}<0.01$ or ${ }^{*} \mathrm{p}<0.05$. Error bars are $\pm$ SE.
[0080] FIG. 7 (FIG. 7 A to E) shows the content of BXDs compounds DIMBOA-Gle (A), DIMBOA (B), HMBOAGlc (C), and DIM ${ }_{2}$ BOA-Glc (D), HDMBOA-Glc (E) in second leaves at 10 dpi . Further information is provided in Example 12 below. The statistics were conducted using Student's $t$ test ( $\mathrm{P}=0.05$ ) in eight biological replicates. The asterisks represent a significant difference of $* * \mathrm{p}<0.01$ or * $\mathrm{p}<0.05$. The ns stands for no significance. Error bars are $\pm$ SE.
[0081] FIG. 8 (FIG. 8 A to D) (see also Example 12) shows that compromising the biosynthesis of BXDs decreases the susceptibility of NCLB disease at the seedling stage. (FIGS. 8 A and B): Visual symptoms and quantified NCLB disease severity in bx mutants. (FIG. 8 C): The transcriptional level of ZmWAK -RLK1 at 10 dpi . (FIG. 8 D ) shows the proposed model of ZmWAK-RLK1 underlying NCLB disease resistance. The resistance allele suppressed the biosynthesis of major BXDs compounds, which likely served as the sus-
ceptibility component for promoting NCLB disease. Statistic test was conducted using Student's $t$ test. The asterisks represent a significant difference of $* * p<0.01$ or $* p<0.05$. The ns stands for no significance. Error bars are $\pm$ SE.
[0082] FIG. 9 (FIG. 9 A to D) shows the content of BXDs compounds DIMBOA-Glc (A), DIMBOA (B), HMBOAGlc (C), and HDMBOA-Glc (D) in second leaves of Htn1 NILs and mutants at 21 days after sowing. Further information is provided in Example 12 below. The statistics were conducted using Student's $t$ test ( $\mathrm{P}=0.05$ ) in eight biological replicates. The asterisks represent a significant difference of ${ }^{* *} \mathrm{p}<0.01$ or ${ }^{*} \mathrm{p}<0.05$. The ns stands for no significance. Error bars are $\pm$ SE.
[0083] FIG. 10 shows relative RLK1 expression in tissues. These samples were harvested from 21 days old seedlings without pathogen inoculation. Different lower case letters in the graphs indicate a difference which is statistically different. See also Example 13 below.
[0084] FIG. 11 (FIGS. 11 A and P) shows the transcription levels of genes in Htn1-NILs and the corresponding parental lines. The expression of genes (FIG. 11 A) ZmWAK-RLK1, (FIG. 11 B) Bx1, (FIG. 11 C) Igl, (FIG. 11 D) Bx2, (FIG. 11 E) Bx3, (FIG. 11 F) Bx4, (FIG. 11 G) Bx5, (FIG. 11 H) Bx6, (FIG. 11 I) Bx7, (FIG. 11 J) Bx8, (FIG. 11 K) Bx9, (FIG. 11 L) Bx10/11, (FIG. 11 M) Bx12, (FIG. 11 N) Bx13, (FIG. 11 O) Glu1 and (FIG. 11 P) Glu2 were quantified. The different colors and patterns of the bars indicate timepoints before and after infection as shown in the legend for FIG. 11 A which also applies for FIG. 11 B to P. The statistics were conducted separately in w22 and B37 genetic background using Tukey's HSD ( $\mathrm{P}=0.05$ ) in four biological replicates. Error bars are $\pm$ SE. Different lower case letters in the graphs indicate a difference which is statistically different. See also Example 10 below.
[0085] FIG. 12 (FIG. 12 A to C) shows ZmWAK-RLK1 localization to the plasma membrane. (FIG. 12 A-B) Fluorescent signals in onion epidermal cells after transient expression of ZmWAK -RKL1-eGFP (SEQ ID NO: 9) and the positive control PIP2A-mCherry that is known to localize to the plasma membrane (Kammerloher, Werner, et al. "Water channels in the plant plasma membrane cloned by immunoselection from a mammalian expression system." The Plant Journal 6.2 (1994): 187-199). Signals are shown before (FIG. 12 A) and after (FIG. 12 B) plasmolysis with 0.8 M mannitol. (FIG. 12 C ) Fluorescent signals in $N$. benthamiana leaves two days after infiltration. Notably, the signals shown in white in the respective graphs correspond to the originally green (column 1 RLK_eGFP), red (column 2 PIP2A_mCherry), and yellow (merge, column 4) fluorescent signal. Column 3 (DIC) represents the differential interference contrast to visualize the cellular structures as control.
[0086] FIG. 13 is a table showing the $\log$ FC and annotation of 215 the differentially expressed genes (DEGs) detected in B37Htn1/B37 and w22Htn1/w22 in at least one of timepoints.

## DETAILED DESCRIPTION

[0087] Based on the experiments and data underlying the present invention, it was found that the genes involved in the biosynthesis of benzoxazinoids (BXDs) and derivatives thereof, mainly hydrolysis based derivatives like hydroxamic acids, are not only involved in the defense mechanism against $E$. turcicum but rather can also effect and
mediate plant-defense, i.e., resistance mechanisms against various other fungal pathogens in a series of crop plants. The present invention thus implements both the link between a wall associated kinases (WAK), downstream signaling molecules, such as $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Bx} 6, \mathrm{Bx} 14$ and Igl , or any other enzyme involved in the benzoxazinoid synthesis pathway, and the decrease of BXD secondary metabolites and further technically implements the finding that this decrease of BXD secondary metabolites is associated with increased fungal resistance.
[0088] The present invention thus provides in a first aspect a method for producing a plant having increased fungal resistance, wherein the fungal resistance is regulated by at least one wall-associated kinase, the method comprising: (i) (a) providing at least one plant cell, tissue, organ, or whole plant having a specific genotype with respect to the presence of at least one gene encoding a wall-associated kinase in the genome of said plant cell, tissue, organ, or whole plant; or (i) (b) introducing at least one gene encoding at least one wall-associated kinase into the genome of at least one cell of at least one of a plant cell, tissue, organ, or whole plant; and (ii) (a) modifying at least one gene encoding at least one wall-associated kinase in the at least one plant cell, tissue, organ, or whole plant; and/or (ii) (b) modulating the expression level of at least one wall-associated kinase and/or the transcription level, the expression level, or the function of at least one molecule within the signaling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid or within the synthesis pathway of at least one benzoxazinoid in the at least one plant cell, tissue, organ, or whole plant; and (iii) producing a population of plants from the at least one plant cell, tissue, organ, or whole plant; and (iv) selecting a plant having an increased fungal resistance, from the plant population, based on the determination of a reduced synthesis of a benzoxazinoid preferably in response to a fungal infection, wherein the selected plant have an increased fungal resistance based on the reduced synthesis of a benzoxazinoid, and/or wherein the synthesis of the benzoxazinoid is regulated by the at least one wallassociated kinase.
[0089] Wall associated kinases (WAKs) have recently been identified as major components of fungal and bacterial disease resistance in several cereal crop species. However, the molecular mechanisms of WAK-mediated resistance are presently largely unknown. According to this invention, the function of the maize gene ZmWAK-RLK1 (Htn1) that confers quantitative resistance to northern corn leaf blight (NCLB) caused by the hemibiotrophic fungal pathogen Exserohilum turcicum was investigated. ZmWAK-RLK1 (Htn1) was found to localize to the plasma membrane and its presence resulted in a modification of the infection process by specifically reducing pathogen penetration into host tissues. Furthermore, the ubiquitous expression of ZmWAK RLK1 and the findings on the signaling pathway downstream of ZmWAK-RLK1 demonstrate the function of this and associated wall-associated kinases as master regulators and crucial signaling mediators in plant defense against fungal disease.
[0090] A transcriptome analysis of near-isogenic lines (NILs) differing for ZmWAK-RLK1 revealed that several genes involved in the biosynthesis of the secondary metabolites benzoxazinoids (BXDs) were differentially expressed in the presence of ZmWAK-RLK1. Particularly the content of BXD compounds DIMBOA-Glc, DIMBOA, HMBOA-

Glc and $\mathrm{DIM}_{2} \mathrm{BOA}$-Glc were significantly lower in the NILs with ZmWAK-RLK1. Furthermore, DIM 2 BOA-Glc, which is an inactive glucoside of BXDs, was significantly elevated in ZmWAK-RLK1 mutants with compromised NCLB resistance. In addition, maize mutants that were affected in BXDs biosynthesis showed reduced susceptibility to E. turcicum infection at the seedling stage. We thus conclude that BXD biosynthesis increases susceptibility to E. turcicum infection and that the ZmWAK-RLK1-mediated NCLB resistance results from a reduction of these compounds. These findings indicate a novel link between WAKs underlying quantitative disease resistance and the defense mechanism mediated by the secondary metabolites BXDs that have been known for their involvement in cereal insect resistance. The term "WAK" as used herein may comprise a plant receptor-like kinase associated with the signal transduction directly or indirectly effecting the biosynthesis of genes involved in the BXD synthesis, or interacting with signaling mechanism and/or protein-protein interactions being involved in the BXD synthesis.
[0091] The plant immune response "caused" by a WAK can thus be of direct or indirect nature. As it is known to the skilled person, receptor-like kinases usually comprise at least one extracellular signaling domain, e.g., for sensing PAMPs and/or DAMPs, a transmembrane domain, and an intracellular kinase domain. The kinase domain allows the WAK to transform the extracellular signal into an intracellular response transferred via a cascade of proteins involved in the downstream signal transduction. Usually, receptor kinases thus indirectly initiate the activation and transfer into the nucleus/organelle of a transcription factor which regulates the transcription of a target gene. Furthermore, plant WAKs can trigger defense responses such as reactive oxygen species (ROS) accumulation through the activation of a NADPH oxidase, nitric oxide production, callose deposition, besides a MAP kinase-mediated activation of defense gene expression. The terms "causing" or "caused" as used herein in the context of a WAK or another plant receptor kinase is thus to be construed broadly to comprise any direct or indirect effect the activity of the WAK can have on downstream signaling molecules, wherein the molecules can be selected from at least one amino acid sequence, preferably an enzyme in the signal transduction cascade downstream of the WAK or a peptide being able to stimulate or inhibit complex formation downstream of the WAK or signal transduction downstream of a WAK, a metabolite, such as any secondary metabolite produced by a plant, a ROS, or an indirect effect on the regulation of the transcription and/or translation of another downstream gene/protein. A physical interaction of the WAK in the form of a signaling complex may occur to cause an action. In another embodiment, the action caused by the WAK is mediated by a downstream molecule, e.g., a downstream kinase phosphorylating another molecule, in an indirect way. In the terminal part of the WAK signaling cascade, a transcription activator or repressor can be induced to regulate the transcription of a target gene of a WAK, preferably a target gene in the jasmonic acid and/or BXD biosynthesis pathway. Besides a protein-DNA interaction, WAK signaling can also imply protein-protein interactions influencing the BXD biosynthesis pathway.
[0092] In another aspect, the methods of the present invention further may comprise the step of introducing, modifying and/or modulating at least one further or other gene into at
least one plant cell, tissue, organ, or whole plant to provide a synergistic effect in increasing fungal disease by decreasing the synthesis of at least one BXD compound associated with fungal resistance. In preferred embodiments, the at least one further or other gene is selected from a bx1, bx2, ig1, bx6, bx11, bx14, opr2, lox3 or aoc1 gene (SEQ ID NOs: $10,12,14,16,18,20,22,24$ or 26 , respectively), or a homologous gene thereof, or the respective proteins encoded by said genes as set forth exemplary in SEQ ID NOs: 11, 13, $15,17,19,21,23,25$ or 27 , respectively, or homologs thereof. As disclosed herein, certain genes involved in the jasmonic acid pathway, the ethylene pathway, the lignin synthesis pathway, a plant defense pathway, a further recep-tor-like kinase pathway, or a cell wall pathway, and preferably certain genes involved in the jasmonic acid pathway, contribute to the signaling pathway of at least one functional WAK, wherein there may be a synergistic effect provided by the presence of a specific functional WAK and a specific non-functional or less functional gene of the jasmonic acid pathway, as the presence of both will contribute to an even significantly reduced amount of a BXD compound of interest and thus a more than additive increase in fungal resistance.
[0093] The present invention thus provides specific target genes which can be modulated in addition or alternatively to the at least one WAK of interest to provide a significantly improved fungal defense strategy for a plant of interest. These results are based on different functional studies including comparative transcriptome analysis in defined specific WAK genotypes, namely in two pairs of near isogenic lines, W 22 and W 22 Htn 1 as well as B37 and B37Htn1 (see Example 10 below), after fungal specific stimuli by analyzing the RNA sequencing datasets. Furthermore, additional RT-qPCR experiments and systematic RNA sequencing were conducted to decipher the plant immune network as triggered by a WAK, e.g., Htn1, (Examples 6 and 10 and Tables 1 and 2). These data demonstrated a cross-talk between the WAK and the benzoxazinoid synthesis and jasmonic acid pathway and thus provided new candidates to provide new elite plant lines comprising both a specific WAK as well as a specific genotype with respect to enzymes involved in the benzoxazinoid synthesis and jasmonic acid pathway.
[0094] In one embodiment according to the present invention, the method for producing a plant having increased fungal resistance may comprise the modification of at least one gene encoding at least one wall-associated kinase, and optionally at least one further or other gene, for example a $\mathrm{bx} 1, \mathrm{bx} 2, \mathrm{ig} 1, \mathrm{bx} 6, \mathrm{bx} 11, \mathrm{bx} 14, \mathrm{opr} 2, \operatorname{lox} 3$ or aoc1 gene, in the at least one plant cell, tissue, organ, or whole plant. The modification can be conducted by any means of plant breeding, including classical and modern methods of plant breeding, and/or techniques of molecular biology. Classical plant breeding methods may comprise the deliberate interbreeding (crossing) of closely or distantly related species to produce new crops with desirable properties. Plants are crossed to introduce traits/genes from a particular variety into a new genetic background to provide plants having modified and/or increased quality, yield, tolerance (against abiotic stress), resistance (against biotic stress), etc., characteristics. Breeding nowadays also includes methods like marker-assisted selection, reverse breeding and the targeted combination with molecular biology tools known and available to the skilled person.
[0095] In one embodiment according to the present invention, the modulation or modulating of at least one wallassociated kinase, and/or of at least one further or other gene, for example a bx1, bx2, igl, bx6, bx11, bx14, opr2, lox 3 or aoc 1 gene, can thus comprise at least one of modulating the expression level of at least one wall-associated kinase, preferably increasing the expression at least one wall-associated kinase, and/or modulating the function or activity of and/or activity of at least one wall-associated kinase, for example, by providing at least one molecule interacting with the extracellular signalling domain of at least one WAK, e.g., an activator, or by providing at least one molecule interacting with the intracellular signalling domain of at least one WAK, such as a molecule inducing or inhibiting kinase activity. In one embodiment, the modulation or modulating of at least one wall-associated kinase, and/or of at least one further or other gene, for example a bx 1 , bx2, ig1, bx6, bx11, bx14, opr2, lox3 or aoc1 gene, can comprise the targeted introduction of at least one mutation into a WAK and/or a further or other gene of interest to modulate the activity of the WAK and the further or other protein encoded by the at least one further or other gene in a targeted way. Embodiments comprising the modulation of at least one wall-associated kinase thus aim at influencing the activity of the at least one WAK within without modifying the nucleic acid sequence and thus possibly the amino acid sequence of a WAK of interest. In certain embodiments, wherein at least one further or other gene, for example a bx1, bx2, ig1, bx6, bx11, bx14, opr2, lox3 or aoc1 gene, is modulated, the modulation may aim at reducing the activity of a at least one allele of a bx1, bx2, igl, bx6, bx11, bx14, opr2, lox3 or aocl gene to decrease the amount of BXD compound synthesized. For example, BX1 and IGL enzymes are accountable for the bulk of BX biosynthesis. Therefore, inhibiting the presence of a functional BX enzyme, preferably a BX1, BX2 or BX6 enzyme, or an Ig1 enzyme can contribute to the provision of a reduced BXD synthesis and thus an increased fungal resistance in a plant of interest.
[0096] The modulation according to the present invention can comprise any direct or indirect interaction between two molecules, i.e., a receptor-ligand interaction, a transcription factor-transcription factor binding site interaction, an interaction of an enzyme, e.g., a kinase with its target site, an interaction of a peptide or nucleic acid modulator with a target site, an antibody-antigen interaction, an interaction with a DNA or histone binding protein and its cognate ligand (DNA or histone), a hybridization between two nucleic acid sequences/molecules and the like.
[0097] In one embodiment, the transcription level of at least one WAK within at least one cell of at least one of a plant cell, tissue, organ, or whole plant can be modified or modulated by specifically influencing a regulatory sequence of a WAK gene. In another embodiment, the modulation affects at least one gene, for example a bx1, bx2, igl, bx6, bx11, bx14, opr2, lox3 or aocl gene. This modulation or modification can comprise the introduction of at least one specific mutation, for example to activate a promoter of interest, or the modulation or modification can be in trans by providing a transcription factor modulating the transcription of at least one WAK gene, wherein the at least one WAK gene according to all embodiments of the present invention may comprise an endogenously occurring WAK gene, or a

WAK gene introduced into at least one cell of at least one of a plant cell, tissue, organ, or whole plant.
[0098] According to the various aspects and embodiments of the present invention, a signalling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid in at least one plant cell, tissue, organ, or whole plant thus implies the whole chain of molecular actions downstream of a WAK as sensing molecule triggering a signalling cascade involving various different effectors until the synthesis of a BXD compound.
[0099] In one embodiment according to the various aspects of the present invention, the at least one wallassociated kinase is WAK-RLK1, preferably selected from Htn1, Ht2, or Ht3, or an allelic variant thereof, a mutant or a functional fragment thereof, or a gene encoding the same, preferably wherein the at least one wall-associated kinase a) is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 7, or a functional fragment thereof, $b$ ) is encoded by a nucleic acid molecule comprising the nucleotide sequence having at least $60 \%$, $65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%$, $87 \%, 88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%$, $97 \%, 98 \%$ or $99 \%$ sequence identity to nucleotide sequence of SEQ ID NO: 1 or 7, preferably over the entire length of the sequence, c ) is encoded a nucleic acid molecule hybridizing with a complementary sequence to a) or b) under stringent conditions, $d$ ) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence of SEQ ID NO: 2 or 8 , or a functional fragment thereof, e) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence having at least $60 \%, 65 \%, 70 \%, 75 \%, 80 \%$, $81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%, 87 \%, 88 \%, 89 \%, 90 \%$, $91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to amino acid sequence of SEQ ID NO: 2 or 8 , preferably over the entire length of the sequence, f) comprising the amino acid sequence of SEQ ID NO: 2 or 8 , or g) comprising an amino acid sequence having at least $60 \%, 65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%$, $86 \%, 87 \%, 88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%$, $96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to amino acid sequence of SEQ ID NO: 2 or 8, preferably over the entire length of the sequence, provided that any sequence of a) to g), optionally after expression, still encodes at least one functional Htn 1 , Ht 2 , or Ht 3 , or an allelic variant, a mutant, or a functional fragment thereof. In a preferred embodiment, the at least one wall-associated kinase is selected from Htn1 (RLK1) or an allelic variant, a mutant or a functional fragment thereof, or a gene encoding the same. Variants may further comprise any functional splice variant of a WAK gene. As it is known to the skilled person, eukaryotic mRNA comprising introns is spliced during processing from a precursor mRNA into a mature mRNA giving rise to a protein after translation (protein biosynthesis).
[0100] "Functional" or "functional fragment" or "variant" as used in connection with a WAK or any other receptor-like kinase or any at least one further gene/protein, for example a bx1, bx2, igl, bx6, bx11, bx14, opr2, lox3 or aoc 1 gene, or the corresponding proteins $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Ig} 1, \mathrm{Bx} 6, \mathrm{Bx} 11, \mathrm{Bx} 14$, Opr2, Lox3 or Aoc1, according to the present disclosure means a fragment of an amino acid or nucleic acid sequence with reference to the respective (longer) sequence occurring in the natural environment of a plant genome of interest, whereas the functional fragment still comprises optionally
after transcription, processing and translation-at least one function of the respective parent sequence. The functional fragment may be less sterically demanding and thus more convenient for certain approaches. Furthermore, the functional fragment may be fused to another domain to create a fusion molecule for functional assays, e.g., a fusion with a gene encoding a protein having fluorescence activity. In another embodiment, the functional fragment may be fused to a tag and the like. Therefore, a functional fragment may also comprise a sequence comprising codon optimizations on the nucleic acid level, or comprising certain mutations, said mutations not influencing the activity or function of a WAK, or another receptor-like kinase of interest.
[0101] Preferably, any function variant at least comprises a truncated form of the extracellular signalling domain of a WAK and an active intracellular kinase domain, wherein the intracellular kinase domain is able to initiate downstream signalling. Notably, the extracellular domain, the transmembrane domain and/or the intracellular kinase domain of a WAK according to the present invention can comprise at least one mutation. Said mutation may lead to an increased signalling activity to represent a functional variation or functional mutation in the sense of the present invention.
[0102] In certain aspects according to the present invention, at least one further or other gene, for example a bx1, bx2, igl, bx6, bx11, bx14, opr2, lox3 or aoc1 gene, is introduced, and/or modified and/or modulated according to the methods of the present invention, variants or mutants representing "loss-of-function", or having reduced activity might be specifically preferred for the purpose of the present invention in case that the at least one variant or mutant results in a decreased BXD synthesis. Particularly, it was found according to the present invention that there is a cross-talk between the WAK signaling pathway and the BXD synthesis pathway, mainly the BXD synthesis pathway as mediated by $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Bx} 6, \mathrm{Bx} 11$ and BX 14 and/or Ig 1 , wherein the targeted insertion, modulation or modification of at least one WAK, or the gene encoding the same, and a further effector, or the gene encoding the same, for example a bx1, bx2, igl, bx6, bx11, bx14, opr2, lox3 or aoc1 gene, contribute to a enhanced fungal resistance, in particular NCLB resistance, in a plant as the regulation of both pathways leads to a reduced BXD signature. Wherein the WAK pathway plays the role of the general "pacemaker" in this regulatory network which senses and forwards signals due to its recognition and kinase function, there is also a feedback regulation between the further effectors involved in the jasmonic acid and BXD synthesis pathway. The master regulator function of WAK is demonstrated by the fact that the combined expression of Bx 1 and Ig 1 was consistently lower in genotypes with ZmWAK-RLK1 (FIGS. 11 B and C and Example 10) demonstrating that ZmWAK-RLK1 and other WAKs have the capacity to induce a concerted action also regulating the benzoxazinoid pathway and the jasmonic acid pathway.
[0103] In one embodiment according to the various aspects of the present invention, the method for producing a plant having increased fungal resistance thus comprises the introduction and/or modification and/or modulation of at least one WAK, or a gene encoding the same, wherein the WAK at least comprises a functional intracellular kinase domain, for example a sequence selected from SEQ ID NOs: $1,2,7$, or 8 , or an allelic variant or mutant thereof, and wherein the method further comprises the introduction and/
or modification and/or modulation of at least one BX or Ig1 protein, or a gene encoding the same, wherein the corresponding bx gene, or the Igl gene comprises at least one mutation, or wherein the bx gene, or the Igl gene is of a specific genotype is knocked-out, so that the WAK activity and the decreased or deleted BX protein or Igl protein activity results in a decreased BXD biosynthesis.
[0104] Receptor-like kinases can be further divided into RD and non-RD kinases, depending on the presence or absence of an arginine residue at the catalytic site of the kinase domain. ZmWAK-RLK2 contains an RD kinase and ZmWAK-RLK1 has a non-RD kinase domain (cf. for instance positions 505 and 506 of SEQ ID NO: 2, amino acids F (phenylalanine) and D (aspartic acid), respectively). Most receptor-like kinases involved in plant immunity identified so far belong to the non-RD kinases, whereas RD kinases are thought to play a role in other processes such as development. Variants of SEQ ID NO: 2 have been constructed (cf. SEQ ID NOs: 3 to 6 and Hurni et al., 2015). It was found that mutations at positions M455, G497 and G548 (with reference to SEQ ID NO: 2) may result in a higher susceptibility to NCLB. All said positions reside in the serine threonine kinase domain of ZmWAK-RLK1. A functional variant according to the present invention will thus avoid any mutation or combination of mutations in the kinase domain of a WAK which results in decreased fungal resistance. Exemplary mutants of SEQ ID NO: 2 are presented with SEQ ID NOs: 3 and 4 (RLK1b, M455I) and SEQ ID NOs: 5 and 6 (RLK1d, G497E). A further mutant analyzed herein, RLK1f, comprises a mutation G548R in comparison to the wild-type sequence according to SEQ ID NO: 2 . All mutants were tested in comparison to the respective sister lines as described herein. Based on these structural data the importance of a functional intracellular kinase domain of a WAK could be deduced. Therefore, a functional variant or a functional mutant of a WAK may comprise at least one mutation in comparison to the cognate wild-type sequence which at least one mutation does not disturb the downstream signaling of the WAK in that sense that a functional mutant or variant will decrease the level of a specific BXD compound to in turn increase fungal resistance of a plant, plant cell, tissue, or organ comprising such a functional variant of a WAK, or the sequence encoding the same.
[0105] According to certain embodiments of the present invention, more than one gene encoding a WAK, or a functional fragment thereof, or the sequence encoding the same, can be introduced into, or modulated or modified in at least one plant cell, tissue, organ, or whole plant. The introgression of several WAKs can have a synergistic effect in providing enhanced fungal resistance, particularly in case an elite line can be established based on the staggering of more than one WAK into the genome of a plant of interest according to the disclosure of the present invention. As described herein, WAKs represent the key signalling molecules initiating an immune cascade downstream of and mediated by the intracellular kinase domain of the WAKs. Therefore, more than one WAK may thus have a dosage effect positively downregulating BXD synthesis and thus increasing fungal resistance in a plant, in particular a crop plant, of interest. Furthermore, at least one further gene or protein, preferably being selected from any one of SEQ ID NOs: 10 to 27 or homologous genes or homologs thereof, can be additionally or alternatively modified as detailed
above to provide a plant cell, tissue, organ or whole plant as material for producing a plant with improved fungal resistance properties, preferably resistance against NCLB. Further target sequences to be modified having an implication in the cross-talk between WAK signalling and BXD biosynthesis are disclosed in Tables 1 and 3 herein.
[0106] In a further embodiment according to the present invention, there is provided a method, wherein the reduced synthesis of at least one benzoxazinoid is achieved by providing at least one wall-associated kinase, an allelic variant, a mutant or a functional fragment thereof, or a gene encoding the same, wherein the at least one wall-associated kinase comprises a sequence which can directly or indirectly influence the benzoxazinoid pathway and at least one further plant metabolic pathway, preferably a disease resistance associated pathway, wherein the plant metabolic pathway is selected from the group consisting of the jasmonic acid pathway, the ethylene pathway, the lignin synthesis pathway, a defense pathway, a receptor-like kinase pathway, a cell wall associated pathway, preferably, wherein the at least one further plant metabolic pathway is the jasmonic acid pathway and wherein the reduced synthesis of at least one benzoxazinoid is achieved by an decreased or down-regulated Ig1 and/or Bx1 expression as induced by at least one WAK of interest.
[0107] Several differentially expressed genes (DEGs) identified by the inventors of the present invention belonged to several different immune networks and to different disease resistance associated pathways including benzoxazinoids (BXDs) biosynthesis, (phytohormone) jasmonic acids (JAs), ethylene, lignin, defense and receptor-like kinases as well as cell wall were found in Htn1 NILs (Example 10, FIG. 13). Surprisingly, six genes of the BXDs biosynthesis pathway showed differential expression in at least one timepoint, including Bx1 (SEQ ID NOs: 10 and 11), Bx2 (SEQ ID NOs: 12 and 13), Igl-like (SEQ ID NOs: 14 and 15), Bx6 (SEQ ID NOs: 16 and 17), Bx11 (SEQ ID NOs: 18 and 19) and Bx14 (SEQ ID NOs: 20 and 21) (see also FIG. 13, column 2 of table for further reference to publicly available data base entries for gene IDs and names) demonstrating a cross-regulatory network between the WAK and further pathways in fungal defense. This was particularly surprising because BXDs as secondary metabolites have so far not been associated with defense against fungi mediated by WAK kinases. More surprisingly, the transcriptome data and functional assays also, for the first time, revealed DEGs that are part of immune networks including the phytohormone jasmonic acids that plays a central role in regulating resistance against hemibiotrophic and necrotrophic diseases. JAs treatment can induce the accumulation of BXD compounds (Oikawa, Akira, Atsushi Ishihara, and Hajime Iwamura. "Induction of HDMBOA-Glc accumulation and DIM-BOA-Glc 4-O-methyltransferase by jasmonic acid in poaceous plants." Phytochemistry 61.3 (2002): 331-337; Oikawa, Akira, et al. "Accumulation of HDMBOA-Glc is induced by biotic stresses prior to the release of MBOA in maize leaves." Phytochemistry 65.22 (2004): 2995-3001). The present invention thus provides evidence that there is an additional link between the WAK kinase signaling pathway and the jasmonic acid pathway which paves the way for a variety of new disease and particularly fungal resistance strategies as disclosed herein. The enzymatic properties of IGL are similar to BX1, but the transcriptional regulation of their corresponding genes is different. Like other Bx genes,

Bx1 is constitutively expressed during the early developmental stages of the plant, which correlates with endogenous BX levels. Plants carrying the mutant alleles of the Bx 1 gene produce only a fraction of the BXs that are found in Bx1 wild-type plants. Therefore, a WAK according to the present invention may act as a master regulator bridging anti-fungal signalling with the effectors of the jasmonic acid pathway and other pathways, preferably an effector selected from the group consisting of SEQ ID NOs: 10 to 27 or homologous genes or homologs thereof.
[0108] In one embodiment, the introduction at least one additional gene encoding at least one wall-associated kinase into at least one cell of at least one of a plant cell, tissue, organ, or whole plant may comprise the introduction of a nucleic acid sequence, comprising DNA and/or RNA in a single stranded and/or double stranded form, or an amino acid sequence, by means of breeding techniques, or by means of molecular biology to transfer a functional WAK of interest, or an additional functional WAK of interest, or the sequence encoding the same, into at least one cell of interest. Said at least one additional gene can be also any gene, wherein the resulting protein/enzyme is involved in the BXD biosynthesis pathway or in a jasmonic acid pathway, such as $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Bx} 3, \mathrm{Bx} 4, \mathrm{Bx} 5, \mathrm{Bx} 7, \mathrm{Bx} 8, \mathrm{Bx} 9, \mathrm{Bx} 10$, Bx11, Bx12, Bx13, Bx14, Ig1, Glu1, Glu2, OPR2, LOX3 or AOC1 (see FIG. 13 and SEQ ID NOs: 10 to 27), or any variant thereof, or a combination of the aforementioned genes/proteins. Preferably, the at least one additional gene comprises at least one mutation which changes the function of the naturally occurring respective additional gene, wherein the mutation, in the coding or within a regulatory region, causes decreased synthesis of the respective BXD compound, or wherein the mutation, in a regulatory region, such as a promoter region, or in a coding region, causes a reduced signal transduction from a WAK kinase located upstream in the signalling cascade so the said mutation results in a decreased synthesis of a BXD compound. In another embodiment, the gene encoding at least one of Bx1, $\mathrm{Bx} 2, \mathrm{Bx} 3, \mathrm{Bx} 4, \mathrm{Bx} 5, \mathrm{Bx} 7, \mathrm{Bx} 8, \mathrm{Bx} 9, \mathrm{Bx} 10, \mathrm{Bx} 11, \mathrm{Bx} 12$, Bx13, Bx14, Igl, Glu1, Glu2, OPR2, LOX3 or AOC1 may be deleted or partially deleted within the genome of a plant cell of interest, or the gene may be modified in a targeted way.
[0109] Further enzymes involved in the regulation of the BXD synthesis which can be modulated, introduced or modified according to the methods of the present invention to achieve an increased fungal resistance in a plant cell, plant or plant material pathway are selected from the group of jasmonic synthesis pathway enzymes, including 12 -oxophytodienoic acid reductase 2 (OPR2), Lipoxygenase 3 (LOX3) or Allene oxide cyclase 1 (AOC1), ethylene pathway enzymes, such as S -adenosylmethionine synthase, lignin pathway enzymes, such as, for example, CaffeoylCoA O-methyltransferase 1 (OMT1) or OMT2, enzymes and proteins involved in plant defense mechanisms, such as, for example SAF1-Safener induced 1; Glu2athione S-transferase, and any combination thereof.
[0110] Presently, WAKs are the only known proteins that can physically link the cell wall to the plasma membrane (Brutus, Alexandre, et al. "A domain swap approach reveals a role of the plant wall-associated kinase 1 (WAK1) as a receptor of oligogalacturonides." Proceedings of the National Academy of Sciences 107.20 (2010): 9452-9457). Therefore, further structurally and functionally related cell
wall spanning or associated kinases are suitable as WAKs according to the present invention, e.g., maize qHSR1 (Zuo, Weiliang, et al. "A maize wall-associated kinase confers quantitative resistance to head smut." Nature genetics 47.2 (2015): 151-157), or rice OsWAK/Xa4 gene conferring quantitative rice blight resistance by strengthening the cell wall (Hu et al. 2017).
[0111] In another embodiment according to the present invention, the step of introducing at least one gene into at least one cell of at least one of a plant cell, tissue, organ, or whole plant may comprise the introduction of a gene, wherein the amino acid sequence or enzyme encoded by said gene is involved in the catalytic pathway downstream of a WAK kinase, wherein the additional gene is introduced alone, or together with at least one gene encoding a WAK kinase or a variant thereof.
[0112] "Benzoxazinoids" or "BXDs" are a class of indolederived plant chemical defenses comprising compounds with a 2 -hydroxy- 2 H -1,4-benzoxazin- $3(4 \mathrm{H}$ )-one skeleton and their derivatives. BXDs have been described as phytochemicals in monocots, including grasses, including important cereal crops such as maize, wheat and rye, as well as a certain dicot species. The term "BXDs" as used herein refers to both benzoxazinones (glucosides and corresponding aglucones containing a 2 -hydroxy- $2 \mathrm{H}-1,4$-benzoxazin $3(4 \mathrm{H}$ )one skeleton) and their downstream derivative products during metabolic pathways, benzoxazolinones, as well as any intermediates. The term BXD may thus also comprise a derivative being the result of the activity of hydrolyzing glucosidases found in plastids, cytoplasm, and cell walls, or derivatives and intermediated being the result of degradation to benzoxazolinones via oxo-cyclo/ring-chain tautomerism. Further comprised are downstream metabolites directly being derivable from any benzoxazolinone. The term "BXDs" shall further comprise any open form, nitrenium form or complex, e.g., a metal complex from a BXD. BXD basic structures are represented in FIG. 1.
[0113] By the term "reduced/decreased synthesis of a benzoxazinoid" or "reduced synthesis of at least one benzoxazinoid" or "reducing the amount of at least one benzoxazinoid" or "reduction on BXDs content" or "reduced amount of a BXD compound" or the like, is meant that the plant cell, tissue, organ, or whole plant according to the present invention exhibit an amount of a benzoxazinoid, at least one benzoxazinoid or the benzoxazinoid of interest which is reduced by at least $10 \%, 15 \%, 20 \%$ or $25 \%$, preferably by at least $30 \%, 35 \%, 40 \%$ or $45 \%$, more preferably by at least $50 \%, 60 \%$ or $70 \%$ as compared to a corresponding control plant cell, control tissue, control organ, or control whole plant of the same genotype, but lacking the modification of the at least one gene encoding at least one wall-associated kinase or the modulation of the expression level of at least one wall-associated kinase and/or the transcription level, the expression level, or the function of at least one molecule within the signaling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid or within the synthesis pathway of at least one benzoxazinoid. In one embodiment according to the various aspects of the present invention, the benzoxazinoid whose synthesis is regulated by the at least one wallassociated kinase and optionally regulated by the at least one further enzyme of the jasmonic acid and/or benzoxazionoid pathway is selected from at least one of DIM $_{2} \mathrm{BOA}$, DIM$\mathrm{BOA}, \mathrm{HMBOA}, \mathrm{HM}_{2} \mathrm{BOA}, \mathrm{HDMBOA}, \mathrm{HDM}_{2} \mathrm{BOA}$,

HBOA, DHBOA, DIBOA or TRIBOA, the aforementioned benzoxazinoid being in the glucoside or aglucone form, or a benzoxazolinone, or any combination of the aforementioned benzoxazinoids, preferably wherein the benzoxazinoid whose synthesis is regulated by the at least one wallassociated kinase is selected from at least one of DIM $_{2} \mathrm{BOA}$, DIMBOA, HMBOA or HDMBOA, the aforementioned benzoxazinoid being in the glucoside or aglucone form, or any combination of the aforementioned benzoxazinoids.
[0114] In one embodiment according to the various aspects of the present invention, a reduced content of BXDs can be achieved by introducing at least one gene encoding at least one wall-associated kinase into at least one cell of at least one of a plant cell, tissue, organ, or whole plant, wherein the at least one wall-associated kinase causes a reduced synthesis of at least one BXD. More than one WAK encoding gene and different allelic variants of a WAK gene may be introduced into a cell of interest in addition to a WAK gene potentially already being present in the genome of a plant cell of interest. The presence of several WAKs or receptor-like kinases involved in the BXD synthesis may thus be favourable in order to increase the copy number and thus the dosage effect of a gene of interest.
[0115] In one embodiment, quantitative NCLB disease resistance is based on a decrease of the biosynthesis of at least one secondary metabolite BXDs, preferably $\mathrm{DIM}_{2} \mathrm{BOA}-\mathrm{Glc}$, DIMBOA, HMBOA, DIMBOA-Glc or HMBOA-Glc, and the methods according to the various aspects of the present invention comprise the addition of a scavenger molecules interacting with and this neutralizing the activity of at least one secondary metabolite BXD to reduce the amount of the of at least one secondary metabolite BXD susceptibility component to decrease fungal infection at least one plant cell, tissue, organ, or whole plant.
[0116] According to the present invention, there are thus provided methods for producing a plant having increased fungal resistance, wherein the fungal resistance is regulated by at least one wall-associated kinase. "Regulated" in this context thus implies a direct or indirect regulation mediated by at least one wall-associated kinase. This regulation may imply a signalling cascade initiated by the at least one wall-associated kinase and proceeding through further molecules involved in the signalling cascade. The regulation can be on a protein, RNA or nucleic acid level. Furthermore, the regulation may imply a cross-talk or feedback regulation, for example implying a $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Bx} 3, \mathrm{Bx} 4, \mathrm{Bx} 5, \mathrm{Bx} 7, \mathrm{Bx} 8$, Bx9, Bx10, Bx11, Bx12, Bx13, Bx14, Igl, Glu1, Glu2, OPR2, LOX3 or AOC1 enzyme, or the gene encoding the same, or the transcriptional regulation of such a further gene encoding $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Bx} 3, \mathrm{Bx} 4, \mathrm{Bx} 5, \mathrm{Bx} 7, \mathrm{Bx} 8, \mathrm{Bx} 9, \mathrm{Bx} 10$, Bx11, Bx12, Bx13, Bx14, Ig1, Glu1, Glu2, OPR2, LOX3 or AOC1, or a modulation or modification of a gene encoding $\mathrm{Bx} 1, \mathrm{Bx} 2$, $\mathrm{Bx} 3, \mathrm{Bx} 4, \mathrm{Bx} 5, \mathrm{Bx} 7, \mathrm{Bx} 8, \mathrm{Bx} 9, \mathrm{Bx} 10$, Bx 11 , Bx12, Bx13, Bx14, Ig1, Glu1, Glu2, OPR2, LOX3 or AOC1.
[0117] In one embodiment, the pathogen according to the present disclosure is a fungal pathogen infesting a plant. The disease caused by a fungal pathogen and the respective fungus may be selected from Plume blotch Septoria (Stagonospora) nodorum, Leaf blotch (Septoria tritici), Ear fusarioses (Fusarium spp.), Late blight (Phytophthora infestans), Anthrocnose leaf blight or Anthracnose stalk rot (Colletotrichum graminicola (teleomorph: Glomerella graminicola Politis) Glomerella tucumanensis), Curvularia leaf spot (Curvularia clavata, C. eragrostidis, $=$ C. maculans
(teleomorph: Cochliobolus exagrostidis), Curvularia inaequalis, C. intermedia (teleomorph: Cochliobolus intermedius), Curvularia lunata (teleomorph: Cochliobolus lunatus), Curvularia pallescens (teleomorph: Cochliobolus pallescens), Curvularia senegalensis, C. tuberculata (teleomorph: Cochliobolus tuberculatus), Didymella leaf spot (Didymella exitalis), Diplodia leaf spot or streak (Stenocarpella macrospora=Diplodialeaf macrospora), Brown stripe downy mildew (Sclerophthora rayssiae var. zeae), Crazy top downy mildew (Sclerophthora macrospora=Sclerospora macrospora), Green ear downy mildew (Sclerospora graminicola), Leaf spots (various minor leaf spots) (Alternaria alternata, Ascochyta maydis, A. tritici, A. zeicola, Bipolaris victoriae $=$ Helminthosporium victoriae (teleomorph: Cochliobolus victoriae), C. sativus (anamorph: Bipolaris sorokiniana $=H$. sorokinianum $=H$. sativum), Epicoccum nigrum, Exserohilum prolatum=Drechslera prolata (teleomorph: Setosphaeria prolata) Graphium penicillioides, Leptosphaeria maydis, Leptothyrium zeae, Ophiosphaerella herpotricha, (anamorph: Scolecosporiella sp.), Paraphaeosphaeria michotii, Phoma sp., Septoria zeae, S. zeicola, S. zeina, Northern corn leaf blight (Setosphaeria turcica (anamorph: Exserohilum turcicum $=$ Helminthosporium turcicum), Northern corn leaf spot (Cochliobolus carbomum (anamorph: Bipolaris zeicola=Helminthosporium carbonum), Phaeosphaeria leaf spot (Phaeosphaeria maydis=Sphaerulina maydis), Rostratum leaf spot (Setosphaeria rostrata, (anamorph: Helminthosporium rostratum), Java downy mildew (Peronosclerospora maydis=Sclerospora maydis), Philippine downy mildew (Peronosclerospora philippinensis=Sclerospora philippinensis), Sorghum downy mildew (Peronosclerospora sorghi=Sclerospora sorghi), Spontaneum downy mildew (Peronosclerospora spontanea $=$ Sclerospora spontanea), Sugarcane downy mildew (Peronosclerospora sacchari $=$ Sclerospora sacchari), Sclerotium ear rot (southern blight) (Sclerotium rolfsii Sacc. (teleomorph: Athelia rolfsii)), Seed rot-seedling blight (Bipolaris sorokiniana, B. zeicola=Helminthosporium carbonum, Diplodia maydis, Exserohilum pedicillatum, Exserohilum turcicum=Helminthosporium turcicum, Fusarium avenaceum, F. culmorum, F. moniliforme, Gibberella zeae (anamorph: F. graminearum), Macrophomina phaseolina, Penicillium spp., Phomopsis sp., Pythium spp., Rhizoctonia solani, R. zeae, Sclerotium rolfsii, Spicaria sp.), Selenophoma leaf spot (Selenophoma sp.), Yellow leaf blight (Ascochyta ischaemi, Phyllosticta maydis (teleomorph: Mycosphaerella zeae-maydis), Zonate leaf spot (Gloeocercospora sorghi).
[0118] Further plant pathogenic fungi include Plasmodiophoromycota, such as Plasmodiophora brassicae (clubroot of crucifers), Spongospora subterranea, Polymyxa graminis, Oomycota, such as Bremia lactucae (downy mildew of lettuce), Peronospora (downy mildew) in snapdragon ( $P$. antirrhini), onion ( $P$. destructor), spinach ( $P$. effusa), soybean ( $P$. manchurica), tobacco ("blue mold"; $P$. tabacina) alfalfa and clover ( $P$. trifolium), Pseudoperonospora humuli (downy mildew of hops), Plasmopara (downy mildew in grapevines) ( $P$. viticola) and sunflower ( $P$. halstedii), Sclerophthora macrospora (downy mildew in cereals and grasses), Pythium (for example damping-off of Beta beet caused by P. debaryanum), Phytophthora infestans (late blight in potato and in tomato and the like), Albugo spec., Ascomycota, such as Microdochium nivale (snow mold of
rye and wheat), Fusarium, Fusarium graminearum, Fusarium culmorum (partial ear sterility mainly in wheat), Fusarium oxysporum (Fusarium wilt of tomato), Blumeria graminis (powdery mildew of barley (sp. hordei) and wheat (f. sp. tritici)), Erysiphe pisi (powdery mildew of pea), Nectria galligena (Nectria canker of fruit trees), Uncinula necator (powdery mildew of grapevine), Pseudopeziza tracheiphila (red fire disease of grapevine), Claviceps purpurea (for example, rye and grasses), Gaeumannomyces graminis (take-all on wheat, rye and other grasses), Magnaporthe grisea, Pyrenophora graminea (leaf stripe of barley), Pyrenophora teres (net blotch of barley), Pyrenophora tritici-repentis (leaf blight of wheat), Venturia inaequalis (apple scab), Sclerotinia sclerotium (stalk break, stem rot), Pseudopeziza medicaginis (leaf spot of alfalfa, white and red clover), Basidiomycetes, such as Typhula incarnata (typhula blight on barley, rye, wheat), Ustilago maydis (blister smut on maize), Ustilago nuda (loose smut on barley), Ustilago tritici (loose smut on wheat, spelt), Ustilago avenae (loose smut on oats), Rhizoctonia solani (rhizoctonia root rot of potato), Sphacelotheca spp. (head smut of sorghum), Melampsora lini (rust of flax), Puccinia graminis (stem rust of wheat, barley, rye, oats), Puccinia recondita (leaf rust on wheat), Puccinia dispersa (brown rust on rye), Puccinia hordei (leaf rust of barley), Puccinia coronata (crown rust of oats), Puccinia striiformis (yellow rust of wheat, barley, rye and a large number of grasses), Uromyces appendiculatus (brown rust of bean), Sclerotium rolfsii (root and stem rots of many plants), Deuteromycetes (Fungi imperfecti), such as Septoria (Stagonospora) nodorum (glume blotch) of wheat (Septoria tritici), Pseudocercosporella herpotrichoides (eyespot of wheat, barley, rye), Rynchosporium secalis (leaf spot on rye and barley), Alternaria solani (early blight of potato, tomato), Phoma betae (blackleg on Beta beet), Cercospora beticola (leaf spot on Beta beet), Alternaria brassicae (black spot on oilseed rape, cabbage and other crucifers), Verticillium dahliae (verticillium wilt), Colletotrichum, such as Colletotrichum lindemuthianum (bean anthracnose), Phoma lingam (blackleg of cabbage and oilseed rape), Botrytis cinerea (grey mold of grapevine, strawberry, tomato, hops and the like).
[0119] Preferred fungal diseases to be prevented and the corresponding causative pathogens which can be combated based on the disclosure of the present invention in a crop plant of interest are selected from a fungus from the order of Pleosporales, comprising E. turcicum/H. turcicum causing northern corn leaf blight (NCLB), particularly affecting maize and wheat plants, or comprising Bipolaris maydis causing southern corn leaf blight, the order of Pucciniales causing rust disease, comprising Puccinia sorghi causing common rust, or Diploida macrospora causing Diploida leaf streak/blight, or Colletotrichum graminicola causing Anthracnose, or Fusarium spp., preferably Fusarium verticilioides causing Fusarium stalk rot, or Gibberella spp., e.g., Gibberella zeae causing Giberella stalk rot, or Sphacelotheca reiliana causing maize head smut are thus plant diseases caused by pathogenic fungi which can be prevented in the plants and by the methods of the present invention.
[0120] In one embodiment according to the various aspects of the present invention the at least one gene encoding at least one wall-associated kinase may be stably integrated into the genome of the at least one plant cell, tissue, organ, or whole plant, or the at least one gene
encoding at least one wall-associated kinase may transiently introduced into a plant cell, tissue, organ, or whole plant.
[0121] In another embodiment according to the various aspects of the present invention at least one further gene encoding at least one enzyme within the signalling cascade downstream of a wall-associated kinase may be stably integrated into the genome of the at least one plant cell, tissue, organ, or whole plant, or the at least one further gene encoding at least one enzyme within the signalling cascade downstream of a wall-associated kinase may transiently introduced into a plant cell, tissue, organ, or whole plant.
[0122] Methods for introducing a gene of interest into a plant cell of interest by means of molecular biology or conventional and modern breeding and associated tools and methodologies are disclosed herein and are known to the skilled person.
[0123] In one embodiment, the transient introduction may comprise the direct introduction of an amino acid effector instead of the introduction of a gene of interest.
[0124] In one embodiment according to the various aspects of the present invention the at least one gene encoding at least one wall-associated kinase may be stably integrated into the genome of the at least one plant cell, tissue, organ, or whole plant, wherein the introduction of the at least one gene encoding at least one wall-associated kinase comprises the introgression of the at least one gene during plant breeding.
[0125] Any of a number of standard breeding techniques can be used, depending upon the species to be crossed. Since expression of the genes or nucleic acids of the invention may lead to phenotypic changes, plants comprising the recombinant nucleic acids of the invention can be sexually crossed with a second plant to obtain a final product. Thus, the seed of the invention can be derived from a cross between two transgenic plants of the invention, or a cross between a transgenic or mutant plant of the invention and another plant. The desired effects, e.g., expression of the at least one WAK gene or a mutant allele of the invention to produce a plant having a modified BXD synthesis profile, or a modulated $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Bx} 3, \mathrm{Bx} 4, \mathrm{Bx} 5, \mathrm{Bx} 7, \mathrm{Bx} 8, \mathrm{Bx} 9, \mathrm{Bx} 10$, Bx11, Bx12, Bx13, Bx14, Ig1, Glu1, Glu2, OPR2, LOX3 or AOC1 profile, can be enhanced when both parental plants express the genes or mutant alleles of the invention, or if both allels are modified or even deleted, depending on the target to be modified in accordance with the disclosure of the present invention. The desired effects can be passed to future plant generations by standard propagation means. "Introgressing", as also detailed above, thus means the integration of a gene or allele in a plant's genome by natural means, i.e. by crossing a plant comprising the gene or allele of interest described herein with a plant not comprising said gene or allele. The offspring can be selected for those comprising the gene or allele of interest.
[0126] Furthermore, the methods of the present invention can result in the creation or provision of a plant material, comprising grains or seeds, relating to any means known in the art to produce further plants, plant parts or seeds and includes inter alia vegetative reproduction methods, such as, for example, air or ground layering, division, (bud) grafting, micropropagation, stolons or runners, storage organs such as bulbs, corms, tubers and rhizomes, striking or cutting, or twin-scaling, sexual reproduction, comprising crossing with another plant, and asexual reproduction, such as e.g. apomixis, somatic hybridization and the like.
[0127] In one embodiment according to the various aspects of the present invention, the modification of the at least one gene encoding at least one wall-associated kinase within step (ii) (a) or (ii) (b) of the method for producing a plant having increased fungal resistance, or a modification of a gene encoding $\mathrm{Bx} 1, \mathrm{Bx} 2, \mathrm{Bx} 3, \mathrm{Bx} 4, \mathrm{Bx} 5, \mathrm{Bx} 7, \mathrm{Bx} 8$, Bx9, Bx10, Bx11, Bx12, Bx13, Bx14, Igl, Glu1, Glu2, OPR2, LOX3 or AOC1, may be performed by at least one of a site-specific nuclease (SSN) or a catalytically active fragment thereof, or a nucleic acid sequence encoding the same, oligonucleotide directed (ODM) mutagenesis (ODM), chemical mutagenesis, or TILLING.
[0128] TILLING, initially a functional genomics tool in model plants, has been extended to many plant species and become of paramount importance to reverse genetics in crops species. A major recent change to TILLING has been the application of next-generation sequencing (NGS) to the process, which permits multiplexing of gene targets and genomes. NGS will ultimately lead to TILLING becoming an in silico procedure. Because it is readily applicable to most plants, it remains a dominant non-transgenic method for obtaining mutations in known genes and thus represents a readily available method for non-transgenic approaches according to the methods of the present invention. As it is known to the skilled person, TILLING usually comprises the chemical mutagenesis, e.g., using ethyl methanesulfonate (EMS), or UV light induced modification of a genome of interest, together with a sensitive DNA screening-technique that identifies single base mutations in a target gene, wherein the target gene may encode a protein being selected from the group of a receptor-like kinase, such as a WAK, an enzyme involved in benzoxazinoid synthesis or metabolism, defense, the lignin pathway, the jasmonic acid synthesis pathway, or a transcription factor involved in one of the aforementioned metabolic and/or signalling pathways.
[0129] SSNs and ODM mutagenesis both are suitable techniques for precision genome engineering in plant cells. As it is known to the skilled person, ODM offers a rapid, precise and non-transgenic breeding alternative for trait improvement in agriculture to address this urgent need. ODM is a precision genome editing technology, which uses oligonucleotides to make targeted edits in plasmid, episomal and chromosomal DNA of plant systems.
[0130] In one embodiment according to the various aspects and embodiments of the present invention, the at least one site-specific nuclease (SSN), or the nucleic acid sequence encoding the same, may be selected from at least one of a CRISPR nuclease, including Cas or Cpf1 nucleases, a TALEN, a ZFN, a meganuclease, a base editor complex, a restriction endonuclease, including Fold or a variant thereof, or two site-specific nicking endonucleases, or a variant or a catalytically active fragment thereof. Said targeted genome engineering SSNs can be suitable for both, the introduction of a gene of interest not yet present in a specific genotype, as well as the targeted mutagenesis of a gene of a given specific genotype to modulate (up- or downregulate) the activity of an enzyme encoded by a gene of interest to be modified in a highly precise way.
[0131] SSNs meanwhile emerged as indispensable prerequisite for site-directed genome engineering. SSNs are (programmable) nucleases, which can be used to break a nucleic acid of interest at a defined position to induce either a double-strand break (DSB) or one or more single-strand breaks. Alternatively, said nucleases can be chimeric or
mutated variants, no longer comprising a nuclease function, but rather operating as recognition molecules in combination with another enzyme. Those nucleases or variants thereof are thus key to any gene editing or genome engineering approach. In recent years, many suitable nucleases, especially tailored endonucleases have been developed comprising meganucleases, a base editor complex, zinc finger nucleases, TALE nucleases, and CRISPR nucleases, comprising, for example, Cas, Cpf1, CasX or CasY nucleases as part of the Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) system. The use of those SSNs and the necessary accessory molecules, for example crRNAs, tracrRNAs, or gRNAs, and delivery systems are thus envisaged for performing the methods according to the present invention.
[0132] A "base editor" as used herein refers to a protein or a fragment thereof having the same catalytical activity as the protein it is derived from, which protein or fragment thereof, alone or when provided as molecular complex, referred to as base editing or base editor complex herein, has the capacity to mediate a targeted base modification, i.e., the conversion of a nucleotide base of interest resulting in a point mutation of interest which in turn can result in a targeted mutation, if the base conversion does not cause a silent mutation, but rather a conversion of an amino acid encoded by the codon comprising the position to be converted with the base editor. Preferably, the base editor is temporarily or permanently linked to at least one site-specific effector, or optionally to a component of at least one site-specific effector complex. The linkage can be covalent and/or non-covalent. Multiple publications have shown targeted base conversion, primarily cytidine (C) to thymine ( T ), using a CRISPR/Cas9 nickase or non-functional nuclease linked to a cytidine deaminase domain, Apolipoprotein B mRNA-editing catalytic polypeptide (APOBEC1), e.g., APOBEC derived from rat. The deamination of cytosine (C) is catalyzed by cytidine deaminases and results in uracil ( U ), which has the base-pairing properties of thymine (T). Most known cytidine deaminases operate on RNA, and the few examples that are known to accept DNA require single-stranded (ss) DNA.
[0133] A "CRISPR nuclease" according to the present invention can be a CRISPR-based nuclease, or the nucleic acid sequence encoding the same, which is selected from the group consisting of (a) Cas9, including SpCas9, SaCas9, SaKKH-Cas9, VQR-Cas9, StlCas9, or (b) Cpfl, including AsCpfl, LbCpfl, FnCpfl, (c) CasX, or (d) CasY, or any variant or derivative of the aforementioned CRISPR-based nucleases, or a CRISPR-based nuclease comprising a mutation in comparison to the respective wild-type sequence so that the resulting CRISPR-based nuclease is converted to a single-strand specific DNA nickase, or to a DNA binding effector lacking all DNA cleavage ability. A "CRISPR(based) nuclease", as used herein, is thus any nuclease which has been identified in a naturally occurring CRISPR system, which has subsequently been isolated from its natural context, and which preferably has been modified or combined into a recombinant construct of interest to be suitable as tool for targeted genome engineering. Any CRISPR-based nuclease can be used and optionally reprogrammed or additionally mutated to be suitable for the various embodiments according to the present invention as long as the original wild-type CRISPR-based nuclease provides for DNA recognition, i.e., binding properties. Said DNA recognition can be PAM dependent. CRISPR nucleases having optimized
and engineered PAM recognition patterns can be used and created for a specific application. The expansion of the PAM recognition code can be suitable to target the site-specific effector complexes to a target site of interest, independent of the original PAM specificity of the wild-type CRISPR-based nuclease. Cpfl variants can comprise at least one of a S542R, K548V, N552R, or K607R mutation, preferably mutation S542R/K607R or S542R/K548V/N552R in AsCpf1 from Acidaminococcus (cf. SEQ ID NO: 24). Furthermore, modified Cas variant, e.g., Cas 9 variants, can be used according to the methods of the present invention as part of a base editing complex, e.g. BE3, VQR-BE3, EQRBE3, VRER-BE3, SaBE3, SaKKH-BE3 (see Kim et al., Nat. Biotech., 2017, doi:10.1038/nbt.3803). Therefore, according to the present invention, artificially modified CRISPR nucleases are envisaged, which might indeed not be any "nucleases" in the sense of double-strand cleaving enzymes, but which are nickases or nuclease-dead variants, which still have inherent DNA recognition and thus binding ability. Other suitable Cpfl-based effectors for use in the methods of the present invention are derived from Lachnospiraceae bacterium (LbCpfl, e.g., NCBI Reference Sequence: WP_051666128.1), or from Francisella tularensis (FnCpf1, e.g., UniProtKB/Swiss-Prot: A0Q7Q2.1). Variants of Cpf1 are known (cf. Gao et al., BioRxiv, http://dx.doi.org/10. 1101/091611). Variants of AsCpf1 with the mutations S542R/K607R and S542R/K548V/N552R that can cleave target sites with TYCV/CCCC and TATV PAMs, respectively, with enhanced activities in vitro and in vivo are thus envisaged as site-specific effectors according to the present invention. Genome-wide assessment of off-target activity indicated that these variants retain a high level of DNA targeting specificity, which can be further improved by introducing mutations in non-PAM-interacting domains. Together, these variants increase the targeting range of AsCpf1 and thus provide a useful addition to the CRISPR/ Cas genome engineering toolbox.
[0134] Due to the fact that receptor-like kinases and BX enzymes (cf. SEQ ID NOs: 10 to 13 and 16 to 21), Igl (SEQ ID NOs: 14 and 15), OPR2 (SEQ ID NOs:22 and 23), LOX3 (SEQ ID NOs:24 and 25), and AOC1 (SEQ ID NOs:26 and 27) are ubiquitously found in a variety of plants, particularly monocotyledonous plants (monocots) and dicotyledonous plants (dicots) of agronomic interest, the methods according to the present invention can be used for the targeted optimization of several important monoct and dicot crop plants.
[0135] In one embodiment according to the various aspects of the present invention, the at least one plant cell, tissue, organ, or whole plant provided in step (i) (a) may be selected from the group consisting of Hordeum vulgare, Hordeum bulbusom, Sorghum bicolor, Saccharum officinarium, Zea spp., including Zea mays, Setaria italica, Oryza minuta, Oryza sativa, Oryza australiensis, Oryza alta, Triticum aestivum, Triticum durum, Secale cereale, Triticale, Malus domestica, Brachypodium distachyon, Hordeum marinum, Aegilops tauschii, Daucus glochidiatus, Beta spp., including Beta vulgaris, Daucus pusillus, Daucus muricatus, Daucus carota, Eucalyptus grandis, Nicotiana sylvestris, Nicotiana tomentosiformis, Nicotiana tabacum, Nicotiana benthamiana, Solanum lycopersicum, Solanum tuberosum, Coffea canephora, Vitis vinifera, Erythrante guttata, Genlisea aurea, Cucumis sativus, Marus notabilis, Arabidopsis arenosa, Arabidopsis lyrata, Arabidopsis thaliana, Crucihimalaya himalaica, Crucihimalaya wallichii,

Cardamine nexuosa, Lepidium virginicum, Capsella bursa pastoris, Olmarabidopsis pumila, Arabis hirsute, Brassica napus, Brassica oleracea, Brassica rapa, Raphanus sativus, Brassica juncacea, Brassica nigra, Eruca vesicaria subsp. sativa, Citrus sinensis, Jatropha curcas, Populus trichocarpa, Medicago truncatula, Cicer yamashitae, Cicer bijugum, Cicer arietinum, Cicer reticulatum, Cicer judaicum, Cajanus cajanifolius, Cajanus scarabaeoides, Phaseolus vulgaris, Glycine max, Gossypium sp., Astragalus sinicus, Lotus japonicas, Torenia fournieri, Allium cepa, Allium fistulosum, Allium sativum, Helianthus annuus, Helianthus tuberosus and Allium tuberosum, or any variety or subspecies belonging to one of the aforementioned plants, preferably wherein the plant cell, tissue, organ, or whole plant in step (i) is selected from Zea mays or Triticum spp., or any variety or subspecies belonging to one of the aforementioned plants.
[0136] In one aspect of the present invention, there is thus disclosed a plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, obtainable by any one of the methods according to the various aspects disclosed herein. The plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof obtained according to the present invention will have at least one optimized agronomic trait, wherein this trait is disease resistance or tolerance, preferably fungus resistance or tolerance, more preferably resistance or tolerance against NCLB caused by E. turcicum or a related fungal diseases caused by any one of the related fungal pathogens disclosed herein. Based on the disclosure provided herein demonstrating the functional mechanism of a WAK induced quantitative NCLB resistance, said resistance being associated with a reduction of the BXD biosynthesis, which in turn inhibits the hemibiotrophic fungus E. turcicum and related fungi, the teachings provided herein can be used to provide a plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof having a favourable BXD content, preferably a reduced BXD content, so that the plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof has an increased resistance against fungal infection, i.e., fungal infestation and persistence.
[0137] In yet a further embodiment according to the present invention, more than one agronomic property of a plant cell or plant of interest can be modified in addition to the introduction, modulation and/or modification of a WAK or WAK gene of interest. Said agronomic properties are selected from seed emergence, vegetative vitality, stress tolerance, disease resistance or tolerance against a further fungus, or against another pathogen, comprising a virus, bacterium, a nematode, an insect etc., herbicide resistance, branching tendency, flowering time, seed clusters, seed density, stability and storability, threshing capability (uniform ripening), lodging resistance, increased yield (seed size, yield etc.), or a modified composition of a molecule of agronomic importance (e.g. starch, carbohydrate, protein etc.) of interest, and the like.
[0138] In another aspect according to the present invention there is provided method for identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material the method comprising: (i) determining the genotype of at least one plant cell, tissue, organ, whole plant, or plant material with respect to the presence of at least one gene encoding a wall-associated
kinase in the genome of said plant cell, tissue, organ, whole plant or plant material; (ii) optionally: determining the benzoxazinoid signature of the at least one plant cell, tissue, organ, whole plant, or plant material of step (i); (iii) exposing the at least one plant cell, tissue, organ, whole plant, or plant material of step (i) or (ii) to a stimulus, optionally wherein the stimulus is correlated with the benzoxazinoid signature in the at least one plant cell, tissue, organ, whole plant, or plant material, preferably wherein the stimulus is associated with a fungal pathogen infection; (iv) performing an analysis of at least one analyte obtained from the at least one plant cell, tissue, organ, whole plant, or plant material of step (i) or (ii) after exposition to the stimulus; (v) determining at least one gene being regulated upon exposition to a stimulus according to step (iii) in at least one cell of the at least one plant cell, tissue, organ, whole plant, or plant material as derivable from the analysis of at least one analyte as defined in step (iv), (vi) subjecting the at least one gene as determined in step (v) to a functional characterization; and (vii) providing at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material.
[0139] In one embodiment, the determination of the genotype of at least one plant cell, tissue, organ, whole plant, or plant material with respect to the presence of at least one gene encoding a wall-associated kinase may be performed by determining in the genome of a plant cell, tissue, organ, whole plant, or plant material of interest the presence and/or transcript level of a WAK gene of interest, preferably a WAK gene comprising a nucleotide sequence according to SEQ ID NO: 1 or 7 , or comprising a nucleotide sequence having at least $60 \%, 65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%$, $85 \%, 86 \%, 87 \%, 88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%$, $95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to one of the nucleotide sequence according to SEQ ID NO: 1 or 7 , preferably over the entire length of the sequence, or comprising a nucleotide sequence hybridizing with a nucleotide sequence complementary to the nucleotide sequence according to SEQ ID NO: 1 or 7 preferably under stringent conditions, or comprising a nucleotide sequence encoding for an amino acid sequence of SED ID NO: 2 or 8 or for an amino acid sequence having at least $60 \%, 65 \%, 70 \%, 75 \%$, $80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%, 87 \%, 88 \%, 89 \%$, $90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to one of SEQ ID NO: 2 or 8 .
[0140] In another embodiment, determining the benzoxazinoid signature comprises a step of determination of the presence and/or the transcript level of at least one gene from the BXD biosynthesis pathway and/or the jasmonic acid pathway, The gene may be selected from any one of SEQ ID NOs: $10,12,14,16,18,20,22,24$ or 26 , or a variant, homologous gene, allel or mutant or a fragment thereof. Bioinformatic tools for the determination and/or alignment of sequences of interest are disclosed herein, or are readily available to the skilled person.
[0141] In one embodiment, the determination of the genotype of at least one plant cell, tissue, organ, whole plant, or plant material with respect to the presence of at least one gene encoding a wall-associated kinase may also comprise the sequencing of a gene having a certain sequence identity, e.g., $80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%, 87 \%, 88 \%$, $89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to one of the gene sequences disclosed herein, which gene has not yet been annotated in a
publicly available genome database to determine the precise sequence of said gene by means of molecular biology, e.g., PCR techniques.
[0142] In one embodiment, the method for identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material may comprise the determination of the benzoxazinoid (BXD) signature of the at least one plant cell, tissue, organ, whole plant, or plant material of step (i). The benzoxazinoid signature means the qualitative and/or quantitative determination of at least one BXD secondary metabolite of interest as disclosed herein. This determination can provide a reference value for any subsequent analysis. The benzoxazinoid signature determination, which can be performed at different timepoints and with or without the addition of a stimulus, thus can provide information on the background level of a specific BXD present before and after addition of a stimulus. Furthermore, the BXD signature may provide data on the total amount of mixed BXD compounds synthesized in a plant, plant cell, tissue, organ or whole plant under suitable and defined conditions. The BXD signature may thus serve as reference value to have a benchmark for any subsequent modifications and/or modulations performed in accordance with the methods of the present invention. Due to the fact that BXD synthesis depends on the action of different enzymes in the terminal branch of the synthesis pathway, more than one different BXD compound may be analyzed to provide a BXD signature of a plant cell, tissue, organ, or whole plant of interest representing a full picture of the different BXD compounds synthesized by the plant under defined conditions (timepoint, stimulus, stimulus amount and environmental factors, for example, biotic or abiotic stress).
[0143] In one embodiment, the method for identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material may comprise the exposition of the at least one plant cell, tissue, organ, whole plant, or plant material of step (i) or (ii) to a stimulus, optionally wherein the stimulus is correlated with the benzoxazinoid signature in the at least one plant cell, tissue, organ, whole plant, or plant material, preferably wherein the stimulus is associated with a fungal pathogen infection.
[0144] A "stimulus" in this context refers to any naturally occurring, endogenous or exogenous, or non-naturally occurring substance chemical substance stimulating a plant cell, tissue, organ, whole plant. Preferably, the stimulus is a stimulus derived from or associated with a pathogen, preferably a fungal pathogen. The stimulus may be a known PAMP or DAMP triggering an immune response mediated by a receptor-like kinase in a plant cell, tissue, organ, whole plant. The correlation may be of direct or indirect nature. The "stimulus" may also be an endogenous substance, e.g., a BXD or jasmonic acid, or a synthetic variant thereof, as BXD compounds and jasmonic acids may induce feedback regulation mechanisms in a plant cell. The "stimulus" may the pathogen by itself causing the desired response in a plant.
[0145] The stimulus may thus be any environmental stimulus which will cause a response in a plant, wherein the response is effected by a signal cascade, or reaction within a plant cell, tissue, organ, whole plant, e.g., resulting in a different transcriptome profile in comparison to the transcriptome profile of a non-stimulated plant. Preferably, the
stimulus is correlated with a benzoxazinoid signature in at least one plant cell, tissue, organ, whole plant, or plant material. In one embodiment, where the correlation between a stimulus and the BXD signature is not known, a correlation between a stimulus of interest and the BXD signature can be easily determined by measuring the up- or down-regulation of genes within the BXD signalling pathway upon addition of a stimulus of interest to determine a direct or indirect correlation.
[0146] In a preferred embodiment, the stimulus is associated with a fungal pathogen, but is not restricted thereto. As it is known in the field of plant pathophysiology, plants evolved sophisticated strategies to respond to a stimulus as provided by a variety of different plant pathogens to initiate defense responses. Certain response may be highly specific for a pathogen, or one specific molecule associated or produced by said pathogen, whereas other defense strategies are part of a global regulatory network as associated by a stimulus of interest. According to the methods of the present invention it is thus possible to analyze the effect of a stimulus of interest a pathway of interest to identify any implication in the BXD or jasmonic acid biosynthesis pathway having a favourable effect on plant fungal response as disclosed herein in a highly targeted way to identify new target genes contributing to a favourable fungal defense response in a plant cell, tissue, organ, or whole plant of interest.
[0147] In one embodiment, the method for identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material according to the present invention can comprise an additional step of electronically transmitting and/or electronically storing data on a computer readable medium.
[0148] An "analyte" obtained from the at least one plant cell, tissue, organ, or whole plant may comprises a nucleic acid, including DNA and RNA, an amino acid sequence, or a plant metabolite.
[0149] In one embodiment, a transcriptome analysis, i.e., an analysis of the sum total of all the messenger RNA molecules expressed from the genes of an organism, using RNA obtained from the at least one plant cell, tissue, organ, or whole plant of step (ii) after exposition to the stimulus is performed to obtain data on any changes in the transcription profile of certain genes in a plant cell, tissue, organ, whole plant treated with a stimulus of interest in comparison to plant cell, tissue, organ, or whole plant not treated with the respective stimulus. A variety of different tools to perform a transcriptome analysis of genome-wide differentially expressed RNA and to analyze altered gene expression/ transcription is available to the skilled person. In one embodiment, the determination of at least one gene being regulated upon exposition to a stimulus according to step (iii) of the above method for identifying at least one gene involved in increased pathogen resistance in at least one cell of the at least one plant cell, tissue, organ, whole plant thus comprises the determination of the transcription level of a gene. Preferably, differentially regulated, or highly regulated genes, e.g., genes being significantly up- or down-regulated in comparison to a non-treated plant or plant cell, may be further analyzed.
[0150] In another embodiment, a proteome analysis, i.e., an analysis of the entire complement of proteins that is or can be expressed by a plant cell, tissue, or organism, using
amino acids obtained from the at least one plant cell, tissue, organ, or whole plant of step (ii) after exposition to the stimulus is performed to obtain data on any changes in the transcription profile in a plant cell, tissue, organ, whole plant treated with a stimulus of interest in comparison to plant cell, tissue, organ, or whole plant not treated with the respective stimulus. Several methods for quantitative and qualitative proteome analysis, of the whole proteome or parts thereof, are available to the skilled person.
[0151] In yet another embodiment, an analysis of a metabolite, e.g., a substance produced by the at least one plant cell, tissue, organ or whole plant and representing an intermediate or product of its metabolism, is performed to identify the effect of a stimulus has on the overall constitution and production level with respect to said metabolite of interest.
[0152] In one embodiment of the method for identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material, a gene of interest determined, said gene being regulated upon exposition to a stimulus, preferably a stimulus influencing a BXD signature, may be subjected to a functional characterization. The functional characterization may comprise an in silico analysis, an in vitro analysis, an in vivo analysis, or a combination of the aforementioned analyses. The in silico analysis may comprise the determination of any known function of said gene in different plant, or information on available allelic variants of said gene in different plants or different germplasm. Furthermore, the in silico analysis may comprise the determination of the locus of a gene such determined in the genome of a plant of interest, or the determination of regulatory sequences associated with the gene of interest. An in vitro analysis or manipulation may comprise the cloning, sequencing and characterization of the gene of interest and/or the creation of an expression construct, or vector, or a fusion construct, or the creation of mutants of a gene of interest. An in vitro analysis or manipulation may further comprise the introduction of a gene of interest, comprised by a suitable construct, into a target plant, tissue, organ or whole plant of interest by a suitable delivery vector. The in vivo analysis may comprise the analysis of different plants or plant cells, tissues or organs from different species, cultivars or varieties comprising or not comprising the gene of interest in their genome to provide a functional characterization of the phenotype the gene of interest may participate in, optionally by subjecting the different plants or plant cells, tissues or organs from different species, cultivars or varieties to different stimuli and controlled conditions to be able to compare the respective results.
[0153] In one embodiment, at least one gene involved in increased pathogen resistance as identified according to the methods of the present invention can be further subjected to directed mutagenesis studies and subsequent functional analyses to identify mutations positively or negatively effecting a phenotype of interest, wherein the phenotype is a change in the BXD signature, or a change of fungal resistance in comparison to the respective wild-type. Methods to introduce (multiple) site-directed mutations into a given gene of interest are available to the skilled person.
[0154] In one aspect of the present invention there is provided a plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, obtainable by introducing at least one gene as provided by the method for
identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance into the genome of at least one cell of at least one of a plant cell, tissue, organ, or whole plant.
[0155] In one embodiment, the plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, comprises at least one wall-associated kinase (WAK) selected from Htn1, Ht2, or Ht3, or an allelic variant, a mutant or a functional fragment thereof, or a gene encoding the same, preferably wherein the at least one wallassociated kinase a) is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 7 , or a functional fragment thereof, $b$ ) is encoded by a nucleic acid molecule comprising the nucleotide sequence having at least $60 \%, 65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%$, $85 \%, 86 \%, 87 \%, 88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%$, $95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to nucleotide sequence of SEQ ID NO: 1 or 7, preferably over the entire length of the sequence, c ) is encoded a nucleic acid molecule hybridizing with a complementary sequence to a) or b) under stringent conditions, $d$ ) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence of SEQ ID NO: 2 or 8, or a functional fragment thereof, e) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence having at least $60 \%, 65 \%, 70 \%, 75 \%$, $80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%, 87 \%, 88 \%, 89 \%$, $90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to amino acid sequence of SEQ ID NO: 2 or 8 , preferably over the entire length of the sequence, f) comprising the amino acid sequence of SEQ ID NO: 2 or 8 , or g) comprising an amino acid sequence having at least $60 \%, 65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%$, $86 \%, 87 \%, 88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%$, $96 \%, 97 \%, 98 \%$ or $99 \%$ sequence identity to amino acid sequence of SEQ ID NO: 2 or 8 , preferably over the entire length of the sequence, provided that the sequence, optionally after expression, still encodes at least one functional Htn1, Ht2, or Ht3, or an allelic variant, a mutant, or a functional fragment thereof. In a preferred embodiment, the plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, comprises at least one wall-associated kinase or an allelic variant, a mutant or a functional fragment thereof, or a gene encoding the same, which has been introduced or introgressed, or which at least one wall-associated kinase or an allelic variant, a mutant or a functional fragment thereof, or a gene encoding the same, comprises at least one mutation enhancing the kinase activity of the at least one WAK.
[0156] In another preferred embodiment, the plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, comprises at least one further introduced or introgressed enzyme, or the gene encoding the same, wherein the at least one further gene or enzyme is selected from a bx1, bx2, igl, bx6, bx11, bx14, opr2, lox3 or aocl gene (SEQ ID NOs: 10, 12, 14, 16, 18, 20, 22, 24 or 26 , respectively), or a homologous gene thereof, or the respective proteins encoded by said genes (SEQ ID NOs: 11, $13,15,17,19,21,23,25$ or 27 , respectively), or a homolog thereof or an allelic variant or mutant thereof, preferably a mutant resulting in decreased transcription and/or translation of the bx1, bx2, igl, bx6, bx11, bx14, opr2, lox 3 or aoc1 gene or protein, respectively. The at least one mutation may thus reside in a regulatory region of such a gene leading to
a reduced transcription, or the mutation may result in at least one point mutation affecting the catalytic activity of the translated protein so that said protein or enzyme has a decreased capability to synthesize a BXD compound
[0157] In one embodiment, the introduction of at least one gene into plant cell, tissue, organ, whole plant or plant material, obtainable by introducing at least one gene as provided by the method for identifying at least one gene involved in increased pathogen resistance, preferably increased fungal resistance, is a stable introduction, preferably a stable introduction mediated by plant breeding, or a stable introduction mediated by means of molecular biology, comprising Agrobacterium-mediated transformation, genome editing, or a combination thereof.
[0158] In one embodiment, the introduction may be effected by introgression of the at least one gene identified, and/or the introduction may be effected may any means of molecular biology. In one embodiment the introduction of a gene or allele determined can take place by recombination between two donor genomes, e.g., in a fused protoplast, wherein at least the donor protoplast carries the gene allele of interest in its genome. In any case, any progeny or derivatives comprising the gene allele of interest can then be subjected to repeated back-crossing steps with a plant line carrying a genetic background of interest to select for the gene allele of interest in the resulting derivatives or progeny. The result may be the fixation of the gene allele of interest such introgressed in a selected genetic background. The whole process of introgression can, for example, take place by a mixture of breeding strategies and techniques of molecular biology to achieve at a genotype/phenotype of interest for a given germplasm, plant, plant cell or plant material.
[0159] In one embodiment, there is thus provided an improved donor source of germplasm having, e.g. by introgression, enhanced resistance to a fungus of interest, preferably wherein the fungus resistance against which resistance is increased, or the disease caused by said fungus is selected from a fungus of the order of Pleosporales, comprising E. turcicum $/$ H. turcicum causing northern corn leaf blight (NCLB), particularly affecting maize and wheat plants, southern corn leaf blight (Bipolaris maydis), the order of Pucciniales causing rust disease, comprising common rust (Puccinia sorghi), or Diploida leaf streak/blight (Diploida macrospora/Stenocarpella macrospora), or Colletotrichum graminicola, or Fusarium spp., preferably Fusarium verticilioides causing Fusarium stalk rot, or Gibberella spp., e.g., Gibberella zeae causing Giberella stalk rot, rust, stalk rot, maize head smut (Sphacelotheca reiliana), and Diploida leaf streak/blight. This germplasm can then serve as basis for further breeding steps.
[0160] In another embodiment, the introduction of at least one gene as identified and provided by the method for identifying at least one gene involved in increased pathogen resistance into at least one plant cell, tissue, organ, whole plant may be effected by at least one means of molecular biology, comprising the use of a delivery vehicle or vector. Optionally, the method can further comprise the modification or modulation of a gene of interest using at least one of a site-specific nuclease (SSN) or a catalytically active fragment thereof, or a nucleic acid sequence encoding the same, oligonucleotide directed mutagenesis, chemical mutagenesis, or TILLING, wherein the at least one site-specific nuclease (SSN), or the nucleic acid sequence encoding the
same, is selected from at least one of a CRISPR nuclease, including Cas or Cpfl nucleases, a TALEN, a ZFN, a meganuclease, a base editor complex, a restriction endonuclease, including Fok1 or a variant thereof, or two sitespecific nicking endonucleases, or a variant or a catalytically active fragment thereof.
[0161] In yet a further aspect according to the present invention, there is provided a method of increasing pathogen resistance, preferably fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material, the method comprising: (i) providing at least one plant cell, tissue, organ, whole plant or plant material; (ii) (a) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance neutralizing the effect of at least one benzoxazinoid, and/or (ii) (b) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance activating the signalling pathway downstream of at least one wall-associated kinase; and/or (ii) (c) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance modulating or modifying the activity of at least promoter or at least one regulatory sequence of at least one gene of the at least one plant cell, tissue, organ, whole plant or plant material of step (i), wherein said at least promoter or at least one regulatory sequence is involved in the regulation of transcription of at least on gene involved in the signalling pathway of, or downstream of at least one wall-associated kinase or involved in the synthesis pathway of at least one benzoxazinoid; (ii) (d) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance inhibiting the synthesis of at least one benzoxazinoid; (iii) reducing the amount of at least one benzoxazinoid and thereby increasing pathogen resistance, preferably fungal resistance, in at least one plant cell, tissue, organ, whole plant, or plant material.
[0162] A "a substance neutralizing the effect of at least one benzoxazinoid" as used herein is to be construed broadly and comprises any naturally occurring or synthetic molecule, which can interact with a BXD compound to decrease the natural effect of the BXD compound said BXD compound would exert (endogenously and/or exogenously) on a plant or the plant environment. Preferably, the substance neutralizing the effect of at least one benzoxazinoid can be added to a plant cell, tissue, organ, or whole plant, optionally coated or together with a suitable delivery vehicle, so that the substance can be transferred into a plant cell of interest. Alternatively, the substance can be added to a plant cell, tissue, organ or whole plant to neutralize the effect of a volatile compound released by a plant cell, tissue, organ or whole plant. Preferably, the substance neutralizing the effect of at least one benzoxazinoid is not toxic to the plant cell, tissue, organ, or whole plant, or to the environment. As it is known that jasmonic acid (JA) treatment can induce the accumulation of BXD compounds (Oikawa et al, 2002 and 2004), a substance according to the present invention may also be a substance scavenging or reducing the amount of jasmonic acid to decrease the accumulation of a BXD compound, which in turn leads to the increased fungal resistance of a plant cell, tissue, organ or whole plant of interest. The substance may also interfere with the transcription of at least one $\mathrm{Bx}, \mathrm{Igl}$ or a further gene involved in the BXD or jasmonic acid biosynthesis pathway.
[0163] In a further embodiment, alone or in combination with the use of a neutralizing substance, at least one plant cell, tissue, organ, whole plant or plant material can be treated with a substance activating the signalling pathway downstream of at least one wall-associated kinase. As used in the context of molecular biology, the terms "upstream" and "downstream" can refer to the temporal and mechanistic order of cellular and molecular events. For example, in signal transduction cascade, the second messenger or an intracellular kinase acts downstream to-that is to say, temporally after-activation of cell membrane receptors, for example a WAK. The other way around, activation of cell membrane receptors occurs upstream of - that is to say, prior to - the production of second messengers or the activation or inhibition of further enzymes acting later and intracellularly in the signalling cascade. Such an activating substance can be selected from a substance acting from the exterior of a plant or plant cell, for example, a substance being a PAMP or DAMP for a receptor-like kinase, e.g., a WAK, so that a stronger signal is received and the receptor mediated response is enhanced. Furthermore, the substance may activate the kinase function of a WAK, or any kinase downstream of the WAK. Finally, the substance may act at the interface between the WAK and a further BXD or jasmonic acid biosynthesis pathway.
[0164] For the wheat WAK gene TaWAK/Snn1 it was shown that it is hijacked by the necrotrophic effector SnTox1 that triggers programmed cell death allowing a pathogen to feed and grown on the dead tissue (Shi et al. 2016). Furthermore, these data show that elicitors recognized by WAKs can both be cell wall derived degraded polysaccharides (e.g. OGs) or pathogenic short peptides (SnTox1) (Brutus et al. 2010; Shi et al. 2016). Thus, there is increasing evidence for a complex nature and functional divergence of WAKs in perception of types of ligands and in their role of interacting with biotic diseases in a direct as well as an indirect way. Preferably, an activating substance according to the present invention is a substance directly activating a WAK of interest which in turn, directly or indirectly, leads to a decreased synthesis of at least one BXD compound, which in turn increases the fungal resistance of a plant cell, tissue, organ or whole plant.
[0165] The inventors of the present invention demonstrated that the WAK ZmWAK-RLK1 functions upstream of the BXDs biosynthesis pathway and decreases the content of secondary metabolites BXDs compounds, e.g., DIM ${ }_{2}$ BOAGlc. As the BXD class of secondary metabolites has been found in many of cereal species such maize, wheat and rice, which are the most important food crops worldwide, the methods according to the various aspects of the present invention can thus be used to effect the WAK signaling cascade intrinsically linked to the BXD synthesis, which in turn was found to be key to provide new strategies in fungal defense in plants, preferably for reducing susceptibility to northern corn leaf blight already at the seeding stage. For example, the storage glucoside $\mathrm{DIM}_{2} \mathrm{BOA}$-Glc was found to be constantly lower in susceptible ZmWAK-RLK1 mutants, which suggested DIM $_{2}$ BOA-Gle severed as a candidate susceptibility compound for promoting E. turcicum infection. Knock-out of this compound has been shown to slightly increase the performance of corn leaf aphids Rhopalosiphum maidis (Handrick, Vinzenz, et al. "Biosynthesis of 8-Omethylated benzoxazinoid defense compounds in maize." The Plant Cell 28.7 (2016): 1682-1700), a completely
different class of plant pathogens, not infecting, yet feeding on a plant, whereas the functional mechanism of $\mathrm{DIM}_{2} \mathrm{BOA}$-Glc in interaction with phloem-feeding insects as presently known is possibly different and antagonistic. The methods and findings according to the present invention and mainly the new insights in gap bridge of WAKs and the secondary defense metabolite BXDs can also be used to provide new defense mechanisms against aphids and other phloem feeding insects to a plant, preferably a crop plant.
[0166] In one preferred embodiment, the methods comprise the modulation or modification of at least one further gene from a BXD and/or jasmonic acid biosynthesis pathway as disclosed herein to further decrease the content of secondary metabolites BXDs compounds, e.g., $\mathrm{DIM}_{2} \mathrm{BOA}-$ Glc and thus to enhance fungal resistance in a plant.
[0167] In yet a further embodiment of the method of increasing pathogen resistance, preferably fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material according to the present invention, the method comprises treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance modulating the activity of at least promoter or at least one regulatory sequence of at least one gene of the at least one plant cell, tissue, organ, whole plant or plant material of step (i), wherein said at least promoter or at least one regulatory sequence is involved in the regulation of transcription of at least on gene involved in the signalling pathway of, or downstream of at least one wall-associated kinase, or involved in the synthesis pathway of at least one benzoxazinoid. By modulating or modifying the activity of a promoter or regulatory sequence, the transcription level of a gene of interest and in turn the expression level of a protein of interest can be influenced in a targeted way on a molecular level, or by introducing a transcription factor, preferably a synthetic transcription factor like TAL efector activator/ repressor or CRISPR-dCas9 activator/repressor, for a given promoter/gene into a cell. In embodiments, where a promoter is modified in a targeted way, the modification is performed by at least one of a site-specific nuclease (SSN) or a catalytically active fragment thereof, or a nucleic acid sequence encoding the same, oligonucleotide directed mutagenesis, chemical mutagenesis, or TILLING.
[0168] In one embodiment, the at least one site-specific nuclease (SSN), or the nucleic acid sequence encoding the same, is selected from at least one of a CRISPR nuclease, including Cas or Cpfl nucleases, a TALEN, a ZFN, a meganuclease, a base editor complex, a restriction endonuclease, including Fold or a variant thereof, a recombinase, or two site-specific nicking endonucleases, or a variant or a catalytically active fragment thereof. Preferably, a targeted point mutation is introduced modifying the promoter region, wherein the modification can make use of a transient introduction of the site-specific nuclease tools to obtain a nontransgenic plant cell, tissue, organ or whole plant.
[0169] In yet another or further embodiment of the method of increasing pathogen resistance, preferably fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material according to the present invention, the method comprises treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance inhibiting the synthesis of at least one benzoxazinoid. A substance inhibiting the synthesis of at least one benzoxazinoid can be a double stranded RNA (dsRNA) which is suitable to reduce the expression level of at least on
gene involved in the signalling pathway of, or downstream of at least one wall-associated kinase, or involved in the synthesis pathway of at least one benzoxazinoid, wherein by said reduction of the expression level the synthesis or the amount of at least one benzoxazinoid and thereby increasing pathogen resistance, preferably fungal resistance, in at least one plant cell, tissue, organ, whole plant, or plant material. This down regulating of gene expression is well-known to a person skilled in art as RNAi approach or miRNA interference approach (Fire, A, Xu, S, Montgomery, M, Kostas, S, Driver, S, Mello, C. (1998). Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature 391 (6669): 806-811). Preferably the substance inhibiting the synthesis of at least one benzoxazinoid is at least one siRNA or an siRNA library directed to at least on gene involved in the signalling pathway of, or downstream of at least one wall-associated kinase, or involved in the synthesis pathway of at least one benzoxazinoid. The siRNA or siRNA library can be part of one or more expression cassettes. The siRNA may comprise a first strand of RNA of 15 to 30 nucleotides in length having a $5^{\prime}$ end and a $3^{\prime}$ end, wherein the first strand is complementary to at least 15 nucleotides of the at least on gene involved in the signalling pathway of, or downstream of at least one wallassociated kinase, or involved in the synthesis pathway of at least one benzoxazinoid, and an second strand of RNA of 15 to 30 nucleotides in length having a $5^{\prime}$ end and a $3^{\prime}$ end, and wherein at least 12 nucleotides of the first and second strands are complementary to each other and form a small interfering RNA (siRNA) duplex under physiological conditions, and wherein the siRNA silences the at least on gene involved in the signalling pathway of, or downstream of at least one wall-associated kinase, or involved in the synthesis pathway of at least one benzoxazinoid.
[0170] The various embodiments of the aspect of the present invention being directed to a method of increasing pathogen resistance, preferably fungal resistance, in a plant cell, tissue, organ, whole plant, or plant material, alone or in combination, may result in the targeted reduction of the amount of at least one benzoxazinoid and thereby may lead to an increased pathogen resistance, preferably fungal resistance, in at least one plant cell, tissue, organ, whole plant, or plant material. In yet a further aspect according to the present invention there is thus provided use of a substance a for increasing pathogen resistance, preferably fungal resistance, in at least one plant cell, tissue, organ, whole plant, or plant material. The substance may act as a plant protective agent and may be applied to a plant exogenously, or the substance may be a scavenger of any plant molecule or material, or the substance may act as a modulator of WAK, of the downstream signalling cascade, or of a cellular pathway disclosed herein being related to the WAK signalling pathway, preferably a BXD and/or jasmonic acid biosynthesis pathway, or the substance may act on the transcription of any gene involved in the WAK or an associated pathway as disclosed herein, wherein the substance can thus directly or indirectly influence, preferably decrease, the amount of a BXD compound produced and stored in a plant cell. Thereby the use of the substance according to the present invention will lead to a decreased BXD level and thus an increased fungal resistance in a plant cell, tissue, organ, or whole plant of interest.

## Delivery Methods:

[0171] A variety of suitable delivery techniques suitable according to the methods of the present invention for introducing genetic material into a plant cell are known to the skilled person., e.g. by choosing direct delivery techniques ranging from polyethylene glycol (PEG) treatment of protoplasts (Potrykus, Ingo, et al. "Direct gene transfer to cells of a graminaceous monocot." Molecular and General Genetics MGG 199.2 (1985): 183-188), procedures like electroporation (D'Halluin, Kathleen, et al. "Transgenic maize plants by tissue electroporation." The plant cell 4.12 (1992): 1495-1505), microinjection (Neuhaus, G., et al. "Transgenic rapeseed plants obtained by the microinjection of DNA into microspore-derived embryoids." Theoretical and Applied Genetics 75.1 (1987): 30-36), silicon carbide fiber whisker technology (Kaeppler, H. F., et al. "Silicon carbide fiber-mediated stable transformation of plant cells." Tag Theoretical and Applied Genetics 84.5 (1992): 560566 ), viral vector mediated approaches (Gelvin, Nature Biotechnology 23, "Viral-mediated plant transformation gets a boost", 684-685 (2005)) and particle bombardment (see e.g. Sood et al., 2011, Biologia Plantarum, 55, 1-15). [0172] Despite transformation methods based on biological approaches, like Agrobacterium transformation or viral vector mediated plant transformation, and methods based on physical delivery methods, like particle bombardment or microinjection, have evolved as prominent techniques for introducing genetic material into a plant cell or tissue of interest. Helenius et al. ("Gene delivery into intact plants using the Helios ${ }^{\text {TM }}$ Gene Gun", Plant Molecular Biology Reporter, 2000, 18 (3):287-288) discloses a particle bombardment as physical method for introducing material into a plant cell. Currently, there thus exists a variety of plant transformation methods to introduce genetic material in the form of a genetic construct into a plant cell of interest, comprising biological and physical means known to the skilled person on the field of plant biotechnology and which can be applied to introduce at least one gene encoding at least one wall-associated kinase into at least one cell of at least one of a plant cell, tissue, organ, or whole plant. Notably, said delivery methods for transformation and transfection can be applied to introduce the tools of the present invention simultaneously. A common biological means is transformation with Agrobacterium spp. which has been used for decades for a variety of different plant materials. Viral vector mediated plant transformation represents a further strategy for introducing genetic material into a cell of interest. Physical means finding application in plant biology are particle bombardment, also named biolistic transfection or microparticle-mediated gene transfer, which refers to a physical delivery method for transferring a coated microparticle or nanoparticle comprising a nucleic acid or a genetic construct of interest into a target cell or tissue. Physical introduction means are suitable to introduce nucleic acids, i.e., RNA and/or DNA, and proteins. Likewise, specific transformation or transfection methods exist for specifically introducing a nucleic acid or an amino acid construct of interest into a plant cell, including electroporation, microinjection, nanoparticles, and cell-penetrating peptides (CPPs). Furthermore, chemical-based transfection methods exist to introduce genetic constructs and/or nucleic acids and/or proteins, comprising inter alia transfection with calcium phosphate, transfection using liposomes, e.g., cationic liposomes, or transfection with cationic polymers, including

DEAD-dextran or polyethylenimine, or combinations thereof. Said delivery methods and delivery vehicles or cargos thus inherently differ from delivery tools as used for other eukaryotic cells, including animal and mammalian cells and every delivery method has to be specifically fine-tuned and optimized so that a construct of interest for introducing and/or modifying at least one gene encoding at least one wall-associated kinase in the at least one plant cell, tissue, organ, or whole plant; and/or can be introduced into a specific compartment of a target cell of interest in a fully functional and active way. The above delivery techniques, alone or in combination, can be used for in vivo (in planta) or in vitro approaches.
[0173] In one embodiment, a regulatory sequence according to the present invention may be a promoter sequence, wherein the editing or mutation or modulation of the promoter comprises replacing the promoter, or promoter fragment with a different promoter (also referred to as replacement promoter) or promoter fragment (also referred to as replacement promoter fragment), wherein the promoter replacement results in any one of the following or any one combination of the following: an increased promoter activity, an increased promoter tissue specificity, a decreased promoter activity, a decreased promoter tissue specificity, a new promoter activity, an inducible promoter activity, an extended window of gene expression, a modification of the timing or developmental progress of gene expression in the same cell layer or other cell layer, for example, extending the timing of gene expression in the tapetum of anthers, a mutation of DNA binding elements and/or a deletion or addition of DNA binding elements. The promoter (or promoter fragment) to be modified can be a promoter (or promoter fragment) that is endogenous, artificial, pre-existing, or transgenic to the cell that is being edited. The replacement promoter or fragment thereof can be a promoter or fragment thereof that is endogenous, artificial, pre-existing, or transgenic to the cell that is being edited.
[0174] The present invention will now be illustrated by the following Examples, which are not construed to limit the scope of the present invention.

## EXAMPLES

Example 1: Plant Material and Growth Conditions
[0175] Seventeen maize inbred lines were used, including: (1) historical cultivars B37 and w22, and the NILs B37Htn1 and w 22 Htn 1 that contain the NCLB resistance gene Htn1; (2) Breeding line RP3 and its NIL line RP3Htn1 carrying Htn1 from KWS (see US 2016/0201080 A1); (3) three pairs of mutants RLK1b (S, compromising Htn1 resistance), RLK1d and RLK1f, and corresponding sister lines RLK1bwt (R, carrying functional Htn1), RLK1d-wt, and RLK1fwt, which were produced by EMS-mutagenesis in RP3Htn1 (Hurni et al. 2015); (4) three maize mutants (bx1, bx2 and bx6) and parental line w22, which were provided by Prof. Georg Jander (Cornell University, Ithaca, US). Two or three maize seeds were sown in each Jiffy pot ( $\varnothing 8 \mathrm{~cm}$ ), and fifteen pots were placed in one tray. Seedling plants were grown in a greenhouse condition of 16 h at $20^{\circ} \mathrm{C}$. in the day, 8 h at $18^{\circ} \mathrm{C}$. in the night and approximately $60 \%$ relative humidity.

Example 2: NCLB Infection Tests in the Greenhouse
[0176] Testing for NCLB resistance using E. turcicum isolate Passau-1 was performed as previously described with minor modification (Hurni et al. 2015). After the second leaves had fully emerged, the newly emerged leaves were cut and removed until the end of each test experiment. Single spore inoculation and culture on PDA medium plate, harvest and quantification of progeny spores were described (Hurni et al. 2015). Instead of infection by dropping $80 \mu \mathrm{l}$ spore suspension into the leaf sheath of the second leaf twice, here maize seedlings were infected once by spray (sprayer: ø28 mm, Semadeni, Ostermundigen, Switzerland). Each 4 trays (ca. 60-80 seedlings) were sprayed with 4 ml of spore suspension $\left(4.5 \times 10^{4}\right.$ spores $\left./ \mathrm{ml}\right)$. A very high humidity mic-condition was produced by placing plastic hoods on top of each tray after infection. Each plant was scored for disease symptom between 11 and 25 days and the severity was evaluated by calculating the area under the disease progress curve (AUDPC) or by quantifying the diseased leaf area of the inoculated second leaves (PrimDLA). About 15 seedling plants were scored in each genotype in each experiment.

## Example 3: Vector Construction and Subcellular Localization

[0177] The coding sequence of ZmWAK -RLK1 was amplified using a cDNA clone as template, which was initially amplified in NCLB resistance genotype RP1Htn1 (Hurni et al. 2015). The PCR fragment was introduced into the Gateway donor vector pDONR 207 using the Gateway $\left.{ }^{( }\right)$ BP Clonase ${ }^{\circledR}$ II Enzyme mix (Thermo Fisher Scientific, Wilmington, USA). The generated entry vector carrying the target ZmWAK-RLK1 sequence was inserted by recombination with the destination vector pUBC -GFP-DEST, to produce an in-frame ZmWAK -RLK1+c'-eGFP fusion protein construct driven by Arabidopsis ubiqutin-10 (UBQ10) gene promotor (Grefen, Christopher, et al. "A ubiquitin-10 promoter-based vector set for fluorescent protein tagging facilitates temporal stability and native protein distribution in transient and stable expression studies." The Plant Journal 64.2 (2010): 355-365). The UBQ10::ZmWAK-RLK1-$c^{\prime}$-eGFP construct (SEQ ID NO:9) together with a reference plasmid PIP2A-mCherry (Cutler et al., Random GFP:: cDNA fusions enable visualization of subcellular structures in cells of Arabidopsis at a high frequency. Proc. Natl Acad. Sci. USA 97, 3718-3723, (2000) contains 35S::PIP2A_c'_ RFP construct, which is localized to the plasma membrane) were mixed with nanograde gold particles and co-bombarded into onion epidermal cells, which were subsequently incubated at $20^{\circ} \mathrm{C}$. in the dark for 2-3 days until being ready for observation using a confocal microscope. Plasmolysis was induced by adding a 0.8 M mannitol solution. Furthermore, both plasmids were transformed into Agrobacterium GV3101 and co-infiltrated into 4 -week-old N. bentaniana leaves, which were ready for observation 2 days post infiltration. The primers used for vector construct are provided in the below Table 1.

TABLE 1

| Forward ( F ) and reverse ( R ) primers used for vector constructs |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: |
|  | Target genes | Primers <br> ( $5^{\prime}$ to $3^{\prime}$ ) | PCR efficiency <br> (E) $R^{2}$ of <br> Calibration <br> curve slope | Description |
|  | Actin | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 28 \\ & \text { R - SEQ ID } \\ & \text { NO: } 29 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=109.8 \%, \\ & R^{2}=0.995, \\ & \text { Slope }=-3.107 \end{aligned}$ | Reference gene |
|  | FPGS | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 30 \\ & \text { R - SEQ ID } \\ & \text { NO: } 31 \end{aligned}$ | $\begin{aligned} & E=104.9 \%, \\ & R^{2}=0.990, \\ & \text { Slope }=-3.209 \end{aligned}$ | Reference gene |
| 3 | ZmWAK-RLK1 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 32 \\ & \text { R - SEQ ID } \\ & \text { NO: } 33 \end{aligned}$ | $\begin{aligned} & E=104.0 \%, \\ & R^{2}=0.996, \\ & \text { Slope }=-3.229 \end{aligned}$ | WAK-RLK1 = ZmWAK-RLK1 herein. |
|  | BX1 (BX: benzoxazinless) | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 34 \\ & \text { R - SEQ ID } \\ & \text { NO: } 35 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=100.1 \%, \\ & \mathrm{R}^{2}=0.994, \\ & \text { Slope }=-3.319 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX2 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 36 \\ & \text { R - SEQ ID } \\ & \text { NO: } 37 \end{aligned}$ | $\begin{aligned} & E=126.1 \%, \\ & R^{2}=0.989, \\ & \text { Slope }=-2.821 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX3 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 38 \\ & \text { R - SEQ ID } \\ & \text { NO: } 39 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=107.4 \%, \\ & \mathrm{R}^{2}=0.994, \\ & \text { Slope }=-3.156 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX4 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 40 \\ & \text { R - SEQ ID } \\ & \text { NO: } 41 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=100.9 \%, \\ & \mathrm{R}^{2}=0.994, \\ & \text { Slope }=-3.300 \end{aligned}$ | Benzoxazinoid pathway |
|  | Bx5 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 42 \\ & \text { R - SEQ ID } \\ & \text { NO: } 43 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=109.7 \%, \\ & \mathrm{R}^{2}=0.992, \\ & \text { Slope }=-3.109 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX6 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 44 \\ & \text { R - SEQ ID } \\ & \text { NO: } 45 \end{aligned}$ | $\begin{aligned} & E=107.6 \%, \\ & R^{2}=0.961, \\ & \text { Slope }=-3.153 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX7 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 46 \\ & \text { R - SEQ ID } \\ & \text { NO: } 47 \end{aligned}$ | $\begin{aligned} & E=106.9 \%, \\ & R^{2}=0.989, \\ & \text { Slope }=-3.167 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX8 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 48 \\ & \text { R - SEQ ID } \\ & \text { NO: } 49 \end{aligned}$ | $\begin{aligned} & E=114.0 \%, \\ & R^{2}=0.987, \\ & \text { Slope }=-3.027 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX9 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 50 \\ & \text { R - SEQ ID } \\ & \text { NO: } 51 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=117.3 \%, \\ & \mathrm{R}^{2}=0.999, \\ & \text { Slope }=-2.967 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX10 + BX11 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 52 \\ & \text { R - SEQ ID } \\ & \text { NO: } 53 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=109.5 \%, \\ & \mathrm{R}^{2}=0.999, \\ & \text { Slope }=-3.114 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX12 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 54 \\ & \text { R - SEQ ID } \\ & \text { NO: } 55 \end{aligned}$ | $\begin{aligned} & E=95.4 \%, \\ & R^{2}=0.996, \\ & \text { Slope }=-3.437 \end{aligned}$ | Benzoxazinoid pathway |
|  | BX13 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 56 \\ & \text { R - SEQ ID } \\ & \text { NO: } 57 \end{aligned}$ | $\begin{aligned} & E=99.3 \%, \\ & R^{2}=0.961, \\ & \text { Slope }=-3.340 \end{aligned}$ | Benzoxazinoid pathway |
|  | IGL (Indole <br> Glycerol <br> Phosphate <br> Lyase) | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 58 \\ & \text { R - SEQ ID } \\ & \text { NO: } 59 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=111.8 \%, \\ & R^{2}=0.996, \\ & \text { Slope }=-3.069 \end{aligned}$ | Benzoxazinoid pathway |
|  | GLU1 (GLU: <br> beta <br> glucosidase) | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 60 \\ & \text { R - SEQ ID } \\ & \text { NO: } 61 \end{aligned}$ | $\begin{aligned} & E=110.6 \%, \\ & R^{2}=0.998, \\ & \text { Slope }=-3.092 \end{aligned}$ | Benzoxazinoid pathway |

TABLE 1-continued

| Forward (F) and reverse (R) primers used for vector constructs |  |  |  |
| :---: | :---: | :---: | :---: |
| Or- Target der genes | Primers $\left(5^{\prime} \text { to } 3^{\prime}\right)$ | PCR efficiency <br> (E) $R^{2}$ of <br> Calibration curve slope | Description |
| 18 GLU2 | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 62 \\ & \text { R - SEQ ID } \\ & \text { NO: } 63 \end{aligned}$ | $\begin{aligned} & \mathrm{E}=110.4 \% \\ & \mathrm{R}^{2}=0.985 \\ & \text { Slope }=-3.095 \end{aligned}$ | Benzoxazinoid pathway |
| 19 ZmWAK-RLK1 plasmid construction | $\begin{aligned} & \text { F - SEQ ID } \\ & \text { NO: } 64 \\ & \text { R - SEQ ID } \\ & \text { NO: } 65 \end{aligned}$ |  |  |

## Example 4: Mycelium Development

[0178] The second leaves of 21-day seedling plants were harvested and cut into $2 \times 2 \mathrm{~cm}^{2}$ leaf segments, which were placed and incubated on the phytoagar plates. A spore suspension $\left(4.5 \times 10^{4}\right.$ spores $\left./ \mathrm{ml}\right)$ was painted using swabs on the leaf surface. The petri dishes carrying samples were sealed using PARAFILM and incubated 24 hours at room temperature until harvest. Trypan blue straining was conducted as previously described (Chung, Chia-Lin, et al. "Resistance loci affecting distinct stages of fungal pathogenesis: use of introgression lines for QTL mapping and characterization in the maize-Setosphaeria turcica pathosystem." BMC plant biology 10.1 (2010): 103). The infected segments at 1 dpi were incubated overnight in an acetic acid:ethanol $(1: 3, \mathrm{v} / \mathrm{v})$ solution, and then in a mixed solution of acetic acid:ethanol:glycerol ( $1: 5: 1, \mathrm{v} / \mathrm{v} / \mathrm{v}$ ) for 4 hours. The samples were stained overnight in $0.01 \%$ (w/v) trypan blue lactophenol solution, and then washed once using $\mathrm{ddH}_{2} \mathrm{O}$ and stored in $60 \%$ glycerol ready for use. Specimens were placed on slides and examined under the ZEISS Axio Imager 2 microscope system (CARL ZEISS, Jena, Germany). The numbers of germinated spores, germ tubes, appressoria and successful penetrations (hyphae inside of cell or between cell walls) were counted. Three independent experiments were performed.

## Example 5: RNA Extraction, RNA Sequencing and Data Analysis

[0179] The second leaves of seedling plants were harvested with four biological replicates at $0,9-\mathrm{hpi}, 3$-dpi and 10 -dpi, which corresponded to before inoculation, the germination/penetration, biotrophic growth and necrotrophic growth, respectively (Jennings, P. R., and A. J. Ullstrup. "A HISTOLOGICAL STUDY OF 3 HELMINTHOSPORIUM LEAF BLIGHTS OF CORN." Phytopathology 47.12 (1957): 707-714; Hilu, H. M., and A. L. Hooker. "Hostpathogen relationship of Helminthosporium turcicum in resistant and susceptible corn seedlings." (1964): 570-5). Forty-eight samples ( 4 genotypes, 4 time points, 3 biological replicates) were subjected for total RNA extraction using SV Total RNA Isolation Kits (Promega, Dübendorf, Switzerland). $1 \mu \mathrm{l}$ of total RNA was checked by Nanodrop 1000 Spectrophotometer (Thermo Fisher Scientific, Wilmington, USA) to estimate the RNA concentration. Meanwhile, 15 plants in each genotype were evaluated for the AUDPC value to control if the infection worked.
[0180] The quantity and quality in RNA sequencing were determined using Qubit® 1.0 Fluorometer (Thermo Fisher Scientific, Wilmington, USA) and Bioanalyzer 2100 (Agilent, Waldbronn, Germany). The TruSeq Stranded mRNA Sample Prep Kit (Illumina, Inc., Hayward, USA) was used for library preparation. $1 \mu \mathrm{~g}$ of total RNA per sample was ribosome depleted and then subjected for synthesizing double-strand cDNA. Each cDNA sample was fragmented, end-repaired, polyadenylated and then ligated with TruSeq adaptor that contains the index for multiplexing. The cDNA fragments containing TruSeq adapters at the both ends were enriched with PCR reaction. The enriched libraries were quantified and qualified, and then normalized to 10 nM . The TruSeq SR Cluster Kit v4 cBot (Illumina, Inc., Hayward, USA) was used for cluster generation using 8 pM of pooled normalized libraries. Sequencing was performed on the Illumina HiSeq2500 at single end 125 bp using the TruSeq SBS Kit v4 (Illumina, Inc., Hayward, USA).
[0181] The maize reference genome Zea_mays.AGPv3.27 and the corresponding annotation were downloaded (http:// www.maizegdb.org/). The RNA sequencing reads were mapped on the reference genome with STAR (Dobin, Alexander, et al. "STAR: ultrafast universal RNA-seq aligner." Bioinformatics 29.1 (2013): 15-21) allowing one mismatch per 100 bp and no multimapper with the following command: STAR outFilterMultiMapNmax 1 - outFilterMismatchNoverLmax 0.01 -alignIntronMax 10000. Read counts were determined from the mapping files with featureCounts 1.4.6 (Liao, Yang, Gordon K. Smyth, and Wei Shi. "featureCounts: an efficient general purpose program for assigning sequence reads to genomic features." Bioinformatics 30.7 (2013): 923-930). Statistical analyses were done with the R package edgeR and genes were tested for differential expression with pairwise comparisons and tagwise estimation of dispersion. A gene was considered to be expressed when at least 10 reads were mapped on it and a gene was considered to be differentially expressed with $\log 2 \mathrm{FC} \geq|2|$ and $\mathrm{FDR}<0$. 01 . First, pairwise comparisons were performed between Htn1 and no Htn1 plants for each genotype and each time points separately. The results were then compared between time points and then between the two genotypes. The Gene Ontology analysis for differentially expressed genes (DEGs) was conducted by using online software agriGO (Du, Zhou, et al. "agriGO: a GO analysis toolkit for the agricultural community." Nucleic acids research 38.suppl_2 (2010): W64-W70). The significant terms were colored if adjusted $\mathrm{p} \leq 0.05$.

## Example 6: RT-qPCR Assay

[0182] $1 \mu \mathrm{~g}$ total RNA was subjected for first strand cDNA synthesis using the iScript Advanced cDNA kit (172-5038, Rio-Rad). 1:20 diluted cDNA was applied for quantifying expression using a Real-Time System C1000TM Thermal cycler ( 96 or 384 wells, Bio-Rad). The expression of targets was normalized by the reference genes FPGS and Actin as described (Hurni et al. 2015). The primers for expression analysis are shown in Table 1 above.

## Example 7: Benzoxazinoids (BXDs) Extraction and Measurement

[0183] $60-100 \mathrm{mg}$ leaves (without veins) of the seedling plants were harvested and freezing immediately in liquid nitrogen, grinded and added the extraction buffer ( 1 mg
sample $+10 \mu 1$ extraction buffer). The samples were mixed thoroughly and centrifuged at $13,000 \mathrm{rpm}$ under $4^{\circ} \mathrm{C}$. The supernatant was transferred into new tube and centrifuged once more under same condition, to remove the possible leaf particles. The supernatant was collected being ready for BXDs measurement.
[0184] Benzoxazinoid contents were analyzed by an Acquity UPLC equipment (Waters) coupled to a UV detector and coupled to a mass spectrometer (Waters) (Meihls, Lisa N., et al. "Natural variation in maize aphid resistance is associated with 2, 4-dihydroxy-7-methoxy-1, 4-benzoxazin3 -one glucoside methyltransferase activity." The Plant Cell Online 25.6 (2013): 2341-2355). An Acquity BEH C18 column (Waters) was used. The temperatures of the autosampler and column were $15^{\circ} \mathrm{C}$. and $40^{\circ} \mathrm{C}$., respectively. The mobile phase consisted of $99 \%$ water, $1 \%$ acetonitrile, and $0.1 \%$ Formic acid (A) and acetonitrile and $0.1 \%$ Formic acid (B). Flow rate was set to $0.4 \mathrm{ml} \mathrm{min}^{-1}$ with $3 \% \mathrm{~A}$ and $97 \% \mathrm{~B}$ followed by column reconditioning. The injection volume was $5 \mu$ l. The extracted trace at 275 nm was used for benzoxazinoids quantification. The following extracted ion chromatograms were used for quantification with a mass window of $\pm 0.01 \mathrm{D}$ : mass-to-charge ratio ( $\mathrm{m} / \mathrm{z}$ ) for DIMBOA (retention time [RT] 5.62 min ) and DIMBOAGlc (RT 5.64 min ), m/z for HDMBOA-Glc (RT 8.19 min ), $\mathrm{m} / \mathrm{z}$ for HMBOA-Glc (RT 5.34 min ) and $\mathrm{DIM}_{2}$ BOA-Glc (RT 5.825 min ). Benzoxazinoids absolute concentrations were determined by external calibration curves obtained from purified DIMBOA-Glc, DIMBOA and HDMBOA-Glc standards.

## Example 8: ZmWAK-RLK1 Encodes a Plasma Membrane Localized Protein

[0185] To determine the subcellular localization of the ZmWAK-RLK1 protein, a fusion construct consisting of a full-length coding sequence fused to the sequence of an enhanced green fluorescence protein (eGFP) at the C terminus was generated (cf. SEQ ID NO:9 for the nucleic acid plasmid construct). The ZmWAK-RLK1 fusion protein localized to the plasma membrane before and after plasmolysis when transiently expressed in onion epidermal cells. Furthermore, infiltration into leaves of Nicotiana benthamiana confirmed the localization of ZmWAK-RLK1 to the plasma membrane two days after infiltration (cf. FIG. 12). These data, particularly confocal analysis of onion epidermal cells after transient expression of ZmWAK-RKL1eGFP and the positive control PIP2A-mCherry that is known to localize to the plasma membrane demonstrate that ZmWAK -RLK1 is a plasma membrane protein.

## Example 9: ZmWAK-RLK1 Reduced Fungal Penetrations

[0186] Spores of the hemibiotrophic fungus E. turcicum penetrate the maize epidermis mostly between 6-18 hours after inoculation (hpi) (Jennings and Ullstrup, 1957). To investigate if ZmWAK -RLK1 changes the outcome of fungal penetration attempts, we investigated the infection process at one day post inoculation (dpi) using trypan blue staining (data not shown). The number of successful penetration events were evaluated in three EMS-induced ZmWAK-RLK1 loss-of-function mutant lines (RLK1b, RLK1d and RLK1f) and their corresponding sister lines that were generated in the near isogenic line (NIL) RP3Htn1 (Hurni et al. 2015). No significant difference in the establishment of germ tubes and appressoria was observed in genotypes with/without ZmWAK-RLK1 (data not shown). In contrast, the number of successful penetration events was significantly lower if ZmWAK-RLK1 was functional compared to loss-of-function mutants as demonstrated in FIGS. 2 A and B. This indicates that ZmWAK-RLK1 leads to a reduction of pathogen penetrations into host tissues.

> Example 10: Transcriptome and Metabolism Analysis Identified Alterations to the BXDs Biosynthesis Pathway in the Presence of ZmWAK-RLK1
[0187] To decipher the immune network specifically influenced by ZmWAK-RLK1, we performed a transcriptome analysis by RNA sequencing in two pairs of near isogenic lines, w22 and W22Htn1 as well as B37 and B37Htn1. NCLB development was significantly reduced in the presence of ZmWAK-RLK1 in both NILs (FIG. 3 A-C). Leaf samples were collected at 0 and 9 hpi (penetration stage) as well as 3 (biotrophic growth) and 10 dpi (necrotrophic growth) (Jennings and Ul1strup, 1957). Forty-eight samples were sequenced and 1.159 billion reads were obtained (Table 2). More than 820 million reads were uniquely mapped with an average of 17.08 million reads per sample (70.7\%) (Table 2). No obvious difference of percentage of mapped reads in genotypes with or without Htn1 was observed. A total of 15,345 genes were expressed and they were used for further analysis. By conducting a multidimensional scaling (MDS) analysis using expression normalized by edgeR, the biological replicates for the same genotypetimepoints combination were mostly grouped together, suggesting the repeatability of replicates (data not shown). More differentially expressed gene (DEGs) were detected in B37Htn1/B37 compared to w22Htn1/w22 (FIG. 4). These genes differently expressed in both NILs in at least one of timepoints. To identify DEGs associated with ZmWAKRLK1 and to rule out genetic background effects, only genes that were differentially expressed in both NIL pairs were considered.

TABLE 2

| Statistics of RNA-seq reads sequenced and mapped |  |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: | :---: |

TABLE 2-continued

| Statistics of RNA-seq reads sequenced and mapped |  |  |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Sample number | Samples | Raw reads | Uniquely mapped reads ${ }^{\alpha}$ | Percentage of uniquely mapped reads (\%) | Percentage of multimapped reads (\%) | Percentage of unmapped reads (\%) |
| 5 | 0-w22Htn 1-2 | 19,815,200 | 14,439,891 | 72.87 | 6.07 | 20.44 |
| 6 | 0-w $22 \mathrm{Htn} 1-3$ | 24,173,527 | 16,215,534 | 67.08 | 9.55 | 21.40 |
| 7 | 0-B37-1 | 22,180,888 | 14,689,311 | 66.23 | 5.27 | 28.03 |
| 8 | 0-B37-2 | 24,474,895 | 18,273,286 | 74.66 | 5.96 | 18.75 |
| 9 | 0-B37-3 | 27,774,311 | 20,221,020 | 72.80 | 6.73 | 19.74 |
| 10 | 0-B37Htn1-1 | 26,728,646 | 19,277,404 | 72.12 | 6.16 | 21.04 |
| 11 | $0-\mathrm{B} 37 \mathrm{Htn} 1-2$ | 24,336,731 | 17,640,859 | 72.49 | 6.06 | 20.82 |
| 12 | 0-B37Htn1-3 | 22,625,055 | 16,499,617 | 72.93 | 6.15 | 20.30 |
| 13 | 9h-w22-1 | 25,343,283 | 17,460,901 | 68.90 | 7.81 | 22.49 |
| 14 | 9h-w 22-2 | 26,384,078 | 18,489,206 | 70.08 | 7.16 | 22.03 |
| 15 | 9h-w22-3 | 21,846,924 | 13,680,343 | 62.62 | 5.97 | 30.81 |
| 16 | 9h-w $22 \mathrm{Htn} 1-1$ | 34,074,874 | 23,121,230 | 67.85 | 6.27 | 25.40 |
| 17 | 9h-w $22 \mathrm{Htn1-2}$ | 24,276,403 | 17,299,847 | 71.26 | 7.02 | 21.07 |
| 18 | 9h-w $22 \mathrm{Htn} 1-3$ | 30,200,422 | 20,381,456 | 67.49 | 7.23 | 24.62 |
| 19 | 9h-B37-1 | 17,962,777 | 12,878,288 | 71.69 | 7.38 | 20.10 |
| 20 | 9h-B37-2 | 23,815,810 | 16,892,476 | 70.93 | 7.12 | 21.22 |
| 21 | 9h-B37-3 | 24,188,988 | 17,604,433 | 72.78 | 7.15 | 19.38 |
| 22 | 9h-B37Htnl-1 | 25,195,971 | 17,304,100 | 68.68 | 7.80 | 22.65 |
| 23 | 9h-B37Htn1-2 | 23,902,398 | 16,173,755 | 67.67 | 7.27 | 24.40 |
| 24 | 9h-B37Htnl-3 | 24,731,481 | 17,279,056 | 69.87 | 7.13 | 22.39 |
| 25 | 3d-w22-1 | 22,399,000 | 15,772,632 | 70.42 | 6.44 | 22.49 |
| 26 | 3d-w22-2 | 26,175,191 | 18,816,409 | 71.89 | 6.43 | 21.06 |
| 27 | 3d-w $22-3$ | 23,253,678 | 16,758,123 | 72.07 | 6.45 | 20.82 |
| 28 | 3d-w $22 \mathrm{Htn} 1-1$ | 23,878,639 | 17,185,076 | 71.97 | 5.92 | 21.58 |
| 29 | 3d-w22Htn1-2 | 20,568,384 | 14,338,420 | 69.71 | 7.09 | 22.35 |
| 30 | 3d-w22Htn1-3 | 34,008,596 | 24,127,141 | 70.94 | 5.81 | 22.76 |
| 31 | 3d-B37-1 | 23,690,913 | 14,726,042 | 62.16 | 4.70 | 32.71 |
| 32 | 3d-B37-2 | 27,646,350 | 19,934,380 | 72.10 | 5.89 | 21.42 |
| 33 | 3d-B37-3 | 21,114,803 | 16,208,484 | 76.76 | 5.69 | 16.98 |
| 34 | 3d-B37Htn1-1 | 21,758,134 | 15,409,264 | 70.82 | 5.68 | 23.03 |
| 35 | 3d-B37Htn1-2 | 27,236,811 | 19,866,766 | 72.94 | 5.84 | 20.68 |
| 36 | 3d-B37Htn1-3 | 22,700,637 | 16,553,064 | 72.92 | 5.60 | 21.00 |
| 37 | 10d-w22-1 | 23,051,842 | 16,566,330 | 71.87 | 6.16 | 21.24 |
| 38 | 10d-w22-2 | 28,611,557 | 20,463,896 | 71.52 | 6.01 | 21.77 |
| 39 | 10d-w22-3 | 12,829,435 | 7,480,564 | 58.31 | 4.82 | 36.38 |
| 40 | 10d-w22Htn1-1 | 24,435,356 | 17,199,294 | 70.39 | 5.45 | 23.76 |
| 41 | 10d-w22Htn1-2 | 28,996,022 | 21,442,119 | 73.95 | 5.78 | 19.69 |
| 42 | 10d-w $22 \mathrm{Htn} 1-3$ | 18,649,090 | 13,429,238 | 72.01 | 5.78 | 21.71 |
| 43 | 10d-B37-1 | 13,275,463 | 9,658,508 | 72.75 | 5.46 | 21.16 |
| 44 | 10d-B37-2 | 15,217,491 | 11,288,257 | 74.18 | 5.38 | 19.89 |
| 45 | 10d-B37-3 | 23,349,541 | 17,096,788 | 73.22 | 5.36 | 20.83 |
| 46 | 10d-B37Htn1-1 | 20,104,137 | 14,270,397 | 70.98 | 4.94 | 23.79 |
| 47 | 10d-B37Htn1-2 | 38,203,107 | 27,216,898 | 71.24 | 5.40 | 22.82 |
| 48 | 10d-B37Htn1-3 | 26,094,601 | 18,820,165 | 72.12 | 5.61 | 21.68 |
|  | Total Mean | $\begin{array}{r} 1,159,283,685 \\ 24,151,743 \end{array}$ | $\begin{array}{r} 820,033,238 \\ 17,084,026 \end{array}$ | 70.74 70.74 | $\begin{aligned} & \mathbf{N A}^{b} \\ & \mathbf{N A}^{b} \end{aligned}$ | $\begin{aligned} & \mathbf{N A}^{b} \\ & \mathbf{N A}^{b} \end{aligned}$ |

${ }^{\text {a }}$ Parameters for mapping: less than $1 \%$ mismatch, 1 locus mapped, intron size is less than 10 kb ;
${ }^{b}$ NA $=$ not analyzed.
[0188] Two-hundred and fifteen common DEGs were identified across all time points (FIG. 13). 132 and 83 genes were induced and repressed in the ZmWAK-RLK1-containing NIL compared to the respective susceptible line (heat map and Venn diagram not shown). 108 DEGs were only found at timepoint 0 before inoculation, while 107 of DEGs were found only after infection. Twenty-nine DEGs were differently expressed at all time points including timepoint. An overrepresentation analysis using agriGO was performed to identify enriched Gene Ontology (GO) terms associated with ZmWAK-RLK1. The functional groups were enriched for terms of defense response (e.g. GO:0009814) and metabolic/biosynthetic process (e.g. GO:0006725) (data not shown).
[0189] To further analyze if the presence of ZmWAK RLK1 is associated with BXDs biosynthesis (FIG. 5 A), the
content of major BXDs in second leaves of w22Htn1 and w22 before and after infection was quantified (FIG. 5 B to F). The content of four BXDs DIMBOA-Gle, DIMBOA, HMBOA-Glc and DIM ${ }_{2} \mathrm{BOA}$-Glc was significantly lower in w22Htn1 compared to w22 at all timepoints (data not shown), which indicated a constitutive reduction on BXDs content when ZmWAK-RLK1 is present. Furthermore, via RT-qPCR the transcriptional levels of ZmWAK-RLK1 and specifically the genes in the BXDs biosynthesis pathway before and after pathogen inoculation were determined. The expression of genes (A) ZmWAK-RLK1, (B) Bx1, (C) Igl, (D) Bx 2 , (E) Bx 3 , (F) Bx 4 , (G) Bx 5 , (H) Bx 6 , (I) Bx 7 , (J) Bx8, (K) Bx9, (L) Bx10/11, (M) Bx12, (N) Bx13, (0) Glu1 and (P) Glu2 at different timepoints before and after infection was measured and statistics were conducted separately
in w22 and B37 genetic background using Tukey's HSD ( $\mathrm{P}=0.05$ ) in four biological replicates.
[0190] The ZmWAK-RLK1 expression in NILs showed no significant difference (FIG. 11 A ). Overall, the transcriptional levels of BXD biosynthesis genes were genotypespecific (FIG. 11 A to P)). For instance, BX1 and its protein homolog IGL can convert indole-3-glycerol phosphate into indole, which is the first step of BXD metabolism (Frey et al. 2000). Their coding genes Bx1 and Ig1 showed opposite contributions of gene expression in B37 and w22, but the combined expression of Bx1 and Ig1 was consistently lower in genotypes with ZmWAK-RLK1 (FIGS. 11 B and C).

## Example 11: Mutations in ZmWAK-RLK1 is Associated with the Reduction of Secondary Metabolite DIM $_{2} \mathrm{BOA}$-Glc

[0191] To further analyze the role of different BXD biosynthesis genes as well as the metabolites of this pathway in NCLB resistance, the ZmWAK-RLK1 mutants (RLK1b, d and f, SEQ ID NOs: 3 to 6 and G548R mutant of SEQ ID NO:2) and their sister lines were used (Hurni et al. 2015). The transcript levels of several BXD genes were quantified and the content of major BXD compounds in mutants which lost the resistance caused by ZmWAK-RLK1 (FIG. 6 A to D). In contrast to the NILs, there was no difference in the DIMBOA-Gle, DIMBOA and HMBOA, HDMBOA-Glc concentration. However, the content of DIM ${ }_{2}$ BOA-Glc was significantly lower when ZmWAK-RLK1 was intact (FIG. 6 A , and further data not shown). The reduced $\mathrm{DIM}_{2} \mathrm{BOA}$-Glc correlated with a reduction in Igl transcript levels, while no obvious difference in the transcriptional levels of ZmWAKRLK1 and Bx1 was detected in ZmWAK-RLK1 (FIG. 6 B to D) $\mathrm{Bx} 6, \mathrm{Bx} 7$ and Bx 13 are key genes of the BXDs pathway to produce $\mathrm{DIM}_{2} \mathrm{BOA}$-Glc, and these genes were slightly but not significantly upregulated in mutants (data not shown). This phenomenon can be explained by a feedback regulation. Therefore, ZmWAK -RLK1 clearly seems to be associated with the reduction of secondary metabolite $\mathrm{DIM}_{2} \mathrm{BOA}$-Glc, possibly by reducing the expression levels of Bx1 and/or Igl.

## Example 12: Mutations in BXDs Biosynthesis Genes Decreased NCLB Susceptibility

[0192] To further analyze the role of BXDs in NCLB resistance/susceptibility, mutants in the three BXD biosynthesis genes $\mathrm{Bx} 1, \mathrm{Bx} 2$ and Bx 6 were tested upon inoculation with E. turcicum. These mutants showed strong reduction in several BXDs compounds, including DIM $_{2}$ BOA-Glc (FIG. 7). Interestingly, all three mutants showed a strong reduction of NCLB susceptibility at the seedling stage (FIGS. 8 A and B). This confirmed a negative correlation of BXDs content and NCLB disease resistance. Furthermore, the ZmWAKRLK1 expression at 10 dpi was checked (FIG. 8 C). No
significant difference was detected in the bx mutants if compared to the wild-type. Considering the reduction of Bx 1 and Ig 1 co-expression in $\mathrm{ZmWAK}-\mathrm{RLK} 1$ genotypes (FIG. 6 A, FIGS. 5 B and C, FIG. 9 B), the data suggest that the BXDs synthesis pathway likely acts downstream of ZmWAK-RLK1.
[0193] Therefore, ZmWAK-RLK1 underlying quantitative NCLB disease resistance is based on a decrease of the biosynthesis of secondary metabolite BXDs, and DIM $_{2} \mathrm{BOA}$-Glc served as a candidate susceptibility component for promoting fungal infection (FIG. 8 D ).

## Example 13: Tissue-Specific Expression of WAK-RLK1

[0194] Further to the determination of the subcellular localization of a ZmWAK-RLK1 protein (see Example 8 above), the tissue specific expression of RLK1 in different genotypes, and different time points was determined. The genes FPGS and ACTIN served as reference to normalize the expression. The results shown in FIG. 10 demonstrate that RLK1 is a ubiquitously and steadily expressed gene which further underpins the function of said kinase as master regulator in relevant plant metabolic pathways.

## Example 14: Tilling

[0195] To develop and screen a mutant population of plant material, TILLING was performed. A TILLING mutant population can be created, e.g., starting from KWS line RP3Htn1 according to Kato ( 2000 , The maize handbook, pp. 212-219)). Pollen is harvested from field-grown RP3Htn1 plants and treated with $0.1 \%$ EMS solution for 45 min . Silks of individual plants are then pollinated and emerging ears bagged. From 436 pollinated MO plants seeds were harvested, in one experiment. An additional propagation and selfing led to 10,084 individual M1 plants. Leaf material from these M1 plants was collected for DNA isolation. DNA of dried leaf samples ( 10 leaf discs bunches/sample) was isolated from $10,000 \mathrm{M} 1$ individuals with the CTAB extraction method (Traitgenetics, Gatersleben, Germany). DNA is then aliquoted to $100 \mu 1$ with $20 \mathrm{ng} / \mu 1$. Primer development for mutant screening is performed. The amplification assay consisted of $20 \mathrm{ng} / \mu \mathrm{l}$ DNA, $5 \times$ GoTaq-Buffer, $25 \mu \mathrm{M}$ dNTPs, $10 \mu \mathrm{M}$ forward Primer, $10 \mu \mathrm{M}$ reverse Primer, 5 Units $/ \mu \mathrm{l}$ GoTaq. After denaturation for 300 s at $94^{\circ} \mathrm{C}$. the amplification cycles were performed with 35 cycles of 60 s at $94^{\circ}$ C., 60 s at $60^{\circ} \mathrm{C}$. and 60 s at $72^{\circ} \mathrm{C}$. followed by a final elongation time for 600 s at $72^{\circ} \mathrm{C}$. Next, Sanger-sequencing of PCR products is performed according to established protocols. Sequences are then assembled, for example with the help of the software Lasergene Seqman NGen (DNASTAR) and heterozygote SNPs called with the software default settings. Positive mutant plants were sequenced again with the Sanger-method in order to confirm the polymorphism.

```
<160> NUMBER OF SEQ ID NOS: 65
<210> SEQ ID NO 1
<211> LENGTH: 2004
<212> TYPE: DNA
<213> ORGANISM: Zea mays
```


$<210>$ SEQ ID NO 2
$<211>$ LENGTH: 667
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Zea mays
<400> SEQUENCE: 2


$<210>$ SEQ ID NO 3
$<211>$ LENGTH: 2004
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: RLKIb - mutant Htn1
$<400>$ SEQUENCE: 3
atggctgctc accagcctca cctctccgtc ctcctcctcg tcctcctcge tgcccatgtc 60
ggcgagcctc ctcttccgag cacttacaac gcctccatgt gctcgtcgtt ctggtgtggc 180
ggcgtcgaga tccgctacce gttctatctt gccaacgcaa tcgccgacta cagcgggagc 240
tactactcct gcggctacac cgacttgagc gtttcctgcg aactcgaggt cgaggggtcg 300

$<210>$ SEQ ID NO 4
$<211>$ LENGTH: 667
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: RLKIb - mutant Htn1
$<400>$ SEQUENCE: 4



$<210>$ SEQ ID NO 5
$<211>$ LENGTH: 2004
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: RLKId - mutant Htnl
$<400>$ SEQUENCE: 5


| ggatggtgcg | cctacagcca gaagagagaa | ttcctgggct gcttgtgcag | cggagggaag | 900 |
| :---: | :---: | :---: | :---: | :---: |
| gtgggcagcc | cgttctgcaa accatcgaga | tcaaaaagga aagaaggacc | tattgttggt | 960 |
| gctgttgccg | ttgcattcct gtgtctagtc | attctcacat gcttcttggc | ttgtagacat | 1020 |
| ggttcgetgc | cettcaaatc ggagaacaaa | ccagggacaa ggattgagtc | cttcetacag | 1080 |
| aagaacgaga | gtatacatcc gaaaagatac | acctacgegg acgtgaaagg | aatgacaaaa | 1140 |
| tcettcgctg | tgaagctagg ccaaggtggg | tttggtgctg tatacaaagg | cagcetccac | 1200 |
| gatggcegac | aggtagcagt caagatgctg | aaggacaccc aaggtgacgg | cgaggaattc | 1260 |
| atgaacgagg | tggctagcat cagcaggact | tctcatgtca acgtcgtgac | acttctaggg | 1320 |
| ttttgcttgc | aagggtcgaa aagagcactg | atctacgagt acatgcceaa | tggttcgetc | 1380 |
| gaaaggtatg | ccttcaccgg tgacatgaac | agtgagaatt tgctaacctg | ggaaaggcta | 1440 |
| tttgacatag | caattggcac ggceagaggg | ctcgaatacc tacaccggga | atgcaacact | 1500 |
| cggatcgtgc | attttgacat caagccacac | aacatcctgt tagaccagga | tttctgtcct | 1560 |
| aagatctctg | actttggact ggccaagcta | tgtctgaaca aagagagcgc | tatctccatt | 1620 |
| gctggcgcaa | gagggacgat agggtatatc | gccocggagg tctactcaaa | gcaatttgga | 1680 |
| ataataagca | gcaagtctga tgtctatagc | tatgggatga tggtcettga | gatggttgga | 1740 |
| gcaagggaca | ggaatacaag cgcagatagt | gaccatagca gccaatattt | ccctcagtgg | 1800 |
| ctttatgaac | atttggacga ctattgtgtt | ggtgcttccg agattaatgg | tgagaccaca | 1860 |
| gagctcgtga | ggaagatgat agttgtaggt | ctgtggtgca tacaagtgat | tccgactgat | 1920 |
| cgaccaacaa | tgacgagagt cgtcgagatg | ttggaaggga gcacaagtaa | tctagagttg | 1980 |
| ccacccagag | ttctcttgag ctga |  |  | 2004 |

$<210>$ SEQ ID NO 6
$<211>$ LENGTH: 667
$<212>$ TYPE: PRT
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: RLKId - mutant Htnl
$<400>$ SEQUENCE: 6


|  | 130 |  |  |  | 135 |  |  |  |  | 40 |  |  |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| $\begin{aligned} & \text { Val } \\ & 145 \end{aligned}$ | Arg | His Asn | Val | $\begin{aligned} & \text { Ser } \\ & 150 \end{aligned}$ | Phe | Asp | Glu T | Thr | $\begin{aligned} & \text { Trp } \\ & 155 \end{aligned}$ |  |  |  |  | $\begin{aligned} & \text { Asn } \\ & 160 \end{aligned}$ |
| Ala | Ser | Ala Phe | $\begin{aligned} & \text { Asp } \\ & 165 \end{aligned}$ | Asn | Leu | Thr | Phe | Phe <br> 170 | Phe | Gly | Cys | His | $\begin{aligned} & \text { Trp } \\ & 175 \end{aligned}$ | Gly |
| Pro | Arg | $\begin{array}{r} \text { Asn Thr } \\ 180 \end{array}$ | Pro | Pro | Glu | he | $\begin{aligned} & \text { Ala A } \\ & 185 \end{aligned}$ | Asp | Tyr | n | le | $\begin{aligned} & \text { Ser } \\ & 190 \end{aligned}$ | Cys | Ala |
| Gly P | Phe | $\begin{aligned} & \text { Asn Thr } \\ & 195 \end{aligned}$ | Pro | Thr | Ile | $\begin{aligned} & \text { Ser } \\ & 200 \end{aligned}$ | Gly G | Gly | Arg | Ser | $\begin{aligned} & \text { Phe } \\ & 205 \end{aligned}$ | Val | Phe | Lys |
| Thr | $\begin{aligned} & \text { Gly } \\ & 210 \end{aligned}$ | Asp Leu | Asp | Glu | $\begin{aligned} & \mathrm{Gln} \\ & 215 \end{aligned}$ | Glu | Glu G | Gln | Glu | $\begin{aligned} & \text { Leu } \\ & 220 \end{aligned}$ |  | Leu | His | Cys |
| $\begin{aligned} & \text { Asp } \\ & 225 \end{aligned}$ | Glu. | Val Phe | Ser | $\begin{aligned} & \text { Val } \\ & 230 \end{aligned}$ | Pro | 1 | $g$ | $9$ | $\begin{aligned} & \text { Asp } \\ & 235 \end{aligned}$ | Ala | Leu | Gln |  | $\begin{aligned} & \text { Ile } \\ & 240 \end{aligned}$ |
| Val | Ser | Asn Phe | $\begin{aligned} & \text { Ser } \\ & 245 \end{aligned}$ | Leu | Thr | rg | Asp | $\begin{aligned} & \text { Gly } \\ & 250 \end{aligned}$ | Tyr | Gly | lu | Val | $\begin{aligned} & \text { Leu } \\ & 255 \end{aligned}$ | Arg |
| Gln | Gly | $\begin{array}{r} \text { Phe } \begin{array}{r} \text { Glu I } \\ 260 \end{array} \end{array}$ | Leu | Glu | $\operatorname{Trp}$ | Asn | $\begin{aligned} & \text { Arg } \\ & 265 \end{aligned}$ | Thr | Ser | lu | Asp | $\begin{aligned} & \mathrm{Gln} \\ & 270 \end{aligned}$ | Cys | Gly |
| Arg | Cys | $\begin{aligned} & \text { Glu Gly } \\ & 275 \end{aligned}$ | Ser | Gly | Ser | $\begin{aligned} & \text { Gly } \\ & 280 \end{aligned}$ | Gly T | $\operatorname{Trp}$ | cys | Ala | $\begin{aligned} & \text { Tyr } \\ & 285 \end{aligned}$ | Ser | Gln | Lys |
| Arg | $\begin{aligned} & \text { Glu } \\ & 290 \end{aligned}$ | Phe Leu | Gly | Cys | $\begin{aligned} & \text { Leu } \\ & 295 \end{aligned}$ | Cys | Ser | Gly | Gly | $\begin{aligned} & \text { Lys } \\ & 300 \end{aligned}$ | Val | Gly |  | Pro |
| $\begin{aligned} & \text { Phe } \\ & 305 \end{aligned}$ | Cys | Lys Pro | er | $\begin{gathered} \text { Arg } \\ 310 \end{gathered}$ | Ser | Lys | rg | Lys | $\begin{aligned} & \text { Glu } \\ & 315 \end{aligned}$ | Gly | ro | e | Val | $\begin{aligned} & \text { Gly } \\ & 320 \end{aligned}$ |
| Ala | Val | Ala Val | $\begin{aligned} & \text { Ala } \\ & 325 \end{aligned}$ | Phe | Leu | Cys |  | $\begin{aligned} & \mathrm{Val} \\ & 330 \end{aligned}$ | Ile | Leu | Thr | Cys | Phe $335$ | Leu |
| Ala | Cys | $\begin{array}{r} \text { Arg His } \\ 340 \end{array}$ | Gly | r | u | ro | $\begin{aligned} & \text { Phe } \\ & 345 \end{aligned}$ | Lys | Ser | Glu | sn | $\begin{aligned} & \text { Lys } \\ & 350 \end{aligned}$ | Pro | Gly |
| Thr | Arg | $\begin{aligned} & \text { Ile Glu } \\ & 355 \end{aligned}$ | Ser | Phe | Leu | $\begin{aligned} & \mathrm{Gln} \\ & 360 \end{aligned}$ | Lys | Asn | Glu | er | $\begin{aligned} & \text { Ile } \\ & 365 \end{aligned}$ | His |  | Lys |
| Arg | $\begin{aligned} & \text { Tyr } \\ & 370 \end{aligned}$ | Thr Tyr | Ala | Asp | $\begin{aligned} & \text { Val } \\ & 375 \end{aligned}$ | Lys | Arg | et | Thr | $\begin{aligned} & \text { Lys } \\ & 380 \end{aligned}$ | Ser | Phe | Ala | Val |
| $\begin{aligned} & \text { Lys } \\ & 385 \end{aligned}$ | u | $Y \mathrm{Gln}$ | Gly | $\begin{gathered} \text { Gly } \\ 390 \end{gathered}$ | e | Gly | a | 1 | $\begin{aligned} & \text { Tyr } \\ & 395 \end{aligned}$ | Lys | Gly | Ser | Leu | $\begin{aligned} & \text { His } \\ & 400 \end{aligned}$ |
| Asp | Gly | Arg Gln | $\begin{aligned} & \text { Val } \\ & 405 \end{aligned}$ | Ala | Val | Lys |  | $\begin{aligned} & \text { Leu } \\ & 410 \end{aligned}$ | Lys | Asp | Thr | $\mathrm{Gln}$ | $\begin{aligned} & \text { Gly } \\ & 415 \end{aligned}$ | Asp |
| Gly | Glu | $\begin{array}{r} \text { Lu Phe } \\ 420 \end{array}$ | Met | Asn | Glu | al | Ala $425$ | Ser | Ile | er |  | $\begin{aligned} & \text { Thr } \\ & 430 \end{aligned}$ |  | His |
| Val |  | $\begin{aligned} & \text { Val Val } \\ & 435 \end{aligned}$ | rr | u | Leu | $\begin{aligned} & \text { Gly } \\ & 440 \end{aligned}$ | Phe | Cys | eu | $\ln$ | $\begin{aligned} & \text { Gly } \\ & 445 \end{aligned}$ | Ser | Lys | Arg |
| Ala | $\begin{aligned} & \text { Leu } \\ & 450 \end{aligned}$ | Ile Tyr | Glu | Tyr | Met 455 | Pro | Asn | Gly | Ser | $\begin{aligned} & \text { Leu } \\ & 460 \end{aligned}$ | Glu | Arg | Tyr | Ala |
| Phe 465 | Thr | Gly Asp | Met | $\begin{aligned} & \text { Asn } \\ & 470 \end{aligned}$ | Ser | Glu | sn L | eu | $\begin{aligned} & \text { Leu } \\ & 475 \end{aligned}$ | Thr | Trp | Glu | Arg | $\begin{aligned} & \text { Leu } \\ & 480 \end{aligned}$ |
| Phe | p | Ile Ala | $\begin{aligned} & \text { Ile } \\ & 485 \end{aligned}$ | Gly | Thr | Ala | Arg | $\begin{aligned} & \text { Gly } \\ & 490 \end{aligned}$ | Leu | Glu | Tyr | eu. | $\begin{aligned} & \mathrm{His} \\ & 495 \end{aligned}$ | Arg |
| Glu | Cys | $\begin{array}{r} \text { Asn Thr } \\ 500 \end{array}$ | Arg | Ile | Val | His | Phe $505$ | Asp | Ile | Lys | Pro | $\begin{aligned} & \text { His } \\ & 510 \end{aligned}$ | A.sn | Ile |
| Leu L | Leu. | $\text { Asp Gln } z$ | Asp |  | Cys | $\begin{aligned} & \text { Pro } \\ & 520 \end{aligned}$ | Lys I | Ile | Ser | Asp | Phe 525 | $\mathrm{Gly}$ | Leu | Ala |
| Lys | $\begin{aligned} & \text { Leu } \\ & 530 \end{aligned}$ | Cys Leu | Asn | Lys | $\begin{aligned} & \text { Glu } \\ & 535 \end{aligned}$ | Ser | Ala | Ile | Ser | Ile $540$ | Ala | Gly | Ala | Arg |


$<210>$ SEQ ID NO 7
$<211>$ LENGTH: 2004
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE : 7


$<210>$ SEQ ID NO 8
$<211>$ LENGTH: 667
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE: 8


| 225 |  |  |  |  | 230 |  |  |  |  | 235 |  |  |  | 240 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Asn | Leu | Ser | Leu | $\begin{aligned} & \text { Gly } \\ & 245 \end{aligned}$ | Asp | Gly | Tyr | Gly | $\begin{aligned} & \text { Glu } \\ & 250 \end{aligned}$ |  | Leu | Arg Gln | $\begin{aligned} & \text { Gly } \\ & 255 \end{aligned}$ | Ile |
| Glu | Leu | Glu | $\begin{aligned} & \operatorname{Trp} \\ & 260 \end{aligned}$ | Lys | Arg | Thr | Ser | $\begin{aligned} & \mathrm{Glu} \\ & 265 \end{aligned}$ | Asp | Gln | Cys | $\begin{aligned} & \text { Gly } \mathrm{Gln} \\ & 270 \end{aligned}$ | Cys | Glu |
| Glu | Ser | $\begin{aligned} & \mathrm{Gly} \\ & 275 \end{aligned}$ | Ser | Gly | Gly | Arg | $\begin{aligned} & \text { Cys } \\ & 280 \end{aligned}$ | Ala | Tyr | Ser | $G \ln \frac{L}{2}$ | $\begin{aligned} & \text { Lys Arg } \\ & 285 \end{aligned}$ | Glu | Phe |
| Leu | $\begin{aligned} & \text { Gly } \\ & 290 \end{aligned}$ | Cys | Phe | Cys | er | $\begin{aligned} & \text { Gly } \\ & 295 \end{aligned}$ | Gly | Lys | Ala | Gly | $\begin{aligned} & \text { Asn } \\ & 300 \end{aligned}$ | Pro Phe | Cys | Lys |
| $\begin{aligned} & \text { Pro } \\ & 305 \end{aligned}$ | Ser | Arg | Ser | Thr | $\begin{aligned} & \text { Lys } \\ & 310 \end{aligned}$ | Arg | Arg | Glu | Ala | $\begin{aligned} & \text { Ala } \\ & 315 \end{aligned}$ | Ser | Ile Val | Gly | Ala 320 |
| Val | Ala | Val | Ala | $\begin{aligned} & \text { Phe } \\ & 325 \end{aligned}$ | eu | Cys | Leu | Val | $\begin{aligned} & \text { Ile } \\ & 330 \end{aligned}$ | Leu | Thr | Cys Phe | $\begin{aligned} & \text { Leu } \\ & 335 \end{aligned}$ | Ala |
| Cys | Arg | His | $\begin{aligned} & \text { Cys } \\ & 340 \end{aligned}$ | Ser | Leu | Pro | Phe | $\begin{aligned} & \text { Lys } \\ & 345 \end{aligned}$ | Ser | Lys | Asn | $\begin{aligned} \text { Lys Pro } \\ 350 \end{aligned}$ | Gly | Thr |
| Arg | Ile | $\begin{aligned} & \text { Glu } \\ & 355 \end{aligned}$ | Ser | Phe | eu | Gln | $\begin{aligned} & \text { Lys } \\ & 360 \end{aligned}$ | Asn | Glu | Ser | Ser | $\begin{aligned} & \text { Ile His } \\ & 365 \end{aligned}$ | Pro | Lys |
| Arg | $\begin{aligned} & \text { TYr } \\ & 370 \end{aligned}$ | Thr | TYr | Ala | sp | $\begin{aligned} & \mathrm{Val} \\ & 375 \end{aligned}$ | Lys | Arg | Met | Thr | $\begin{aligned} & \text { Lys } \\ & 380 \end{aligned}$ | Ser Phe | Ala | Val |
| $\begin{aligned} & \text { Lys } \\ & 385 \end{aligned}$ | Leu | Gly | Gln | Gly | $\begin{aligned} & \text { Gly } \\ & 390 \end{aligned}$ | he | Gly | Ala | Val | $\begin{aligned} & \text { Tyr } \\ & 395 \end{aligned}$ | Lys | Gly Ser | Leu | $\begin{aligned} & \text { His } \\ & 400 \end{aligned}$ |
| Asp | Gly | Arg | Gln | $\begin{aligned} & \mathrm{Val} \\ & 405 \end{aligned}$ | Ala | Val | Lys | Met | $\begin{aligned} & \text { Leu } \\ & 410 \end{aligned}$ | Lys | Asp | Thr Gln | $\begin{aligned} & \text { Gly } \\ & 415 \end{aligned}$ | Asp |
| Gly | Glu | Glu | $\begin{aligned} & \text { Phe } \\ & 420 \end{aligned}$ | Met | Asn | Glu | Val | $\begin{aligned} & \text { Ala } \\ & 425 \end{aligned}$ | Ser | Ile | Ser | $\begin{aligned} \text { Arg Thr } \\ 430 \end{aligned}$ | Ser | His |
| Val | Asn | $\begin{aligned} & \text { Val } \\ & 435 \end{aligned}$ | Val | rr |  | u | $\begin{aligned} & \text { GlY } \\ & 440 \end{aligned}$ | e | Cys | Leu | Gln | $\begin{aligned} & \text { Gly Ser } \\ & 445 \end{aligned}$ | Lys | Arg |
| Ala | $\begin{aligned} & \text { Leu } \\ & 450 \end{aligned}$ | Ile | TYr | Glu | Tyr | Met 455 | Pro | Asn | Gly | Ser | $\begin{aligned} & \text { Leu } \\ & 460 \end{aligned}$ | Glu Arg | Tyr | Ala |
| Phe $465$ | Thr | Gly | Asp | et | $\begin{aligned} & \text { Asn } \\ & 470 \end{aligned}$ | er | Glu | n | eu | $\begin{aligned} & \text { Leu } \\ & 475 \end{aligned}$ | Thr | Trp Glu | Arg | $\begin{aligned} & \text { Leu } \\ & 480 \end{aligned}$ |
| Phe | Asp | Ile | Ala | $\begin{aligned} & \text { Ile } \\ & 485 \end{aligned}$ | Gly | r | 1a | Arg | $\begin{aligned} & \text { Gly } \\ & 490 \end{aligned}$ | Leu | Glu | Tyr Leu | $\begin{aligned} & \text { His } \\ & 495 \end{aligned}$ | Arg |
| Gly | Cys | Asn | $\begin{aligned} & \text { Thr } \\ & 500 \end{aligned}$ | Arg | Ile | Val | His | Phe $505$ | Asp | Ile | Lys | $\begin{array}{r} \text { Pro His } \\ 510 \end{array}$ | Asn | Ile |
| Leu | Leu | Asp <br> 515 | Gln | Asp | he | Cys | $\begin{aligned} & \text { Pro } \\ & 520 \end{aligned}$ | Lys | Ile | Ser | Asp | $\begin{aligned} & \text { Phe Gly } \\ & 525 \end{aligned}$ | Leu | Ala |
| Lys | $\begin{aligned} & \text { Leu } \\ & 530 \end{aligned}$ | Cys | eu | Asn | Lys | $\begin{aligned} & \text { Glu } \\ & 535 \end{aligned}$ | Ser | Ala | Ile | Ser | Ile A $540$ | Ala Gly | Ala | Arg |
| $\begin{aligned} & \text { Gly } \\ & 545 \end{aligned}$ | Thr | Ile | ly | Tyr | $\begin{aligned} & \text { Ile } \\ & 550 \end{aligned}$ | la | Pro | Glu | al | $\begin{aligned} & \text { Tyr } \\ & 555 \end{aligned}$ | Ser | Lys Gln | Phe | $\begin{aligned} & \text { Gly } \\ & 560 \end{aligned}$ |
| Thr | Ile | Ser | Ser | $\begin{aligned} & \text { Lys } \\ & 565 \end{aligned}$ | Ser | Asp | Val | Tyr | $\begin{aligned} & \text { Ser } \\ & 570 \end{aligned}$ | Tyr | Gly | Met Met | $\begin{aligned} & \text { Val } \\ & 575 \end{aligned}$ | Leu |
| Glu | Met | Val | $\begin{aligned} & \text { Gly } \\ & 580 \end{aligned}$ | Ala | Arg | Asp | Arg | $\begin{aligned} & \text { Asn } \\ & 585 \end{aligned}$ | Thr | Ser | Ala A | $\begin{array}{r} \text { Asp Ser } \\ 590 \end{array}$ | Asp | His |
| Ser | Ser | $\begin{aligned} & \mathrm{Gln} \\ & 595 \end{aligned}$ | Tyr | Phe | Pro | Gln | $\begin{aligned} & \operatorname{Trp} \\ & 600 \end{aligned}$ | Leu | Tyr | Glu | His | $\begin{aligned} & \text { Leu Asp } \\ & 605 \end{aligned}$ | Asp | Tyr |
| Cys | $\begin{aligned} & \text { Val } \\ & 610 \end{aligned}$ | $\mathrm{Gly}$ | Ala | Ser | Glu | $\begin{aligned} & \text { Ile } \\ & 615 \end{aligned}$ | Asn | Gly | Glu | Thr | $\begin{aligned} & \text { Thr } \\ & 620 \end{aligned}$ | Glu Leu | Val | Arg |
| $\begin{aligned} & \text { Lys } \\ & 625 \end{aligned}$ | Met | Ile |  |  | $\begin{aligned} & \text { Gly } \\ & 630 \end{aligned}$ | Leu | $\operatorname{Trp}$ | Cys | Ile | $\begin{aligned} & \mathrm{Gln} \\ & 635 \end{aligned}$ | Val | Ile Pro | Thr | Asp <br> 640 |

Arg Pro Thr Met Thr Arg Val Val Glu Met Leu Glu Gly Ser Thr Ser
645
650
Asn Leu Glu Leu Pro Pro Arg Val Leu Leu Ser
660
$<210>$ SEQ ID NO 9
$<211>$ LENGTH: 11884
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: ZmWAK-RLKI plasmid
$<400>$ SEQUENCE: 9
tacccgacga gtcagtaata aacggcgtca aagtggttgc agccggcaca cacgagtcgt 60
aacaactttg cgtgtaaaca acgctcaata cacgtgtcat tttattatta gctattgctt 180
caccgcctta gctttctcgt gacctagtcg tcctcgtctt ttcttcttct tcttctataa 240
aacaatacce aagagctct tcttcttcac aattcagatt tcaattctc aaaatcttaa 300
aaactttctc tcaattctct ctaccgtgat caaggtaaat ttctgtgttc cttattctct 360
caaaatcttc gattttgttt tcgttcgatc ccaatttcgt atatgttctt tggtttagat 420
tctgttaatc ttagatcgaa gacgattttc tgggtttgat cgttagatat catcttaatt 480
ctcgattagg gtttcataga tatcatccga tttgttcaaa taatttgagt tttgtcgaat 540
aattactctt cgatttgtga tttctatcta gatctggtgt tagtttctag tttgtgcgat 600
cgaatttgta gattaatctg agtttttctg attaacactc gagtgcggga tcctctaagg 660
gcccatcaca agtttgtaca aaaagcagg ettcatggct gctcaccagc ctcacctctc 720
cgtcetcctc ctegtcctcc tegctgceca tgtcgtctcc acctcegcec atggegagec 780
tcctcttccg agccettaca acacctccgc ccatggegag cctcctcttc cgagcactta 840
caacgcctcc atgtgctcgt cgttctggtg tggcggcgtc gagatccgct accegttcta 900
tcttgccaac gcaatcgccg actacagcgg gagctactac tcctgcggct acaccgactt 960
gagcgtttcc tgcgaactcg aggtcgaggg gtcgccgacg acctggaccc ctaccatccg 1020
tctcggcggc ggcgactaca cegtcaagaa catctcctac ctctacgacc agcagaccat 1080
ctcactggcg gacagagatg tgctcggagg cggcggetgc cecgtcgtcc gccacaacgt 1140
cagcttcgac gagacgtggc tgcacctgca caacgccagc gccttcgaca acctcacctt 1200
cttcttcgga tgccactggg ggccacggaa tacaccgcct gaatttgccg actacaacat 1260
cagctgcgcc gggttcaata ctccaactat cagcggtgga aggtccttcg tgttcaagac 1320

| tggagatctt gacgaacaag aggagcagga gttggcttta cactgcgacg aggttttctc | 1380 |
| :--- | :--- | :--- |
| cgtgccagtg agaagagatg ctctgcaggc gatcgtcagc aacttcagcc tcacacggga | 1440 |
| cgggtacggc gaggtgctta ggcaggggtt cgagttggaa tggaatcgga catcggagga | 1500 |
| tcagtgtggc cggtgcgagg gatcgggctc cggcggatgg tgcgcctaca gccagaagag | 1560 |
| agaattcctg ggctgcttgt gcagcggagg gaaggtgggc agcccgttct gcaaaccatc | 1620 |
| gagatcaaaa aggaaagaag gacctattgt tggtgctgtt gccgttgcat tcctgtgtct | 1680 |
| agtcattctc acatgcttct tggcttgtag acatggttcg ctgccettca aatcggagaa | 1740 |
| caaccaggg acaaggattg agtccttcct acagaagaac gagagtatac atccgaaaag | 1800 |






| gccaggctac gcaggcccgc gccggcctcc tggatgcgct cggcaatgtc cagtaggtcg | 10980 |
| :--- | :--- | :--- |
| cgggtgctgc gggccaggcg gtctagcctg gtcactgtca caacgtcgcc agggcgtagg | 11040 |
| tggtcaagca tcctggccag ctccgggcgg tcgcgcctgg tgccggtgat cttctcggaa | 11100 |
| aacagcttgg tgcagccggc cgcgtgcagt tcggcccgtt ggttggtcaa gtcctggtcg | 11160 |
| tcggtgctga cgcgggcata gcccagcagg ccagcggcgg cgctcttgtt catggcgtaa | 11220 |
| tgtctccggt tctagtcgca agtattctac tttatgcgac taaaacacgc gacaagaaaa | 11280 |
| cgccaggaaa agggcagggc ggcagcctgt cgcgtaactt aggacttgtg cgacatgtcg | 11340 |
| ttttcagaag acggctgcac tgaacgtcag aagccgactg cactatagca gcggaggggt | 11400 |
| tggatcaaag tactttaaag tactttaaag tactttaaag tactttgatc ccgaggggaa | 11460 |
| ccctgtggtt ggcatgcaca tacaaatgga cgaacggata aaccttttca cgccctttta | 11520 |
| aatatccgtt attctaataa acgctctttt ctcttaggtt tacccgccaa tatatcctgt | 11580 |
| caaacactga tagtttaaac tgaaggcggg aaacgacaat ctgatccaag ctcaagctgc | 11640 |
| tctagccaat acgcaaaccg cctctccccg cgcgttggcc gattcattaa tgcagctggc | 11700 |
| acgacaggtt tcccgactgg aaagcgggca gtgagcgcaa cgcaattaat gtgagttagc | 11760 |


$<210>$ SEQ ID NO 11
$<211>$ LENGTH: 347
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE : 11

| $\begin{aligned} & \text { Met } \\ & 1 \end{aligned}$ | Ala | Phe | Ala | $\begin{aligned} & \text { Pro } \\ & 5 \end{aligned}$ | Lys | hr |  | I | $\begin{aligned} & \text { Ser } \\ & 10 \end{aligned}$ | er |  |  |  | $\begin{aligned} & \text { Ser } \\ & 15 \end{aligned}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Leu | Gln | Ala | $\begin{aligned} & \text { Ala } \\ & 20 \end{aligned}$ | Gln |  |  | Pro | $\begin{aligned} & \text { Leu I } \\ & 25 \end{aligned}$ | Leu | Leu | Arg | Arg | $\begin{aligned} & \text { Met } \\ & 30 \end{aligned}$ |  | Ser |
| Thr | Ala | $\begin{aligned} & \text { Thr } \\ & 35 \end{aligned}$ | Pro | Arg | Arg | Arg | $\begin{aligned} & \text { Tyr } \\ & 40 \end{aligned}$ | Asp | Ala | Ala | Val | Val 45 | Val | Thr | Thr |
| Thr | $\begin{aligned} & \text { Thr } \\ & 50 \end{aligned}$ | Thr | Ala | Arg | Ala | $\begin{aligned} & \text { Ala } \\ & 55 \end{aligned}$ | Ala | Ala | Ala | Val | $\begin{aligned} & \text { Thr } \\ & 60 \end{aligned}$ |  | Pro | Ala | Ala |
| $\begin{aligned} & \text { Pro } \\ & 65 \end{aligned}$ | Pro | Gln | Ala | Pro | $\begin{aligned} & \text { Ala } \\ & 70 \end{aligned}$ | Pro | Ala | Pro | Val | $\begin{aligned} & \text { Pro I } \\ & 75 \end{aligned}$ | Pro | Lys | Gln | Ala | $\begin{aligned} & \text { Ala } \\ & 80 \end{aligned}$ |
| Ala | Pro | Ala | Glu | $\begin{aligned} & \text { Arg } \\ & 85 \end{aligned}$ | Arg | Ser | Arg | Pro | $\begin{aligned} & \mathrm{Val} \\ & 90 \end{aligned}$ | Ser | Asp | Thr |  | Ala 95 | Ala |
| Leu | Met | Ala | $\begin{aligned} & \text { Lys } \\ & 100 \end{aligned}$ | Gly | Lys | Thr | Ala | $\begin{aligned} & \text { Phe } \\ & 105 \end{aligned}$ | Ile | Pro | Tyr | Ile | $\begin{aligned} & \text { Thr } \\ & 110 \end{aligned}$ | Ala | Gly |
| Asp | ro | Asp $115$ | Leu | Ala | 'hr | $\mathrm{hr}$ | Ala <br> 120 | Glu | Ala | Leu | Arg | Leu $125$ | Leu | Asp | Gly |
| Cys | $\begin{aligned} & \mathrm{Gly} \\ & 130 \end{aligned}$ | Ala | Asp | Val | Ile | $\begin{aligned} & \text { Glu } \\ & 135 \end{aligned}$ | Leu | Gly | Val | Pro | $\begin{aligned} & \text { Cys } \\ & 140 \end{aligned}$ | Ser | sp | Pro | TYr |
| $\begin{aligned} & \text { Ile } \\ & 145 \end{aligned}$ | Asp | Gly | ro | Ile | $\begin{aligned} & \text { Ile } \\ & 150 \end{aligned}$ | Gln | Ala | jer | Val | $\begin{aligned} & \text { Ala } \\ & 155 \end{aligned}$ | Arg | Ala | Leu. | Ala | $\begin{aligned} & \text { Ser } \\ & 160 \end{aligned}$ |
| Gly | Thr | Thr | et | $\begin{aligned} & \text { Asp } \\ & 165 \end{aligned}$ | Ala | Val | Leu | Glu | $\begin{aligned} & \text { Met } \\ & 170 \end{aligned}$ | Leu | Arg | Glu | Val | $\begin{aligned} & \text { Thr } \\ & 175 \end{aligned}$ | Pro |
| Glu | Leu | Ser | $\begin{aligned} & \text { Cys } \\ & 180 \end{aligned}$ | Pro | Val | al | Leu | $\begin{aligned} & \text { Leu } \\ & 185 \end{aligned}$ | Ser | Tyr | Tyr | Lys | $\begin{aligned} & \text { Pro } \\ & 190 \end{aligned}$ | Ile | Met |
| Ser | Arg | $\begin{aligned} & \text { Ser } \\ & 195 \end{aligned}$ | Leu | Ala | Glu | et | $\begin{aligned} & \text { Lys } \\ & 200 \end{aligned}$ | Glu | Ala | Gly | Val | $\begin{aligned} & \mathrm{His} \\ & 205 \end{aligned}$ | Gly | Leu | Ile |
| Val | $\begin{aligned} & \text { Pro } \\ & 210 \end{aligned}$ | Asp | Leu | Pro | Tyr | $\begin{aligned} & \mathrm{Val} \\ & 215 \end{aligned}$ | Ala | Ala | His | Ser | $\begin{aligned} & \text { Leu } \\ & 220 \end{aligned}$ | $\operatorname{Trp}$ | Ser | Glu | Ala |
| $\begin{aligned} & \text { Lys } \\ & 225 \end{aligned}$ | Asn | Asn | Asn | Leu | $\begin{aligned} & \text { Glu } \\ & 230 \end{aligned}$ | Leu | Val | Leu | Leu | $\begin{aligned} & \text { Thr } \\ & 235 \end{aligned}$ | Thr | Pro | Ala | Ile | $\begin{aligned} & \text { Pro } \\ & 240 \end{aligned}$ |
| Glu | Asp | Arg | et | $\begin{aligned} & \text { Lys } \\ & 245 \end{aligned}$ | Glu | Ile | Thr | $\begin{array}{r} \text { Lys A } \\ 2 \end{array}$ | $\begin{aligned} & \text { Ala } \\ & 250 \end{aligned}$ | Ser | Glu | Gly | Phe | $\begin{aligned} & \text { Val } \\ & 255 \end{aligned}$ | Tyr |
| Leu | Val | Ser | $\begin{aligned} & \mathrm{Val} \\ & 260 \end{aligned}$ | Asn | Gly | al | Thr | $\begin{aligned} & \text { Gly I } \\ & 265 \end{aligned}$ | Pro | Arg | Ala | Asn | $\begin{aligned} & \text { Val } \\ & 270 \end{aligned}$ | Asn | Pro |
| Arg | Val | $\begin{aligned} & \text { Glu } \\ & 275 \end{aligned}$ | Ser | Leu | Ile | $\ln$ | $\begin{aligned} & \text { Glu } \\ & 280 \end{aligned}$ | Val | Lys | Lys | Val | $\begin{aligned} & \text { Thr } \\ & 285 \end{aligned}$ | Asn | Lys | Pro |
| Val | Ala $290$ | Val | Gly | Phe | Gly | $\begin{aligned} & \text { Ile } \\ & 295 \end{aligned}$ | Ser | Lys | Pro | Glu | His $300$ | Val | Lys | Gln | Ile |
| $\begin{aligned} & \text { Ala } \\ & 305 \end{aligned}$ | Gln | Trp | Gly | Ala | $\begin{aligned} & \text { Asp } \\ & 310 \end{aligned}$ | Gly | Val | Ile | Ile | $\begin{aligned} & \text { Gly } \\ & 315 \end{aligned}$ | Ser | Ala | Met | Val | $\begin{aligned} & \text { Arg } \\ & 320 \end{aligned}$ |
| Gln | Leu. | Gly | Glu | $\begin{aligned} & \text { Ala } \\ & 325 \end{aligned}$ | Ala | Ser | Pro | Lys | $\begin{aligned} & \text { Gln } \\ & 330 \end{aligned}$ | Gly I | Leu | Arg | Arg | $\begin{aligned} & \text { Leu } \\ & 335 \end{aligned}$ | Glu |
| Glu | TYı | Ala | Arg $340$ | Gly | Met | Lys | Asn | $\begin{aligned} & \text { Ala I } \\ & 345 \end{aligned}$ | Leu | Pro |  |  |  |  |  |


$<210>$ SEQ ID NO 13
$<211>$ LENGTH: 393
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE : 13


|  |  |  | 100 |  |  |  |  | 105 |  |  |  |  | 110 |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Phe | Pro | $\begin{aligned} & \text { Ser } \\ & 115 \end{aligned}$ | Leu | Gly | Arg | Ile | $\begin{aligned} & \text { Glu } \\ & 120 \end{aligned}$ | Leu | Val | Arg |  | $\begin{aligned} & \text { Val } \\ & 125 \end{aligned}$ | Ala | Cys | Ala |
| Lys | $\begin{aligned} & \text { Thr } \\ & 130 \end{aligned}$ | Arg | Arg | Val | Arg | $\begin{aligned} & \text { Lys } \\ & 135 \end{aligned}$ | Arg | $\operatorname{Trp}$ | Asp | Asp | $\begin{aligned} & \text { Leu } \\ & 140 \end{aligned}$ | Leu | Asp | Lys | Leu |
| $\begin{aligned} & \text { Ile } \\ & 145 \end{aligned}$ | Asp | Asp | His | Ala | $\begin{aligned} & \text { Ala } \\ & 150 \end{aligned}$ | Arg | Met | Ala | Thr | $\begin{aligned} & \text { His } \\ & 155 \end{aligned}$ |  | Asp | Glu | Asp | $\begin{aligned} & \text { Asp } \\ & 160 \end{aligned}$ |
| Asp | Lys | Asp | Phe | Ile <br> 165 | Tyr | Val | Leu | Leu | $\begin{aligned} & \text { Ser } \\ & 170 \end{aligned}$ | Leu | Gln | Lys | Glu | $\begin{aligned} & \text { Tyr } \\ & 175 \end{aligned}$ | Gly |
| Leu | Thr | Arg | $\begin{aligned} & \text { Asp } \\ & 180 \end{aligned}$ | His | Ile | Lys | Ala | $\begin{aligned} & \text { Ile } \\ & 185 \end{aligned}$ | Leu | Ile | Asp | Met | $\begin{aligned} & \text { Phe } \\ & 190 \end{aligned}$ | Glu | Ala |
| Gly | Thr | $\begin{aligned} & \text { Asp } \\ & 195 \end{aligned}$ | Thr | Ser | Tyr | Met | $\begin{aligned} & \text { Thr } \\ & 200 \end{aligned}$ | Leu | Glu | Phe |  | $\begin{aligned} & \text { Met } \\ & 205 \end{aligned}$ |  |  | Leu |
| Ile | $\begin{aligned} & \text { Arg } \\ & 210 \end{aligned}$ | Lys | Pro | His | Leu | $\begin{gathered} \text { Met } \\ 215 \end{gathered}$ | Lys | Lys | Leu | $\mathrm{Gln}$ | $\begin{aligned} & \mathrm{Glu} \\ & 220 \end{aligned}$ | Glu | Val | Arg | Arg |
| $\begin{aligned} & \text { Asn } \\ & 225 \end{aligned}$ | Val | Pro | Ala | Gly | $\begin{aligned} & \mathrm{Gln} \\ & 230 \end{aligned}$ | Glu | Met | Val | Thr | $\begin{aligned} & \text { Glu } \\ & 235 \end{aligned}$ |  | Asn | Leu | Pro | $\begin{aligned} & \text { Gly } \\ & 240 \end{aligned}$ |
| Met | Thr | Tyr L | Leu | $\begin{aligned} & \text { Lys } \\ & 245 \end{aligned}$ | Ala | Val | Ile | Lys | $\begin{aligned} & \text { Glu } \\ & 250 \end{aligned}$ | Thr | Leu | Arg | Leu | $\begin{aligned} & \text { His } \\ & 255 \end{aligned}$ | Pro |
| Pro | Val | Pro | $\begin{aligned} & \text { Leu } \\ & 260 \end{aligned}$ | Leu | Leu | Pro | His | $\begin{aligned} & \text { Tyr } \\ & 265 \end{aligned}$ | Ser | Leu | Asp | Ala | $\begin{aligned} & \text { Cys } \\ & 270 \end{aligned}$ | Glu | Val |
| Ala | Gly | $\begin{aligned} & \text { Tyr } \\ & 275 \end{aligned}$ | Thr | Ile | Pro | Ala | $\begin{aligned} & \text { Asn } \\ & 280 \end{aligned}$ | Thr | Arg | Val |  | $\begin{aligned} & \text { Val } \\ & 285 \end{aligned}$ | Asn | Ala | Trp |
| Ala | $\begin{aligned} & \text { Leu } \\ & 290 \end{aligned}$ | Gly | Arg | His | Ser | $\begin{aligned} & \text { Gly } \\ & 295 \end{aligned}$ | Tyr | $\operatorname{Trp}$ | Glu | Arg | $\begin{aligned} & \text { Glu } \\ & 300 \end{aligned}$ |  | Glu | Phe | Val |
| $\begin{aligned} & \text { Pro } \\ & 305 \end{aligned}$ | Glu. | Arg | Phe L | Leu | $\begin{aligned} & \text { Ser } \\ & 310 \end{aligned}$ | Gly | Asp | Val | Ala | $\begin{aligned} & \text { Gly } \\ & 315 \end{aligned}$ | Gly | Val | Asp | Leu | $\begin{aligned} & \text { Lys } \\ & 320 \end{aligned}$ |
| Pro | Asn | Glu | Phe | $\begin{aligned} & \mathrm{Gln} \\ & 325 \end{aligned}$ | Phe | Leu | Ala | Phe | $\begin{aligned} & \text { Gly } \\ & 330 \end{aligned}$ | Ser | Gly | Arg | Arg | $\begin{aligned} & \text { Met } \\ & 335 \end{aligned}$ | Cys |
| Pro | Gly | Val | His $340$ | Ser | Ala | Ser | Ala | $\begin{aligned} & \text { Thr } \\ & 345 \end{aligned}$ | Ile | Glu |  | Met | $\begin{aligned} & \text { Leu } \\ & 350 \end{aligned}$ | Ser |  |
| Leu | Met | $\begin{aligned} & \text { Tyr } \\ & 355 \end{aligned}$ | Arg | Phe | Asp | $\operatorname{Trp}$ | $\begin{aligned} & \mathrm{Gln} \\ & 360 \end{aligned}$ | Leu | Pro | Ala |  | $\begin{aligned} & \text { Met } \\ & 365 \end{aligned}$ | Lys | Ala | Glu |
| Asp | $\begin{aligned} & \mathrm{Val} \\ & 370 \end{aligned}$ | Asp | Met | Thr | Glu | $\begin{aligned} & \mathrm{Val} \\ & 375 \end{aligned}$ | Phe | Gly | Ile | Thr | $\begin{aligned} & \text { Val } \\ & 380 \end{aligned}$ | Ser | Arg | Lys | Glu |
| $\begin{aligned} & \text { Lys } \\ & 385 \end{aligned}$ | Leu | Leu | Leu | Val | $\begin{aligned} & \text { Pro } \\ & 390 \end{aligned}$ | Gln | Ala | Ala |  |  |  |  |  |  |  |

$<210>$ SEQ ID NO 14
$<211>$ LENGTH: 1020
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE : 14


| ggcgttccet tctcggacce ctacgccgac gggccggtca tccaggcgtc ggcggcgcgg | 420 |
| :--- | :--- |
| gcactggcga gcggcacgac gccggacggc gtgctggcga tgctgaagga ggtgacgccg | 480 |
| gagctgtcct gcccegtggt gctcttctcc tacttcaacc ccatcgtgcg gtggggcetg | 540 |
| gccgacttcg ccgccgccgt caaggaagcc ggcgtgcacg gcctcatagt tcccgacctc | 600 |
| ccgtatggga actcgtgcge tctcactctc aggaccgaag ccatcaagaa caacctcgag | 660 |
| ctggtgctgc tcacaacacc atctacgcca gcggacagga tggaggagat aacacgagct | 720 |
| tcacgaggat tcgtctatct cgcgagcgtc aatggagtta caggtccacg cgcaaacgtg | 780 |
| aacacacgtg tccagtctct cattcaggag gttaaacagg tcactgacat acccgtggct | 840 |
| gtcgggtttg gcatatcgaa acctgagcat gtaaagcaga ttgcagagtg gggtgcagat | 900 |
| ggtgtgatca ttggtagcge aatggtgaga cagttaggcg aagcagcctc tcccaaagaa | 960 |

$<210>$ SEQ ID NO 15
$<211>$ LENGTH: 339
$<212>$ TYPE : PRT
$<213>$ ORGANISM: zea mays
$<400>$ SEQUENCE : 15


$<210>$ SEQ ID NO 16
$<211>$ LENGTH: 1125
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE : 16

| atggctccaa cgaccgccac caaggacgac agtggctacg gcgacgagcg ccggcgcgag | 60 |
| :--- | :--- |
| ctgcaggcgt tcgacgacac gaagctgggg gtgaagggtc tggtggactc cggcgtcaag | 120 |
| tccatcccgt ccatcttcca ccacccgccg gaagccctga gcgacataat ttctccggcg | 180 |
| cctctgccgt cgtcgccacc ctccggcgcc gccatcccgg tggtggacct ctcggtgacg | 240 |
| cggcgcgagg acctagtcga gcaggtgagg cacgcggccg ggacggtggg cttcttctgg | 300 |
| ctggtgaacc acggcgtggc ggaggagctg atgggcggca tgctccgcgg ggtgcgccag | 360 |
| ttcaacgagg gccccgtgga ggcgaagcag gcgctctact ccagggacct ggctcgcaac | 420 |
| ctgcgcttcg cctccaactt cgacctcttc aaggccgctg cggccgactg gcgcgacacg | 480 |
| ctcttctgcg aggtggctcc gaacccgccg ccgcgggagg agctgccgga gccactgagg | 540 |
| aacgtgatgc tggagtacgg cgcggcggtg acgaagctgg cgcggttcgt gttcgagctg | 600 |
| ctgtccgagt ccctcggcat gcccagcgac cacctgtacg agatggagtg catgcagaac | 660 |
| ctgaacgtgg tgtgccagta ctacccgccg tgcccggagc cgcaccgcac cgtgggcgtc | 720 |
| aagaggcaca cggaccctgg cttcttcacc atcctcctgc aggacggcat gggcggcctg | 780 |
| caggtgcgcc tcggcaacaa cgggcagagc ggcggctgct gggtggacat cgctccccgg | 840 |

$<210>$ SEQ ID NO 17
$<211>$ LENGTH: 374
$<212>$ TYPE: PRT
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE: 17


$<210>$ SEQ ID NO 18
$<211>$ LENGTH: 1128
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE: 18

$<210>$ SEQ ID NO 19
$<211>$ LENGTH: 375
$<212>$ TYPE : PRT
$<213>$ ORGANISM: zea mays
$<400>$ SEQUENCE: 19


$<210>$ SEQ ID NO 20
$<211>$ LENGTH: 1101
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE: 20


| gcaaccgccg tttcttcaa gacaactcta tgtgactggg gtgacgacga gtgcatcaag | 840 |
| :--- | :--- |
| atattgaaga attgcaagca agccatatct ccacgggatg agggtgggaa ggtgataatc | 900 |
| atggacgtgg tagtcgggta tgggcagtca aacatgaagc gcctagagac acaagttatg | 960 |
| tttgatttgg ttatgatggc ggtcaatgga gtcgagcgcg acgagcaaga gtggaaggag | 1020 |
| atgttcattg aagctggatt caaagactac aaatccgac cagtagctgg cotcatgtcg | 1080 |
| gtcatcgagg tctatccatg a | 1101 |

$<210>$ SEQ ID NO 21
$<211>$ LENGTH: 366
$<212>$ TYPE : PRT
$<213>$ ORGANISM: zea mays
$<400>$ SEQUENCE : 21


$<210>$ SEQ ID NO 22
$<211>$ LENGTH: 1122
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE : 22

$<210>$ SEQ ID NO 23
$<211>$ LENGTH: 373
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE: 23


$<210>$ SEQ ID NO 24
$<211>$ LENGTH: 2595
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE: 24

| atgctgagcg ggatcatcga cgggctgacg ggggcgaaca agcatgcgcg gctcaagggc | 60 |
| :--- | :--- |
| acggtggtgc tcatgcgcaa gaacgtgctg gacctcaacg acttcggcgc caccgtcgtt | 120 |



| gcgttcaaga ggttcagcga cgcgctggtc aagatcgagg gcaaggtggt gggcgagaac | 2460 |
| :--- | :--- |
| cgcgaccogc agctgaggaa caggaacggc cecgccgagt tcccctacat gctgctctat | 2520 |
| cccaacacct ctgaccacag tggcgccgce gcagggctca ctgccaaggg catccccaac | 2580 |
|  | 2595 |

$<210>$ SEQ ID NO 25
$<211>$ LENGTH: 864
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE : 25

| $1$ |  |  |  | $5$ |  |  |  |  | $\begin{aligned} & \text { Thr } \\ & 10 \end{aligned}$ | Gly |  | sn Lys | $\begin{aligned} & \text { His } \\ & 15 \end{aligned}$ |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| Arg | Leu | Lys | $\begin{aligned} & \text { Gly } \\ & 20 \end{aligned}$ | Thr | Val | Val | Leu | $\begin{aligned} & \text { Met } \\ & 25 \end{aligned}$ | Arg | Lys | Asn | $\begin{gathered} \text { Val Leu } \\ 30 \end{gathered}$ | Asp | Leu |
| Asn | Asp | Phe <br> 35 | Gly | Ala | Thr | Val | $\begin{aligned} & \text { Val } \\ & 40 \end{aligned}$ | Asp | Ser | Ile | Ser | Glu Phe $45$ | Leu | Gly |
| Lys | $\begin{aligned} & \text { Gly } \\ & 50 \end{aligned}$ | Val | Thr | Cys | Gln | $\begin{aligned} & \text { Leu } \\ & 55 \end{aligned}$ | Ile | Ser | Ser | Thr L | Leu $60$ | Val Asp | Ala | Asn |
| $\begin{aligned} & \text { Asn } \\ & 65 \end{aligned}$ | Gly | Asn | Arg | Gly | $\begin{aligned} & \text { Arg } \\ & 70 \end{aligned}$ | Val | Gly | Ala | Glu | $\begin{aligned} & \text { Ala } \\ & 75 \end{aligned}$ | Asn | Leu Glu | Gln | $\begin{aligned} & \text { Trp } \\ & 80 \end{aligned}$ |
| Leu | Thr | Ser | Leu | $\begin{aligned} & \text { Pro } \\ & 85 \end{aligned}$ | Ser | Leu | Thr | Thr | $\begin{aligned} & \text { Gly } \\ & 90 \end{aligned}$ | Glu | Ser | Lys Phe | $\begin{aligned} & \text { Gly } \\ & 95 \end{aligned}$ | Val |
| Thr | Phe | Asp | $\begin{aligned} & \operatorname{Trp} \\ & 100 \end{aligned}$ | Glu | Val | Glu | Lys | $\begin{aligned} & \text { Leu } \\ & 105 \end{aligned}$ | Gly | Val | Pro | $\begin{aligned} & \text { Gly } \text { Ala } \\ & 110 \end{aligned}$ | Val | val |
| Val | Lys | $\begin{aligned} & \text { Asn } \\ & 115 \end{aligned}$ | Asn | His | Ala | Ala | $\begin{aligned} & \text { Glu } \\ & 120 \end{aligned}$ | Phe | Phe | Leu | Lys | $\begin{aligned} & \text { Thr Ile } \\ & 125 \end{aligned}$ | Thr | Leu |
| Asp | $\begin{aligned} & \text { Asp } \\ & 130 \end{aligned}$ | Val | Pro | Gly | Arg | $\begin{aligned} & \text { Gly } \\ & 1.35 \end{aligned}$ | Ala | Val | Thr | Phe | $\begin{aligned} & \mathrm{Val} \\ & 140 \end{aligned}$ | Ala Asn | Ser | Trp |
| $\begin{aligned} & \text { Val } \\ & 145 \end{aligned}$ | Tyr | Pro | $1 a$ | $\mathrm{Gly}$ | $\begin{aligned} & \text { Lys } \\ & 150 \end{aligned}$ | TYr | Arg | TYr | Asn | $\begin{aligned} & \text { Arg } \\ & 155 \end{aligned}$ | Val | Phe Phe | Ser | $\begin{aligned} & \text { Asn } \\ & 160 \end{aligned}$ |
| Asp | Thr | Tyr | Leu | $\begin{aligned} & \text { Pro } \\ & 165 \end{aligned}$ | Ser | $\mathrm{Gln}$ | Met | Pro | $\begin{aligned} & \text { Ala } \\ & 170 \end{aligned}$ | Ala | Leu | Lys Pro | $\begin{aligned} & \text { Tyr } \\ & 175 \end{aligned}$ | Arg |
| Asp | Asp | Glu | $\begin{aligned} & \text { Leu } \\ & 180 \end{aligned}$ | Arg | Asn | Leu | Arg | $\begin{aligned} & \text { Gly } \\ & 185 \end{aligned}$ | Asp | Asp | Gln | $\begin{array}{rl} G l n & G l y \\ 190 \end{array}$ | Pro | TYr |
| Gln | Glu | $\begin{aligned} & \mathrm{His} \\ & 195 \end{aligned}$ | Asp | Arg | Val | Tyr | $\begin{aligned} & \text { Arg } \\ & 200 \end{aligned}$ | Tyr | Asp | Val | Tyr | $\begin{aligned} & \text { Asn Asp } \\ & 205 \end{aligned}$ | Leu | Gly |
| Glu | $\begin{aligned} & \text { Pro } \\ & 210 \end{aligned}$ | Asp | Gly | Gly | Asn | $\begin{aligned} & \text { Pro } \\ & 215 \end{aligned}$ | Arg | Pro | Ile | Leu | $\begin{aligned} & \text { Gly } \\ & 220 \end{aligned}$ | Gly Ser | Ala | Asp |
| $\begin{gathered} \text { His } \\ 225 \end{gathered}$ | Pro | Tyr | Pro | Arg | $\begin{aligned} & \text { Arg } \\ & 230 \end{aligned}$ | Cys | Arg | Thr | Gly | Arg $235$ | Lys | Pro Thr | Lys | $\begin{aligned} & \text { Thr } \\ & 240 \end{aligned}$ |
| Asp | Pro | Asn | Ser | $\begin{aligned} & \text { Glu } \\ & 245 \end{aligned}$ | Ser | Arg | Leu | Ser | $\begin{aligned} & \text { Leu } \\ & 250 \end{aligned}$ |  | Glu | Gln Ile | $\begin{aligned} & \text { Tyr } \\ & 255 \end{aligned}$ | Val |
| Pro | Arg | Asp | $\begin{aligned} & \mathrm{Glu} \\ & 260 \end{aligned}$ | Arg | Phe | Gly | is | $\begin{aligned} & \text { Leu } \\ & 265 \end{aligned}$ | Lys | Met | Ser | $\begin{array}{r} \text { Asp Phe } \\ 270 \end{array}$ | Leu | Gly |
| TYr | Ser | $\begin{aligned} & \text { Ile } \\ & 275 \end{aligned}$ | Lys | Ala | Ile | Thr | $\begin{aligned} & \text { Gln } \\ & 280 \end{aligned}$ | Gly | Ile | Ile P | Pro | $\begin{aligned} & \text { Ala Val } \\ & 285 \end{aligned}$ | Arg | Thr |
| Tyr | $\begin{aligned} & \mathrm{Val} \\ & 290 \end{aligned}$ | Asp | Thr | Thr | Pro | $\begin{aligned} & \text { Gly } \\ & 295 \end{aligned}$ | Glu | Phe | Asp | Ser | $\begin{aligned} & \text { Phe } \\ & 300 \end{aligned}$ | Gln Asp | Ile | Ile |
| $\begin{aligned} & \text { Asn } \\ & 305 \end{aligned}$ |  | Tyr | Glu | Gly | $\begin{aligned} & \text { Gly } \\ & 310 \end{aligned}$ | Ile | Lys |  | Pro | $\begin{aligned} & \text { Lys } \\ & 315 \end{aligned}$ | Ile | Gln Ala | Leu | $\begin{aligned} & \mathrm{Glu} \\ & 320 \end{aligned}$ |




$<210>$ SEQ ID NO 27
$<211>$ LENGTH: 238
$<212>$ TYPE : PRT
$<213>$ ORGANISM: Zea mays
$<400>$ SEQUENCE: 27


$<210>$ SEQ ID NO 28
$<211>$ LENGTH: 21
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 28
$<210>$ SEQ ID NO 29
$<211>$ LENGTH: 20
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 29
gtggcgcaat cactttaacc
$<210>$ SEQ ID NO 30
$<211>$ LENGTH: 20
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 30
$<210>$ SEQ ID NO 31
$<211>$ LENGTH: 20
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 31
agcaccgttc aaatgtctcc 20
$<210>$ SEQ ID NO 32
$<211>$ LENGTH: 20
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 32
tattgttggt gctgttgacg
$<210>$ SEQ ID NO 33
$<211>$ LENGTH: 20
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 33
$<210>$ SEQ ID NO 34
$<211>$ LENGTH: 20
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 34
ccogagcacg taaagcagat 20
$<210>$ SEQ ID NO 35
$<211>$ LENGTH: 20
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 35
cttcatgccc etggcatact
$<210>$ SEQ ID NO 36
$<211>$ LENGTH: 23
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 36
$<210>$ SEQ ID NO 37
$<211>$ LENGTH: 25
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 37
$<210>$ SEQ ID NO 38
$<211>$ LENGTH: 20
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 38
atggccgagc tcatcaacaa
$<210>$ SEQ ID NO 39
$<211>$ LENGTH: 20
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 39
tegtcctcac ctccgtctgt
$<210>$ SEQ ID NO 40
$<211>$ LENGTH: 20
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE : 40
tgttcctccg gatcatctgc
$<210>$ SEQ ID NO 41
$<211>$ LENGTH: 19
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 41
aagaggctgt cccaccgct
$<210>$ SEQ ID NO 42
$<211>$ LENGTH: 20
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEOUENCE: 42
$<210>$ SEQ ID NO 43
$<211>$ LENGTH: 20
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 43
$<210>$ SEQ ID NO 44
$<211>$ LENGTH: 25
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 44
aagttcaaca ccataggact cgatg 25
$<210>$ SEQ ID NO 45
$<211>$ LENGTH: 25
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 45
caggtagcta gagcetgaag tggtc 25
$<210>$ SEQ ID NO 46
$<211>$ LENGTH: 20
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 46
ggctgggttc cgtgactaca
$<210>$ SEQ ID NO 47
$<211>$ LENGTH: 19
$<212>$ TYPE : DNA
$<213>$ ORGANISM: Artificial sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 47
gacctcgatg atggacggg
$<210>$ SEQ ID NO 48
$<211>$ LENGTH: 22
$<212>$ TYPE: DNA
$<213>$ ORGANISM: Artificial Sequence
$<220>$ FEATURE:
$<223>$ OTHER INFORMATION: Primer
$<400>$ SEQUENCE: 48

```
ggaagaggat gaacgagctc aa
\(<210>\) SEQ ID NO 49
\(<211>\) LENGTH: 21
\(<212>\) TYPE: DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 49
\(<210>\) SEQ ID NO 50
\(<211>\) LENGTH: 19
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
<400> SEQUENCE: 50
gggaccagtt cggcaacat
\(<210>\) SEQ ID NO 51
\(<211>\) LENGTH: 18
\(<212>\) TYPE: DNA
\(<213>\) ORGANISM: Artificial sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 51
tgcccacctt ccacacgt
\(<210>\) SEQ ID NO 52
\(<211>\) LENGTH: 20
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE : 52
cagcaggtgg tggtgataat
\(<210>\) SEQ ID NO 53
\(<211>\) LENGTH: 19
\(<212>\) TYPE: DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 53
\(<210>\) SEQ ID NO 54
\(<211>\) LENGTH: 20
\(<212>\) TYPE: DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 54
geccacccaa gtaagcttcg
\(<210>\) SEQ ID NO 55
\(<211>\) LENGTH: 20
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 55
agagacagcg ataggatgga 20
\(<210>\) SEQ ID NO 56
\(<211>\) LENGTH: 20
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 56
\(<210>\) SEQ ID NO 57
\(<211>\) LENGTH: 20
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 57
accggtcatt cgtcacaagc 20
\(<210>\) SEQ ID NO 58
\(<211>\) LENGTH: 20
\(<212>\) TYPE: DNA
\(<213>\) ORGANISM: Artificial sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 58
gectcatagt tccegacctc
\(<210>\) SEQ ID NO 59
\(<211>\) LENGTH: 20
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE : 59
\(<210>\) SEQ ID NO 60
\(<211>\) LENGTH: 19
\(<212>\) TYPE: DNA
\(<213>\) ORGANISM: Artificial sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 60
cctcatgatg tgggtgcag
\(<210>\) SEQ ID NO 61
\(<211>\) LENGTH: 20
\(<212>\) TYPE: DNA
\(<213>\) ORGANISM: Artificial sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 61
\(<210>\) SEQ ID NO 62
\(<211>\) LENGTH: 20
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 62
\(<210>\) SEQ ID NO 63
\(<211>\) LENGTH: 22
\(<212>\) TYPE : DNA
\(<213>\) ORGANISM: Artificial Sequence
\(<220>\) FEATURE:
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 63
attgcatgac gacaatgcta ga
<210> SEQ ID NO 64
\(<211>\) LENGTH: 54
<212> TYPE: DNA
\(<213>\) ORGANISM: Artificial Sequence
<220> FEATURE.
\(<223>\) OTHER INFORMATION: Primer
\(<400>\) SEQUENCE: 64
ggggacaagt ttgtacaaaa aagcaggctt catggctgct caccagcctc acct
<210> SEQ ID NO 65
<211> LENGTH: 54
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Primer
<400> SEQUENCE: 65

\section*{1.-15. (canceled)}
16. A method for producing a plant having increased fungal resistance, wherein the fungal resistance is regulated by at least one wall-associated kinase, the method comprising:
(i) (a) providing at least one plant cell, tissue, organ, or whole plant having a genotype with respect to the presence of at least one gene encoding a wall-associated kinase in the genome of said plant cell, tissue, organ, or whole plant; or
(i) (b) introducing at least one gene encoding at least one wall-associated kinase into the genome of at least one cell of at least one of a plant cell, tissue, organ, or whole plant; and
(ii) (a) modifying at least one gene encoding at least one wall-associated kinase in the at least one plant cell, tissue, organ, or whole plant; and/or
(ii) (b) modulating the expression level of at least one wall-associated kinase and/or the transcription level, the expression level, or a function of at least one molecule within a signalling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid or within a synthesis pathway of at least one benzoxazinoid in the at least one plant cell, tissue, organ, or whole plant;
(iii) producing a population of plants from the at least one plant cell, tissue, organ, or whole plant; and
(iv) selecting a plant having increased fungal resistance from the population of plants, optionally based on a determination of a reduced synthesis of at least one benzoxazinoid in response to a fungal pathogen infec-
tion, wherein the synthesis of the at least one benzoxazinoid is regulated by the at least one wall-associated kinase.
17. The method according to claim 16, wherein the at least one wall-associated kinase is a WAK-RLK1 gene.
18. The method of claim 17, wherein the at least one wall-associated kinase
a) is encoded by a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO: 1 or 7 , or a functional fragment thereof,
b) is encoded by a nucleic acid molecule comprising the nucleotide sequence having at least \(60 \%, 65 \%, 70 \%\), \(75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%, 85 \%, 86 \%, 87 \%\), \(88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%, 94 \%, 95 \%, 96 \%\), \(97 \%, 98 \%\) or \(99 \%\) sequence identity to nucleotide sequence of SEQ ID NO: 1 or 7 ,
c) is encoded a nucleic acid molecule hybridizing with a complementary sequence to a) or b) under stringent conditions,
d) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence of SEQ ID NO: 2 or 8 , or a functional fragment thereof,
e) is encoded by a nucleic acid molecule comprising the nucleotide sequence coding for an amino acid sequence having at least \(60 \%, 65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%\), \(83 \%, 84 \%, 85 \%, 86 \%, 87 \%, 88 \%, 89 \%, 90 \%, 91 \%\), \(92 \%, 93 \%, 94 \%, 95 \%, 96 \%, 97 \%, 98 \%\) or \(99 \%\) sequence identity to amino acid sequence of SEQ ID NO: 2 or 8 ,
f) comprising the amino acid sequence of SEQ ID NO: 2 or 8, or
g) comprising an amino acid sequence having at least \(60 \%, 65 \%, 70 \%, 75 \%, 80 \%, 81 \%, 82 \%, 83 \%, 84 \%\),
\(85 \%, 86 \%, 87 \%, 88 \%, 89 \%, 90 \%, 91 \%, 92 \%, 93 \%\), \(94 \%, 95 \%, 96 \%, 97 \%, 98 \%\) or \(99 \%\) sequence identity to amino acid sequence of SEQ ID NO: 2 or 8 ,
provided that any sequence of a) to g ), optionally after expression, still encodes at least one functional Htnl , \(\mathrm{Ht} 2, \mathrm{Ht} 3\), or an allelic variant, a mutant, or a functional fragment thereof.
19. The method according to claim 16, wherein the benzoxazinoid whose synthesis is regulated by the at least one wall-associated kinase, is selected from at least one of DIMBOA, DIMBOA, HMBOA, HM2BOA, HDMBOA, HDM2BOA, HBOA, DHBOA, DIBOA or TRIBOA, the aforementioned benzoxazinoid being in the glucoside or aglucone form, or a benzoxazolinone, or any combination of the aforementioned benzoxazinoids.
20. The method according to claim 16, wherein the fungal resistance against which resistance to a fungus is increased, or a disease caused by said fungus is selected from a fungus of the order of Pleosporales, comprising Helminthosporium turcicum causing northern corn leaf blight (NCLB), particularly affecting maize and wheat plants, or comprising Bipolaris maydis causing southern corn leaf blight, the order of Pucciniales causing rust disease, comprising Puccinia sorghi causing common rust, or Diploida macrospora causing Diploida leaf streak/blight, or Colletotrichum graminicola causing Anthracnose, or Fusarium spp. causing Fusarium stalk rot, or Gibberella spp., causing Giberella stalk rot, or Sphacelotheca reiliana causing maize head smut.
21. The method according to claim \(\mathbf{1 6}\), wherein the at least one gene encoding at least one wall-associated kinase is stably integrated into the genome of the at least one plant cell, tissue, organ, or whole plant, or wherein the at least one gene encoding at least one wall-associated kinase is transiently introduced into a plant cell, tissue, organ, or whole plant, or wherein the at least one gene encoding at least one wall-associated kinase is stably integrated into the genome of the at least one plant cell, tissue, organ, or whole plant, wherein the introduction of the at least one gene encoding at least one wall-associated kinase comprises the introgression of the at least one gene during plant breeding.
22. The method according to claim 16, wherein the at least one molecule within the signalling pathway from the at least one wall-associated kinase to the synthesis of at least one benzoxazinoid or within the synthesis pathway of at least one benzoxazinoid is selected from the group consisting of the genes bx1 (SEQ ID NO: 10), bx2 (SEQ ID NO: 12), igl (SEQ ID NO: 14), bx6 (SEQ ID NO: 16), bxl1 (SEQ ID NO: 18), bxl4 (SEQ ID NO: 20), opr2 (SEQ ID NO: 22), lox3 (SEQ ID NO: 24) or aocl (SEQ ID NO: 26), or a homologous genes thereof, or the proteins BX1 (SEQ ID NO: 11), BX2 (SEQ ID NO: 13), IGL (SEQ ID NO: 15), BX6 (SEQ ID NO: 17), BX11 (SEQ ID NO: 19), BX14 (SEQ ID NO: 21), OPR2 (SEQ ID NO: 23), LOX3 (SEQ ID NO: 25) or AOC1 gene (SEQ ID NO: 27), or a homolog thereof.
23. The method according to claim 16 , wherein the reduced synthesis of at least one benzoxazinoid is achieved by providing at least one wall-associated kinase, an allelic variant, a mutant or a functional fragment thereof, or a gene encoding the same, wherein the at least one wall-associated kinase comprises a sequence which can directly or indirectly influence the benzoxazinoid pathway and at least one further plant metabolic pathway, wherein the plant metabolic pathway is selected from the group consisting of the jasmonic
acid pathway, the ethylene pathway, the lignin synthesis pathway, a defense pathway, a receptor-like kinase pathway, and a cell wall associated pathway.
24. The method according to claim 16 , wherein the modification of the at least one gene encoding at least one wall-associated kinase within step (ii) (a) or (ii) (b) is performed by at least one of a site-specific nuclease (SSN) or a catalytically active fragment thereof, or a nucleic acid sequence encoding the same; oligonucleotide directed mutagenesis; chemical mutagenesis; or TILLING.
25. The method according to claim 16, wherein the at least one plant cell, tissue, organ, or whole plant provided in step (i) is selected from the group consisting of Hordeum vulgare, Hordeum bulbusom, Sorghum bicolor, Saccharum officinarium, Zea spp., including Zea mays, Setaria italica, Oryza minuta, Oryza saliva, Oryza australiensis, Oryza alta, Triticum aestivum, Triticum durum, Secale cereale, Triticale, Malus domestica, Brachypodium distachyon, Hordeum marinum, Aegilops tauschii, Daucus glochidiatus, Beta spp., including Beta vulgaris, Daucus pusillus, Daucus muricatus, Daucus carota, Eucalyptus grandis, Nicotiana sylvestris, Nicotiana tomentosiformis, Nicotiana tabacum, Nicotiana benthamiana, Solanum lycopersicum, Solanum tuberosum, Coffea canephora, Vitis vinifera, Erythrante guttata, Genlisea aurea, Cucumis sativus, Marus notabilis, Arabidopsis arenosa, Arabidopsis lyrata, Arabidopsis thaliana, Crucihimalaya himalaica, Crucihimalaya wallichii, Cardamine nexuosa, Lepidium virginicum, Capsella bursa pastoris, Olmarabidopsis pumila, Arabis hirsute, Brassica napus, Brassica oleracea, Brassica rapa, Raphanus sativus, Brassica juncacea, Brassica nigra, Eruca vesicaria subsp. sativa, Citrus sinensis, Jatropha curcas, Populus trichocarpa, Medicago truncatula, Cicer yamashitae, Cicer bijugum, Cicer arietinum, Cicer reticulatum, Cicer judaicum, Cajanus cajanifolius, Cajanus scarabaeoides, Phaseolus vulgaris, Glycine max, Gossypium sp., Astragalus sinicus, Lotus japonicas, Torenia fournieri, Allium cepa, Allium fistulosum, Allium sativum, Helianthus annuus, Helianthus tuberosus and Allium tuberosum, or any variety or subspecies belonging to one of the aforementioned plants.
26. A plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, obtainable by a method according to claim 16.
27. A method for identifying at least one gene involved in increased pathogen resistance in a plant cell, tissue, organ, whole plant, or plant material the method comprising:
(i) determining the genotype of at least one plant cell, tissue, organ, whole plant, or plant material with respect to the presence of at least one gene encoding a wall-associated kinase in the genome of said plant cell, tissue, organ, whole plant or plant material;
(ii) optionally determining the benzoxazinoid signature of the at least one plant cell, tissue, organ, whole plant, or plant material of step (i);
(iii) exposing the at least one plant cell, tissue, organ, whole plant, or plant material of step (i) or (ii) to a stimulus, optionally wherein the stimulus is correlated with the benzoxazinoid signature in the at least one plant cell, tissue, organ, whole plant, or plant material;
(iv) performing an analysis of at least one analyte obtained from the at least one plant cell, tissue, organ, whole plant, or plant material of step (i) or (ii) after exposition to the stimulus;
(v) determining at least one gene being regulated upon exposition to a stimulus according to step (iii) in at least one cell of the at least one plant cell, tissue, organ, whole plant, or plant material as derivable from the analysis of at least one analyte as defined in step (iv),
(vi) subjecting the at least one gene as determined in step (v) to a functional characterization; and
(vii) providing at least one gene involved in increased pathogen resistance in a plant cell, tissue, organ, whole plant, or plant material.
28. A plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, obtainable by introducing at least one gene as provided by the method according to claim 27 into at least one cell of at least one of a plant cell, tissue, organ, or whole plant.
29. A plant cell, tissue, organ, whole plant or plant material, or a derivative or a progeny thereof, wherein the introduction of at least one gene into at least one cell of at least one of a plant cell, tissue, organ, or whole plant according to the method according to claim 27 is a stable introduction.
30. A method of increasing pathogen resistance in a plant cell, tissue, organ, whole plant, or plant material, the method comprising:
(i) providing at least one plant cell, tissue, organ, whole plant or plant material;
(ii) (a) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance neutralizing an effect of at least one benzoxazinoid, and/or
(ii) (b) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance activating the signalling pathway downstream of at least one wall-associated kinase; and/or
(ii) (c) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance modulating or modifying the activity of at least one promoter or at least one regulatory sequence of at least one gene of the at least one plant cell, tissue, organ, whole plant or plant material of step (i), wherein said promoter or said regulatory sequence is involved in the regulation of transcription of at least on gene involved in the signalling pathway of, or downstream of at least one wall-associated kinase or involved in the synthesis pathway of at least one benzoxazinoid;
(ii) (d) treating the at least one plant cell, tissue, organ, whole plant or plant material according to step (i) with a substance inhibiting the synthesis of at least one benzoxazinoid; and
(iii) reducing an amount of at least one benzoxazinoid and thereby increasing pathogen resistance in at least one plant cell, tissue, organ, whole plant, or plant material.
31. The method of claim 30, wherein the method is effective to increase fungal resistance in at least one plant cell, tissue, organ, whole plant, or plant material.```

